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ABSTRACT: 
CHAPTER 1: 
Congestive heart failure is a common and lethal disorder. Improved 
understanding of the pathophysiology has led in recent years to more 
rational therapeutic regimes. The historical development of modern 
concepts of the pathophysiology and management of heart failure are 
outlined, concentrating mainly on the role of neurohumoral systems - the 
renin-angiotensin-aldosterone system and sympathetic nervous system. 
Deficiencies in current knowledge are discussed, from which I outline 
the objectives of the studies presented in this thesis. 
CHAPTER 2: 
Only those patients with documented left ventricular dysfunction 
were included in the studies. In this chapter, I outline methods of 
patient selection: referral; definition of heart failure and 
aetiology; 	and finally, inclusion and exclusion criteria. Ethical 
guidelines followed implicitly in the studies are then outlined. 
CHAPTER 3: 
Current methods of assessment of the severity of heart failure and 
underlying left ventricular dysfunction are reviewed. Emphasis is 
placed on those methods used in this thesis: NYHA Functional 
Classification; 	invasive haemodynamics; 	radionuclide angiography; 
echocardiography; and exercise testing. 
CHAPTER 4: 
This chapter is concerned with methodology for measuring 
haemodynamic parameters: intra-cardiac pressure, cardiac output, and 
forearm blood flow. 
CHAPTER 5: 
Correlation of hormone and haemodynamic measurements in heart 
failure under control conditions and following therapeutic intervention 
forms the basis of three studies reported in this thesis. In this 
chapter, I briefly outline assay methods used in our laboratory. 
Metabolic balance was instituted to facilitate the interpretation of 
hormone levels in the studies. Methods for performing these metabolic 
studies are dealt with in this section. 
CHAPTER 6: 
In this study, I document the acute haemodynamic, hormone, and 
electrolyte response to enalapril in heart failure, and correlate these 
changes with the short-term clinical response: Enalapril appears to be 
a long-acting angiotensin converting enzyme inhibitor that effectively 
reduces elevated angiotensin II levels found in heart failure. The 
greatest haemodynamic improvement occurred in those patients with the 
highest baseline angiotensin II levels. Over a period of - 4 to 8 weeks, 
exercise capacity improved in those patients who were most severely 
afflicted, on higher frusemide doses, with the greatest activation of 
the renin-angiotensin-aldosterone system. 
CHAPTER 7: 
The haemodynamic, hormone and electrolyte effects of prenalterol 
infusion were documented in a similar fashion to the previous study. I 
confirmed the positive inotropic action of this drug, a selective beta-1 
receptor agonist. The drug is available in an oral form, thus it may 
have a place in the long-term management of heart failure, but this will 
depend on whether or not the acute haemodynamic response is sustained 
long-term. Prenalterol activated the renin-angiotensin system, 
presumably by direct beta-1 stimulation of the juxta-glomerular 
apparatus. This did not appear to have haemodynamic effects in the 
short-term, however it may ultimately prove to be detrimental during 
long-term therapy. 
ix. 
CHAPTER 8: 
I retrospectively analysed the control data from the preceeding two 
studies and an earlier study performed in our unit (Maslowski et al, 
1981a). Cardiac catheterisation appears to significantly influence 
cardiac and hormone parameters for a period of up to twelve to eighteen 
hours. Thereagter, these parameters are relatively stable and more 
truly represent "baseline" levels, from which haemodynamic-hormone 
relationships and the effects of therapeutic intervention can be more 
accurately assessed. Activation of the renin-angiotensin-aldosterone 
system depends largely on the severity of underlying myocardial 
dysfunction and frusemide dosage, while the sympathetic nervous system 
appears to play a lesser role in determining cardiac function at rest. 
CHAPTER 9: 
This study was the first double-blind, placebo controlled trial to 
investigate the effects of beta-blockade in dilated cardiomyopathy. I 
refute the claims of Swedish workers for therapeutic benefit in this 
condition, claims which are contrary to our current notions concerning 
the role of the sympathetic nervous system in heart failure, and the 
administration of beta-blocking agents in this syndrome. 
CHAPTER 10: 
In this double-blind, controlled study I document haemodynamic 
deterioration associated with diminished exercise capacity following 
withdrawal of long-term captopril therapy for heart failure. This 
confirms the sustained effectiveness of angiotensin-converting enzyme 
inhibitors in the long-term management of heart failure. 
CHAPTER 11: 
x. 
The major findings of the above studies are summarised. 
CONTRIBUTION TO THE SCIENTIFIC AND MEDICAL MILIEU: 
The studies embodied in this thesis contribute significantly to 
knowledge concerning the 	mac.: 	of neurohumoral systems in the 
pathophysiology and management of heart failure. The following 
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CHAPTER 1 
INTRODUCTION 
" Heart failure, the consequence of many forms of heart 
disease, is one of the most common and serious disorders that 
afflicts individuals of all ages" 
Braunwald 	(1981) 
1.1 HEART FAILURE - THE PROBLEM: 
Congestive heart failure is a very common clinical problem 
which leads to incapacitating symptoms and often progresses to the 
point of refractoriness to therapy. From the time of diagnosis, 
mortality over the following five years is about 50% (McKee et al, 
1971). In more severe cases, characterised by marked haemodynamic 
abnormalities, the mortality rate may be even higher (Fuster et al, 
1981). While initial therapy produces symptomatic relief in many 
patients early in the course, progressive worsening of symptoms with 
time is the usual outcome, although sudden death may intervene. 
In the last three decades, cardiology has benefited from 
extensive research efforts. With application of this knowledge, we 
have witnessed more than a 25% decline in age-corrected mortality 
from ischaemic heart disease and a 37% decrease in stroke mortality 
(Fromer 1982). Furthermore, there has been dramatic progress in our 
ability to manage most major types of cardiovascular disease 
(coronary artery disease, arrhythmias, valve and congenital heart 
diseases and hypertension). 
In contrast to these advances our ability to manage major 
derangements of heart muscle function has made very little progress. 
Thus, heart failure is now the leading pathophysiological mechanism 
of death from heart disease in the hospital setting (Fromer, 1982). 
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Despite the prevalence of the syndrome, there has been a remarkable 
lack of information regarding: 
1. Prognosis and mode of death; 
2. Mechanisms of progression of the syndrome; 
3. Timing of therapeutic intervention; and 
4 • Assessment of severity and therapeutic benefit with regard 
to symptoms, and life-expectancy. 
Part of the problem lies in the heterogeneous nature of the 
syndrome, which may arise from any form of heart disease, and from 
imprecision in making a definitive diagnosis and evaluating its 
severity, which are likely to be a strong factors in determining 
prognosis. In the few studies where adequate definitive diagnosis 
has been made (Bruschke et al, 1973; Fuster et al, 1981), the 
prognosis in the presence of heart failure is poor and in many cases 
is worse than that for many forms of malignancy (McKee et al, 1971). 
Traditional therapy involves exercise curtailment, 	salt 
. restriction and administration of digitalis and diuretics, however 
many patients fail to respond or respond poorly. New therapeutic 
modalities (vasodilators, blockade of the renin-angiotensin-
aldosterone system and non-glycoside inotropes) show promise, making 
management of heart failure one of the most rapidly expanding areas 
of cardiac therapeutics (Braunwald, 1982). 
In recent years, increasing attention has been devoted to the 
neurohumoral vasoconstrictor, and dilator systems which contribute 
to fluid retention, increase heart rate and alter regional blood 
flow. These systems include: 
1. The Renin-Angiotensin-Aldosterone system; 
2. The Sympathetic Nervous System; 
3. Antidiuretic hormone; 
4. Kinins; 
& 5. Prostaglandins; 
Alterations in the activity of these vasoactive systems increase 
ventricular afterload, thereby increasing left ventricular work and 
ultimately potentiating heart failure (see section 1.7). 
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The causes and consequences of these disturbed mechanisms are 
not well understood (Braunwald, 1982). Reversal of the increased 
ventricular afterload observed in heart failure is beneficial 
(Franciosa, 1981), however "tolerance" to some vasodilators has been 
attributed to activation of those neurohumoral constrictor systems 
not initially blocked (Colucci et al, 1980b). Furthermore, 
tolerance to inotropic therapy may occur for similar reasons. 
The studies embodied in this thesis contribute significantly to 
the growing fund of knowledge concerning the role of these 
neurohumoral systems in the manifestations of heart failure and its 
therapy. Before describing these studies in detail, it is pertinent 
to review briefly the historical development of concepts in heart 
failure, its manifestations and pathophysiology. Current knowledge 
concerning the role of the neurohumoral systems in heart failure 
will then be outlined with emphasis being placed on those areas 
under investigation, namely the renin-angiotensin-aldosterone 
system, the sympathetic nervous system, and antidiuretic hormone 
(ADH). 
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1.2 HISTORICAL PERSPECTIVES: (Jarcho 1980 & Braunwald 1981) 
The principal clinical manifestations of heart 	failure, 
dyspnoea and oedema, were recognised in antiquity, although heart 
failure as an entity could not be described until the fundamental 
function of the circulation had been identified. The Greeks and 
Romans attributed dyspnoea and oedema to an obstruction of the upper 
airways, and to an abnormality of the urinary system respectively. 
William Harvey (1578-1657), despite his monumental contribution 
to cardiac physiology and his lifelong involvement in the practice 
of medicine, did not write about disorders of the organ whose 
function he had described. In his book "De Corde" (1669), Richard 
Lower pointed out that it is necessary for the two sides of the 
heart to have similar strengths to maintain the circulation. He 
appreciated that inequality of the two sides could lead to symptoms, . 
and he presaged much later work on heart failure by pointing out 
that the cardiac parenchyma may be subject "to various illnesses and 
inflammation", which could interfere with its "pulsations", leading 
to a feeble cardiac output. In this manner, the concept of what we 
now call "forward heart failure" was first formulated. 
Almost simultaneously, in Italy, Marcell° Malpighi (1628-94) 
expressed the belief that dyspnoea was the result of a "heaviness of 
the lungs caused by retarded circulation in the pulmonary vessels" - 
a predecessor of the "backward failure" concept. In 1832, James 
Hope championed this theory, contending that when heart failure 
occurs one or the other ventricle fails to discharge its contents 
normally and the pressures and volumes in the atrium and venous 
system behind the failing ventricle become elevated. 
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A current formulation of this concept would suggest that the 
inability of cardiac muscle to shorten against a load alters the 
relationship between ventricular pressure and volume, so that 
end-systolic volume rises. The following sequence of adaptations 
then occurs: 
1. ventricular end-diastolic volume and pressure increases; 
2. pressure rises in the venous and capillary beds; 
3. transudation occurs; 
4 • extracellular volume icreases. 
Although these adaptations at first tend to maintain normal cardiac 
output, many of the symptoms that are characteristic of heart 
failure result directly from this sequence of fluid sequestration in 
the interstitial spaces of the lungs, liver, subcutaneous tissues, 
and serous cavities. 
In contrast to the "backward theory", proponents of the 
"forward failure theory" expounded most clearly by MacKenzie in 
1913, maintain that the clinical manifestations of heart failure 
result directly from an inadequate discharge of blood into the 
arterial system. According to this formulation, the principal 
clinical manifestations of heart failure arise from reduced cardiac 
output, which results in diminished perfusion of vital organs 
including: the brain, leading to mental confusion; the skeletal 
muscles, leading to weakness; and the kidneys, leading to sodium 
and water retention. Although these two seemingly opposing views 
concerning the pathogenesis of heart failure led to lively 
controversy during the first half of the century, a rigid 
distinction between backward and forward heart failure now seems 
artificial, since both mechanisms appear to operate to varying 
extents in most patients with heart failure. 
Schroeder (1941) first documented the vital role of sodium 
restriction in the treatment of heart failure. This led to the 
realisation that sodium retention (rather than water retention) by 
the kidneys was the primary mechanism by which fluid was retained in 
patients with heart failure (Futcher & Schroeder, 1942). The 
importance of enhanced tubular reabsorption in the diminished 
INTRODUCTION: 
6. 
urinary excretion of sodium was suggested by Schrodeder (1941), and 
later confirmed (Urquhart & Davis, 1963). 
It was not until Parrish (1949) and Deming & Luetscher (1950) 
reported increased sodium-retaining activity in the urine from 
patients with heart failure, that the possibility of hormone-induced 
renal sodium retention received scientific support. Davis et al 
(1956) and Singer (1957) confirmed that this active material was 
aldosterone when they demonstrated increased levels of this 
substance in urine and adrenal vein blood respectively. Davis et al 
. (1962) subsequently suggested that increased circulating angiotensin 
II levels were responsible for hypersecretion of aldosterone in 
experimental heart failure. 
The manifestations of heart failure are now thought to be 
largely due to a disturbance of feed-back control of fluid 
homeostasis in response to a change in renal perfusion (forward 
failure), in association with redistribution of blood flow by . 
neurohumoral reflexes (Hamer, 1982 - p.1). Congestive heart failure ' 
appears when a cardiac output necessary for tissue needs cannot be 
produced by the diseased heart using compensatory mechanisms of the 
sympathetic nervous system, which include: 
1. tachycardia; 
2. ventricular hypertrophy (Strobeck & Sonnenblick, 1981); 
& 3. moving to a higher ventricular function curve (Sarnoff & 
Beglund, 1954) so that compensation is attempted through 
the Starling response. 
The last factor is aided by renal sodium and water retention. The 
retained fluid is distributed by the venous system to provide 
suitable filling pressures in each ventricle to maintain an adequate 
cardiac output (Guyton, 1963), however, this fluid cannot be 
retained in the intravascular compartment. Sequestration in the 
interstitial spaces results in the appearance of oedema. 
Modern diuretic therapy has undoubtedly enabled many patients 
with cardiac decompensation to survive in an oedema-free state for 
longer periods (Mudge, 1980). Thus, the full blown syndrome of 
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congestive heart failure is seen less frequently. Patients are more 
often troubled by symptoms related to diminished cardiac output, 
namely fatigue and reduced exercise capacity. As a result, greater 
research emphasis is now being directed toward agents that can 
improve cardiac output by direct inotropic action or blockade of 
neurohumoral vasoconstrictor systems that adversely effect the 
regional distribution of blood flow in heart failure. 
The investigations in this thesis are concerned largely with 
the neurohumoral changes that are involved in altered regional blood 
flow and sodium retention in heart failure, and in particular, with 
the effect of diuretics, vasodilators and inotropic agents on these 
systems. Renal changes will only be outlined briefly in the next 
section because they are not directly related to this thesis. The 
brevity of this section, however, does not belie the central role 
that the kidney plays in the salt and water retention. 
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1.3 THE KIDNEY IN HEART FAILURE: 
Salt and water retention by the kidney is a major compensatory 
adjustment brought about in an attempt to restore the effectiveness 
of the circulation (Braunwald et al, 1965). Although the 
quantitative role of each mechanism has not been clarified, there 
are at least five mechanisms which have been proposed in heart 
failure: 
1. Renal Haemodynamic changes: 
Renal haemodynamic changes are currently thought to play 
the major role in sodium and water retention in heart failure 
(Hume et al, 1978). A decline in renal blood flow and plasma 
flow is commonly observed (Merrill, 1949 & Mokotoff et al, 
1948), but this is associated with little or no change in 
glomerular filtration rate (Heller & Johnson, 1950). As a 
result of this, a rise in filtration fraction is consistently 
found in heart failure (Vander et al, 1958). The mechanisms by 
which diminished sodium excretion results from these 
haemodynamic alterations are detailed elsewhere (Hume et al, 
1978), and as they are not pertinent to this thesis, they will 
not be discussed further. 
2. Aldosterone: 
Aldosterone contributes to sodium retention by enhancing 
distal sodium reabsorption in exchange for potassium. Its role 
in heart failure will be discussed further in the next section. 
3. "Third Factor": 
The existence of an unidentified "salt-losing hormone" 
(third factor), probably of cerebral origin, that may inhibit 
tubular sodium absorption as the extracellular fluid expands, 
has been postulated (Schrier and de Wardener, 1971; Grekin et 
al, 1979). 
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A disturbance of such a mechanism could contribute to the sodium 
retention seen in heart failure. 
4. Intra-Renal Redistribution of Blood Flow: 
Alterations in the distribution of blood flow within the 
kidney (Kilcoyne et al, 1971) occur as part of the response to 
the general reduction in renal blood flow; the tendency to 
medullary, rather than cortical blood flow may favour nephrons 
with more potent sodium-retaining properties. A local 
intrarenal effect of renin may play a part here (Levens et al, 
1981). 
There are two populations of nephrons in the kidney 
(Britton, 1981): 
1. a cortical group with a juxtaglomerular apparatus which•
maintains perfusion by autoregulation of arterial pressure; 
and 
2. a juxtamedullary group subjected to a passive increase in 
flow as arterial pressure rises. 
A redistribution of blood flow to the juxtamedullary group in 
response to a falling cardiac output could account for the salt 
retention of heart failure (Hamer, 1982 - p.7). 
5. Other Humoral Agents: 
Anti-diuretic hormone contributes to water retention in 
heart failure by effecting distal renal tubular function (see 
section 1.6). Other vasoactive substances such as 
prostaglandins, kallikreins and kinins have also been implicated 
as important factors in sodium balance (McGiff & Itslovitz, 
1973; Mills et al, 1976), but their precise role in heart 
failure is, as yet, unclear and requires further research and 
the development of sensitive assays for these hormones. 
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1.4 THE ROLE OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HEART 
FAILURE : 
1. Physiology: 
Aldosterone, the most potent mineralocorticoid secreted by 
the adrenal cortex, plays a major role in sodium and potassium 
homeostasis. Enhanced distal tubular sodium-potassium exchange 
by aldosterone promotes sodium retention and potassium 
depletion. Four regulators of aldosterone release are well 
defined: 
1. the renin-angiotensin system; 
2. plasma potassium; 
3. ACTH; 
4. plasma sodium. 
Of these, the first two are generally considered to be the most 
important (Hollenberg & Williams, 1981). Other regulators have 
been suggested, including dopamine, which is thought to have a 
tonic inhibitory effect on aldosterone secretion (Campbell et 
al, 1981). Normally, more than 75% of the circulating 
aldosterone is inactivated during a single passage through the 
liver. However, in the presence of heart failure, this 
percentage may be reduced (Tait et al, 1965; Camargo et al, 
1965). In an otherwise normal subject, and in primary 
aldosteronism, excess levels of aldosterone per se do not 
usually lead to oedema formation because of the so-called 
"escape phenomenon". To prevent this from occurring proximal 
sodium reabsorption decreases, but the precise "escape" 
mechanism remains to be explained (Urqbart & Davis, 1963; 
Johnson et al, 1968). In heart failure, however, proximal 
tubular sodium reabsorption is enhanced, and the "escape" from 
aldosterone effect does not occur, thus this hormone contributes 
to the increase in extracellular volume. 
Renin is a proteolytic enzyme produced and stored in the 
granules of the juxtaglomerular cells. Released renin splits 
the deca-peptide angiotensin I from its circulating substrate, 
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the alpha-2 globulin called angiotensinogen. Circulating renin 
has a plasma half-life of 10-15 minutes (Levens, Peach & Carey 
1981). 	In the presence of angiotensin converting enzyme (found 
in all tissues, but predominently pulmonary 	endothelium), 
angiotensin I is converted into the biologically active 
octapeptide, angiotensin II. This hormone is a potent direct 
stimulus both to aldosterone and constriction of vascular smooth 
muscle, while it is destroyed rapidly by angiotensinases, thus 
it has a half-life in the order of minutes. Renin release is 
controlled by a composite of four interdependent factors (Oparil 
& Haber, 1974): 
1. The juxtaglomerular cells act as miniature pressure 
transducers that sense changes in afferent arteriolar 
perfusion pressure. When the circulating blood volume is 
reduced, a corresponding fall in afferent arteriolar 
pressure and renal perfusion pressure occurs. Renin is then 
released by these cells to restore blood volume to normal 
through the effect of angiotensin II on aldosterone, and 
perhaps directly on the kidney (Levens et al, 1981). 
2. The Macula Densa cells are thought 	to 	function as 
chemoreceptors, monitoring the sodium or chloride load 
present in the distal tubule, and feeding this information 
back to the juxtaglomerular cells, where appropriate 
modifications in renin release occur. 
3. The sympathetic nervous system plays a prominent role in 
regulating renin secretion mediated by beta-receptors. 
4. A number of circulating factors may alter renin release. 
These include ADH, angiotensin II, and potassium (Abbrecht & 
Vander, 1970). 
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2. Activity of the Renin-Angiotensin-Aldosterone System in Heart 
Failure: 
Elevation of plasma renin activity and aldosterone 
concentration in subjects with heart failure has not been 
consistently observed (Merrill et al 1946, Brown et al 1970, 
Sanders and Melby 1964, Wolff et al 1959, Genest et al 1968, 
Chonko et al 1977). Recent experimental studies in conscious 
animals with cardiac failure have suggested that the 
renin-angiotensin-aldosterone system is activated soon after the 
induction of a low cardiac output (Watkins et al, 1976; Freeman 
et al, 1979; Morris et al, 1977; Davis 1962). During the 
chronic compensated state of experimental heart failure, plasma 
renin activity and plasma aldosterone concentration decrease 
toward normal as the extracellular fluid volume expands (Watkins 
et al, 1976; Davis, 1962). Thus, the discrepancies in the 
state of the renin-angiotensin-aldosterone system in the 
clinical literature are probably due to lack of clear definition 
of the clinical status of the patients studied, and failure to 
control other factors affecting both renin and aldosterone 
secretion. 
Dzau et al (1981) found that during acute, severe left 
ventricular decompensation, before the development of 
extracellular fluid volume expansion and restoration of systemic 
blood pressure, plasma renin activity and aldosterone were 
markedly elevated. With stabilisation of cardiac failure and 
extracellular fluid expansion, plasma renin activity and 
aldosterone returned to apparently normal levels although they 
remained abnormally elevated for the degree of blood volume 
expansion. 
In patients with severe heart failure, Nicholls et al 
(1974) demonstrated a biphasic response of resting plasma renin 
activity and aldosterone to frusemide induced diuresis. Prior 
to treatment, a modest increase in these hormones was evident. 
During the diuretic phase there was a paradoxical suppression of 
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the renin-angiotensin-aldosterone system, presumably as a result 
of increased distal tubular sodium load (Vander, 1967). As the 
patients approached dry body weight with continued diuretic 
therapy, plasma aldosterone concentrations rose to very high 
levels (Nicholls et al 1974; Knight et al, 1979). The parallel 
rise in plasma renin activity (Nicholls et al, 1974) suggested 
that the renin-angiotensin system (rather than other known 
secretagogues) controlled this pattern of aldosterone change. 
Sodium load to the distal tubule will be low at this stage, as 
there is little further diuresis, and continued intense diuretic 
therapy can maintain dry body weight, while augmenting renin 
release. 
The potentiating effect of diuretic therapy on the activity 
of the renin-angiotensin-aldosterone system in heart failure, 
may increase ventricular afterload and could hasten the 
progression of heart failure (Maslowski et al, 1981a). These 
points are considered in greater detail in Chapter 8, where I 
discuss the stability of hormone, haemodynamic and electrolyte 
observations and their inter-relationships in twenty-one 
patients with heart failure on constant digoxin and diuretic 
therapy. 
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3. Pharmacological Interruption of Renin-Angiotensin Activity: 
The development of agents that block the renin-angiotensin 
system has provided pharmacological probes that are useful in 
assessing more directly angiotensin's contribution to heart 
failure. Blockade may be effected at three levels: 
1. Beta-adrenergic antagonists suppress ream n release, but this 
class of drug has contributed little to our understanding of 
renin's role in heart failure because of confounding effects 
on myocardial function in heart failure (Hollenberg & 
Williams 1981); 
2. Angiotensin converting enzyme inhibitors (eg. 	teprotide, 
captopril, and more recently, enalapril) which block the 
formation of angiotensin II; 
3. Angiotensin II analogues (eg. 	saralasin) which compete 
directly with angiotensin II at its receptor site. These 
antagonists appear to be more specific in their action than 
converting enzyme inhibitors, however they can only be given 
intravenously, are expensive to synthesise, and like most 
receptor antagonists, they have some agonist action. 
It should be noted that there is much debate concerning the 
specificity of the action of converting enzyme inhibitors. This 
enzyme is responsible, in part, for degradation of bradykinin, a 
powerful vasodilator, but levels do not appear to be elevated by 
captopril (Johnston et al 1979, Dzau et al 1980). Clarification 
of bradykinin's role in heart failure, and the effects of 
converting enzyme inhibitors await the development of assays 
which are more sensitive than those currently in use. Captopril 
may affect prostaglandins which also modulate vascular tone, but 
available evidence is divergent (Romankewicz et al, 1983). 
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L. Renin-Angiotensin Blockade in Heart Failure: 
Agents that interrupt the renin-angiotensin axis activity 
have shown promise in animal models (Watkins et al 1976, Freeman 
et al 1979) and clinical studies-(Dzau et al 1980, Faxon et al 
1980, Maslowski et al 1981a, Turini et al 1979). Acute 
pharmacological blockade of the renin-angiotensin system with 
converting enzyme inhibitors or angiotensin analogues has 
produced salutary response in a large majority of patients with 
severe heart failure. Haemodynamic improvement resembles the 
response seen with nonspecific vasodilators (eg. nitroprusside 
- Vrobel et al, 1980). Since both classes of agents have been 
effective, it is very likely that a substantial portion of the 
vascular response in heart failure reflects reversal of the 
vasoconstriction induced by angiotensin (Hollenberg & Williams, 
1981). 
Captopril, the only currently available oral converting 
enzyme inhibitor, has been studied in patients resistant to 
conventional therapy. Although side effects are not common, 
potentially serious complications have been reported (Vidt, 
Bravo & Fouad, 1982). Enalapril, a member of a new group of 
converting enzyme inhibitors which lacks a mercapto function and 
is characterised by weak chelating properties, has recently been 
synthesised (Patchett et al, 1980) and used successfully in 
hypertension (Gavras et al, 1981). Preliminary data suggest it 
is as effective and longer acting than captopril in hypertension 
(Gavras et al, 1981), and so far serious side effects have not 
been observed, paving the way for its use in patients with 
milder degrees of cardiac failure. To date the haemodynamic, 
hormonal and electrolyte response to enalapril in heart failure 
have not been documented. In chapter 6, I report the results of 
such a study in nine patients with heart failure stable on 
digoxin and diuretic therapy. 
In an earlier report from this unit (Maslowski et al, 
1981b), the effects of withdrawal of long term captopril therapy 
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were observed for four days in five patients. 	Acute 
haemodynamic rebound was not seen, which may be taken to suggest 
that the drug has little or no effect in the long-term, or 
alternatively, that four days is insufficient time for the 
return of cardiac failure. In chapter 10, I report the results 
of a one month double-blind trial investigating withdrawal of 
captopril. These are the only investigations that have 
addressed the long-term effectiveness of converting enzyme 
inhibitors in such a manner. 
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1.5 THE ROLE OF THE SYMPATHETIC NERVOUS SYSTEM : 
In view of the well established importance of the sympathetic 
nervous system in normal regulation of the circulation, considerable 
attention has been directed to the activity of this system in heart 
failure. In 1962, Chidsey et al noted that either no change or very 
small increases in plasma norepinephrine occurred in normal subjects 
with exercise, while much greater rises occurred in patients with 
heart failure, presumably reflecting greater activity of the 
sympathetic nervous system during exercise. Measurements of 24 hour 
urinary norepinephrine excretion revealed marked elevations in 
patients with heart failure, suggesting greater activity at rest as 
well (Chidsey, Braunwald & Morrow; 1965). 
Plasma catecholamines provide a view of "global" sympathetic 
activity (Goldstein, 1981), but they do not provide information on 
regional tone. A further limitation is that plasma norepinephrine 
reflects both "spillover" rate from sympathetic nerve endings and 
clearance rate from plasma (Esler et al, 1981). Hence, some caution 
must be exercised in equating plasma norepinephrine with sympathetic 
tone. 
The sympathetic nervous system plays little part in determining 
normal myocardial function in the basal state (Braunwald, 1979). In 
the presence of myocardial failure, however, reliance on enhanced 
sympathetic activity is indicated by intensification of heart 
failure after sympathetic blockade with guanethidine (Gaffney & 
Braunwald, 1963) or propranolol (Epstein & Braunwald, 1966). More 
recently some doubt has been cast on the supportive role of the 
sympathetic nervous system in dilated cardiomyopathy (Waagstein et 
al, 1975; Swedberg et al, 1979, 1980a, 1980b). These researchers 
report paradoxical therapeutic benefit from beta-blockade in 
patients afflicted by this disorder, but these findings have not 
been confirmed by other workers as yet. 
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The investigation described in Chapter 9 provides the first 
double-blind controlled study of the effect of beta-blockade in 
dilated cardiomyopathy. The results from this study do not support 
the Swedish viewpoint, and in that chapter I look critically at the 
Swedish data. 
Depletion of myocardial norepinephrine stores (Chidsey et al 
1965,1966) provides further evidence for abnormal adrenergic 
activity in heart failure. As a result, the heart fails to respond 
to sympathetic input with increasing heart failure. Goldstein et al 
(1975) demonstrated an impaired chronotropic response to atropine 
and baroreceptor-mediated reflexes which appears to be related to 
severity of heart disease. They observed a normal response to 
isoprenaline indicating the abnormality in sympathetic response 
results from presynaptic norepinephrine depletion, rather than a 
reduction in responsiveness of beta-receptors. In pre-terminal 
patients undergoing cardiac transplantation, however, depletion of 
beta-receptors and diminished responsiveness to clatecholamines in 
vitro has recently been reported (Bristow et al, 1982). 
Substantial changes also occur in the function of the 
adrenergic nerves which innervate peripheral blood vessels in heart 
failure. Thus, while adrenergically mediated vasoconstriction 
normally occurs in the vessels supplying the splanchnic viscera and 
kidneys during exercise (Braunwald et al, 1976), neurogenic 
vasoconstriction is even more important when cardiac output is 
seribusly limited, as in heart failure. Increased adrenergically 
mediated vasoconstriction in the limbs occurs at rest only in the 
presence of severe heart failure (Higgins et al, 1972), however even 
in milder forms of heart failure a marked sympatho—adrenal discharge 
occurs during exercise. In the presence of a limited cardiac 
output, this discharge apparently acts to maintain arterial pressure 
and aids in the perfusion of essential organs, such as the brain and 
heart, at the expense of the exercising, metabolically active 
muscles (Higgins et al, 1972). 
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This 	peripheral 	vasoconstriction 	is 	mediated 	by 
alpha-adrenergic receptors (Kramer et al, 1968). In patients with 
heart failure, blockade of these receptors with agents such as 
prazosin reduces ventricular afterload, and acute haemodynamic 
improvement associated with symptomatic improvement has been 
reported (Miller et al, 1977; Mehla et al, 1978). At least two 
centres have presented objective haemodynamic data to suggest that 
tolerance to prazosin occurs and develops rapidly (Packer et al, 
1978; Arnold et al, 1978). Furthermore, Colucci et al (1980b) 
noted an increase in plasma renin activity, with many patients 
requiring an increase in diuretic dosage. Thus activation of the 
renin-angiotensin system may be involved in the development of 
tolerance to long-term prazosin therapy. 
In the later stages of heart failure, when the levels of 
circulating catecholamines are elevated and the cardiac 
norepinephrine stores depleted, the myocardium depends to a large 
extent on greater adrenergic stimulation. Some writers have 
speculated that the heart derives Much of this stimulation, from 
circulating catecholamines, (Braunwald, 1979), but circulating 
norepinephrine is not active on heart, vessels, or metabolism until 
it reaches plasma levels of about 2,000 pg/ml (Silverberg et al, 
1978). Elevated sympathetic activity peripherally, however, 
increases vascular resistance and may present the heart with an 
excessive afterload. Recently, several selective beta-receptor 
agonists have become available (Dawson et al, 1981; Waagstein et 
al, 1979) which may provide inotropic support, without adversely 
affecting ventricular afterload. The haemodynamic, hormonal and 
electrolyte effects of acute administration of one of these new 
agents, prenalterol, are presented in Chapter 7. 
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1.6 ROLE OF ANTIDIURETIC HORMONE IN HEART FAILURE : 
1. Physiology: 
Antidiuretic hormone (ADH or arginine -vasopressin) is 
synthesised in the supraoptic and paraventricular nuclei of the 
hypothalamus. Packaged in neurosecretory granules by the 
endoplasmic reticulum, ADH is then transported along the axons 
to their bulbs in the posterior pituitary where it may be 
released into the circulation by exocytosis (Schrier & Leaf, 
1981). The role of ADH in water homeostasis has received most 
attention but it does have vasoconstrictor properties which may 
be of physiological and pathophysiological importance (Johnston 
et al, 1981). 
Release of ADH is controlled by osmotic and non-osmotic 
pathways (Schrier, Berl & Anderson, 1979): 
1. "Osmoreceptor cells" which apparently lie outside the 
blood-brain barrier sense changes in extracellular 
osmolality induced by fluid deprivation or ingestion and 
increase or decrease ADH release respectively. ADH enhances 
distal tubular water reabsorption, thus water deprivation 
decreases free water clearance, while water excess increases 
its clearance. 
2. The major non-osmotic stimuli for ADH release include 
depletion of the extra-cellular fluid and hypotension, 
however pain, fright, nausea, and hypoxia may also stimulate 
release (Robertson et al, 1977; 	Schrier et al, 1979). 
Major parasympathetic afferent pathways appear to arise from 
low-pressure atrial receptors (vagal), which perceive early 
changes in the volume of the extra-cellular fluid, and from 
high-pressure 	baroreceptors 	of the carotid sinus 
(glossopharyngeal nerve) and aortic arch (vagal) which 
probably perceive more severe derangements in volume and 
pressure. 
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2. ADH Activity in Heart Failure: 
Hyponatraemia occurs frequently in patients with heart 
failure who have a moderate water intake (Bartter, 1964). At 
present it is not clear whether persistent release of ADH which 
diminishes water clearance, or intrarenal factors account for 
this hyponatraemia. The vasoconstrictor role of ADH in heart 
failure has received scant attention. A specific inhibitor of 
the vasoactive action of ADH is now available (Seto et al, 
1980), but it has not yet been used to investigate the role of 
ADH induced direct vasoconstriction in heart failure. 
Early studies using bioassay to measure plasma ADH in 
patients with heart failure have not been definitive (Sztalowicz 
et al, 1981). Using a radioimmunoassay for ADH, these authors 
recently demonstrated higher ADH levels in heart failure 
patients when hyponatraemia and hypo-osmolarity were more 
severe. This supports the role of ADH in impaired water 
excretion in heart failure and implies that nonosmotic pathways, 
rather than osmotic pathways, provide the main stimulus for ADH 
release under these circumstances, confirming findings from 
animal studies (Anderson et al 1975,1976; Handelman et al, 
1979). What factor(s) dictate this "inappropriate" elevation in 
ADH levels is not clear, but possibilities include impaired 
inhibition of ADH release in response to atrial stretch or 
volume receptors (Greenberg et al, 1973) or parasympathetic 
stimulation from high pressure baroreceptors when "effective" 
blood volume is reduced (Schrier & Humphries, 1971). 
To date, plasma levels of ADH measured by radioimmunoassay 
have not been related to haemodynamic parameters and other 
hormonal levels. Such measurements were performed in thirteen 
patients with stable heart failure and results are presented in 
Chapter 8. The effect of diuretic therapy on ADH levels is also 
discussed, while the effect of converting enzyme inhibition is 
discussed in Chapter 6. 
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1.7 POSSIBLE ROLE OF PERIPHERAL VASOCONSTRICTION IN THE NATURAL 
HISTORY OF HEART FAILURE : 
The syndrome of heart failure is a naturally progressive 
disorder that often appears to worsen without any evidence for an 
active process within the myocardium (Cohn et al, 1981). Studies of 
cardiac mechanics have suggested that progression of heart failure 
may represent an inappropriate increase in wall tension associated 
with an enlarging chamber without concomitant increase in wall 
thickness (Strauer, 1979). Peripheral vasoconstriction may well be 
an important mechanism in the genesis of this cardiac dilatation 
(Cohn et al, 1981). Constriction of small arteries and reduced 
distensibility of large arteries increases impedance to left 
ventricular ejection and increases left ventricular end-systolic 
volume. 
Chronic heart failure can be looked upon as a vicious cycle 
initiated by a cardiac lesion that impairs cardiac performance and 
results in reduced cardiac output (see fig 6.2). This low output 
may initially be compensated by activation of neurohumoral systems, 
which eventually elevate systemic vascular resistance, in turn 
increasing resistance to ventricular outflow. For the failing 
ventricle, this further depresses ventricular performance, thereby 
completing a positive feedback loop. 
Conventional treatment often fails to significantly increase 
cardiac output or lower systemic resistance, thus the cycle outlined 
above remains intact. Diuretic therapy may accelerate the cycle by 
activating the renin-angiotensin system (see chapter 8). Blockade 
of the vasoconstrictor systems may well reverse this situation, 
thereby improving prognosis (Franciosa et al, 1981). Much research 
will be required to demonstrate this and also to find the best 
agent(s) to obtain this goal. 
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1.8 OBJECTIVES OF THIS THESIS : 
To summarise, heart failure is associated with a poor 
prognosis, and it is one of the most common causes of death in our 
society. Despite advances in other fields of cardiology, research 
has produced little impact on the morbidity and mortality of this 
serious syndrome. Evidence has been produced to show that 
neurohumoral systems are integrally involved in the pathophysiology 
and possibly with the progression of heart failure. Better therapy 
is likely to follow improved knowledge of the role of these systems 
in heart failure. 
In the studies incorporated in this thesis, I explore some 
facets of this large, and fascinating field of research. The acute 
haemodynamic, hormone and electrolye effects of blockade of the 
renin-angiotensin-aldosterone system and beta-1 adrenergic 
stimulation are discussed in Chapters 6 & 7 respectively. 	The 
current role of vasodilator and inotropic therapy in heart failure 
will be outlined at the beginning of each chapter. 	From these 
Studies, 	control data is utilised to document stability of 
haemodynamic, hormone and electrolyte measurements and their 
inter-relationships in heart failure (Chapter 8). In Chapter 9, I 
investigate the long-term effects of blocking the beta receptor of 
the sympathetic nervous system in dilated cardiomyopathy. Finally, 
in Chapter 10, I discuss the effect of withdrawal of blockade of the 
renin-angiotensin-aldosterone system. These studies contribute 
significantly to our growing fund of knowledge concerning the role 
of neurohumoral systems and applications of this knowledge in 
medical therapy are considered. 
Before describing these studies in detail, methods of patient 
selection will be outlined in the next chapter, then methods used in 
the above studies for non-invasive, haemodynamic, and hormone 
measurements are detailed in the subsequent three chapters.• 
CHAPTER 2 
PATIENT SELECTION: 
2.1 INTRODUCTION : 
Over the past decade the Cardiology and Endocrinology Departments 
of The Princess Margaret Hospital, Christchurch have had an ongoing 
interest in the investigation of the pathophysiology and management of 
heart failure. Consequently, a good rapport has been established 
between these departments and general practitioners and physicians in 
the region so that most patients developing heart failure are referred 
for diagnosis and management of their condition. The Cardiology 
Department serves the province of Canterbury, thus it services a 
population of approximately 400,000 people. 
With diverse aetiology, manifestations and multiple exacerbating 
factors, heart failure is a heterogeneous syndrome. In the studies to 
be described in this thesis, I attempted to select a relatively 
homogeneous group of patients. Patients were only selected if heart 
failure was due to left ventricular dysfunction. Definition of heart 
failure, aetiology, inclusion, and exclusion criteria are outlined in 
this chapter. Ethical considerations are then discussed. 
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2.2 DEFINITION OF HEART FAILURE: 
"Heart failure may be defined as the pathophysiological state in 
which an abnormality of cardiac function is responsible for failure of 
the heart to pump blood at a rate commensurate with the requirements of 
the metabolising tissues." 
Braunwald (1982) 
Heart failure is an imprecise term which is usually defined (as 
above) as a state in which the heart is unable to generate a cardiac 
output equal to the body's demands. Clinical manifestations are largely 
due to circulatory failure (fatigue, diminished exercise capacity, 
dyspnoea, and oedema), manifestations which may occur in other 
conditions other than primary cardiac disease (eg. 	hypovolaemia, 
anaemia, hyperviscosity, hyperthyroidism and pulmonary embolism). 	Left 
ventricular dysfunction was confirmed in all cases by non-invasive or 
invasive investigations (see Chapter 3), while other conditions were 
excluded by specific investigations. 
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2.3 AETIOLOGY OF HEART FAILURE: 
Abnormal cardiac function resulting in circulatory failure may be 
due to: 
1. Pressure overload: 	eg. 	aortic or pulmonary stenosis 	or 
hypertension. 
2. Volume overload: eg. valvular incompetence or shunts. 
3. Impaired myocardial function: eg. myocardial ischaemia/infarction, 
scarring, 	infiltrative disorders, toxic insults, primary and 
secondary cardiomyopathy. 
4. Extrinsic compression of the heart: eg. 	pericardial constriction 
or effusion. 
Prior to enrolment in the following studies, all patients underwent 
exhaustive diagnostic studies, including cardiac catheterisation and . 
coronary angiography in most patients. Thus, precise anatomical 
diagnosis was established. Impaired myocardial function was largely due 
to coronary artery disease or primary dilated cardiomyopathy, although 
hypertension contributed in some patients. When any condition in the 
first two categories is allowed to persist for long periods of time, 
secondary changes may develop in the myocardium that then contribute to 
reduced pump performance and hence to heart failure. Several patients 
were included with valvular incompetence, only when myocardial function 
was severely depressed. 
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2.4 INCLUSION CRITERIA WERE AS FOLLOWS: 
1. Presence of symptoms directly attributable to left ventricular 
failure; 
2. Absence of .a surgically correctable lesion eg. coronary artery 
disease or valvular lesion; 
3. Clinical, radiographic, and/or haemodynamic evidence of left 
ventricular failure; 
4. Absence of exacerbating factors eg. 	infection, 	anaemia, 
thyrotoxicosis, pregnancy, arrhythmias other than atrial 
fibrillation, recent myocardial infarction ( < six months), 
infection or malignant hypertension. 
2.5 EXCLUSION CRITERIA INCLUDED: 
1. Absence of symptoms attributable to myocardial failure; 
2. Unstable clinical condition; 
3. Presence of exacerbating factors; 
4. Unstable angina or myocardial infarction within the previous six 
months; 
5. Diabetes mellitus was an exclusion criteria in some studies because 
hormone responses, especially catecholamines, may be abnormal; 
6. Severe concomitant illness; 
7. Severe peripheral vascular disease where claudication limited 
exercise tolerance much more than cardiac symptoms. 
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2.6 ETHICAL CONSIDERATIONS: 
The guidelines of the Helsinki Convention for human experimentation 
were followed implicitly (18 th World Medical Assembly, Helsinki, 1964 
and subsequently - revised by the 29 th World Medical Assembly, Tokyo, 
1975). For each investigation included in this thesis, the protocol was 
perused by the physicians involved, then submitted to and approved by 
the Ethical Committee of the North Canterbury Hospital Board. Patients 
were fully informed of the techniques used in each study, possible 
dangers and were free to withdraw from the investigation at any time. 
All patients gave written consent. 
In any study involving instrumentation of patients, however 
limited, the question of ethical justification arises. Most patients 
included in the studies documented in this thesis had severe heart 
failure, having had at least one documented episode of pulmonary oedema 
and also documented severe impairment of left ventricular function. 
Invasive measurement is an important method for assessing the efficacy 
of therapy in heart failure (Braunwald, 1980b). It can be performed 
safely, so long as adequate precautions are taken. The low incidence of 
complications in the following studies would confirm this. 
CHAPTER 3 
ASSESSMENT OF THE SEVERITY OF HEART FAILURE 
AND RESPONSE TO THERAPY: 
3.1 INTRODUCTION: 
Over the last decade we have seen a rapid increase in the number of 
methods available for cardiac diagnosis. Aetiology may now be 
determined with greater accuracy, and prognosis may be forecast with 
greater certainty. The quantitative assessment of the severity of heart 
failure and underlying myocardial dysfunction remains a problem in 
clinical cardiology as no single method provides a "gold standard" to 
compare patients or their response to therapy. This is a challenging 
and important task for clinicians, thus a plethora of methods have been 
devised to suit different purposes: 
1. Clinical Assessment: Symptoms and physical findings. 
2. Invasive Methods: 
1. Haemodynamics - Pressure, flow relationships; 
2. Left ventricular force-velocity-length relationships; 
3. Quantitative Angiocardiography. 
3. Non-invasive Methods: 
1. Radionuclide Angiography; 
2. Echocardiography; 
3. Systolic Time intervals; 
4. Apex and phonocardiography; 
5. Assessment of heart size by chest radiography. 
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4. Exercise Testing: Exercise may be accurately assessed on a 
treadmill or bicycle ergometer. Useful adjuncts to this assessment 
include invasive haemodynamics measured during exercise and 
quantification of oxygen uptake, carbon dioxide production and 
anaerobic threshold. 
Quantitative 	angiocardiography 	and 	left 	ventricular 
force-velocity-length relationships require left ventricular 
catheterisation. Due to the risk of embolisation studies can only be 
performed over a short period of time, and were not suitable for the 
present studies. Systolic time intervals and phonocardiography are too 
imprecise for adequate assessment (Braunwald, 1980). 
Methods for assessing cardiac function used in this thesis will be 
detailed in this •chapter. Haemodynamic measurements will be considered 
in greater detail in the next chapter. 
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3.2 CLINICAL ASSESSMENT: 
As muscular exercise places the greatest metabolic stress on the 
heart, it is hardly surprising that the severity of heart failure may be 
assessed clinically by paying attention to exertional symptoms 
particularly dyspnoea and fatigue. The New York Heart Association 
(NYHA) Classification (1973) has been the most widely accepted, and has 
been used throughout this thesis. Patients were classified as follows: 
1. Class I: No limitation - ordinary physical activity does not cause 
undue fatigue or dyspnoea. 
2. Class II: Slight limitation of physical activity - such patients 
are comfortable at rest. Ordinary physical activity results in 
fatigue or dyspnoea. 
3. Class III: 	Marked limitation of physical activity - although 
patients are comfortable at rest, less than ordinary activity will 
lead to symptoms. 
4 • Class IV: Inability to carry on any physical activity without 
discomfort - symptoms of congestive failure are present even at 
rest. With any physical activity, increased discomfort is 
experienced. 
Physical signs of heart failure only become apparent when 
myocardial dysfunction is severe and due to their subjective nature, 
measurement is difficult, thus more precise methods are required to 
quantitatively assess the effect of medications, especially in patients 
who are less severely afflicted. 
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3.3 HAEMODYNAMIC ASSESSMENT OF LEFT VENTRICULAR FUNCTION: 
Direct measurement of haemodynamic parameters, cardiac output and 
vascular pressures, has become the time honoured method for assessing 
the severity of cardiac function and the effects of therapeutic 
intervention (Braunwald, 1980). To aid the interpretation of the 
haemodynamic studies reported in this thesis, it is useful to review 
circulatory dynamics at rest and during exercise in normal and 
pathological circumstances according to the Frank-Starling mechanism: 
1. Normal Myocardial Function: 
The normal relationship between ventricular end-diastolic 
volume and performance is shown in Fig 3.1, curve 1. Assumption of 
the upright posture reduces venous return, thus cardiac output is 
lower than in the recumbent position. During exercise, venous 
return is augmented by increased ventilation, the pumping action of 
exercising muscles and venoconstriction. Increased sympathetic 
activity simultaneously augments the contractile state of the 
myocardium and stroke volume, with either no change or a decline in 
end-diastolic pressure and volume (resulting in a shift from point A 
on curve 1 to point B on curve 2 in fig 3.1). Vasodilatation occurs 
in the exercising muscles, thus cardiac output is greatly elevated 
during exercise at an arterial pressure only slightly higher than 
that in the resting state. During intense exercise, cardiac output 
may be further augmented by utilisation of the Frank-Starling 
mechanism (B - C, fig 3.1). 
2. Impaired Myocardial Function: 
In many cases, such as those represented in curve 3 (fig 3.1), 
cardiac output and external ventricular performance at rest are 
often within normal limits, but are maintained at these levels only 
because the end-diastolic fibre length and ventricular end-diastolic 
volume are elevated. Associated elevation of the pulmonary 
capillary wedge pressure and venous congestion contribute to the 
dyspnoea experienced by patients with heart failure on exertion (D). 
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This diagram shows the inter-relationships of diastolic stretching 
of the myocardium and contractility on vetricular performance. (From 
Braunwald et al, 1976 - see text for detailed description). 
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Ventricular performance curves or contractility cannot be elevated 
to the same extent during exercise (compare curves 3 & 3', fig 3.1) 
because cardiac epinephrine stores are depleted and the inotropic 
response to impulses from the cardiac sympathetic nerves is 
diminished (see Chapter 1). Factors that tend to augment 
ventricular filling during exercise in the normal subject, push the 
failing heart along its flattened length to active tension curve. 
Although ventricular performance may be augmented somewhat, this 
occurs only as a consequence of an inordinate elevation of 
ventricular end-diastolic volume and pressure, and therefore of 
pulmonary capillary wedge pressure. This intensifies dyspnoea and 
plays an important role in limiting the level of exercise that the 
patient can perform. 
Left ventricular failure is thus characterised haemodynamically by 
elevated left ventricular filling pressure and reduced cardiac output 
(especially during exercise), which account for the pulmonary congestion 
and peripheral underperfusion. Heart rate is increased in an effort to 
maintain cardiac output, while systemic arterial pressure is usually 
supported at normal levels, despite reduced cardiac output, consequently 
systemic vascular resistance is usually elevated. Quantitative 
measurement of these parameters allows accurate assessment of the degree 
of myocardial dysfunction (Braunwald, 1980). Furthermore, invasive 
measurement of haemodynamic changes provides a useful tool for assessing 
the efficacy of therapeutic agents (Liander, 1982). Therapeutically 
induced reduction in left ventricular filling pressure and increase in 
cardiac output, is beneficial according to Frank-Starling function 
curves, and has been associated with acute symptomatic benefit and 
long-term efficacy (Braunwald, 1980). 
As with all methods of assessing cardiac function, there are 
limitations which need to be appreciated: 
1. Measurement of left ventricular performance at rest does not 
necessarily provide an accurate assessment of cardiac reserve and 
ability to perform exercise (Franciosa et al, 1979); 
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2. Left ventricular filling pressure is used as an approximation for 
left ventricular end-diastolic volume which determines stretch of 
myocardial fibres. This is a valid extrapolation in the presence of 
normal compliance, however in disease states compliance is often 
abnormal (Liander, 1982); 
3. In disease and health, cardiac output is closely controlled by 
auto-regulation (Guyton, 1981), thus resting cardiac output is only 
depressed when ventricular dysfunction is severe; 
4. Some studies have demonstrated improved exercise capacity during 
long-term therapeutic interventions that were not associated with 
significant haemodynamic changes at rest (Franciosa et al 1978, 
Rubin et al 1979). 
Despite these limitations, haemodynamic measurements remain the 
best method currently available for quantitatively assessing the degree 
of myocardial dysfunction and response to therapy, especially when 
serial measurements over several days are required. Methods for 
measurement of cardiac output, and intra-cardiac pressures will be 
outlined in detail in the next chapter. 
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3.4 RADIONUCLIDE ANGIOGRAPHY: 
1. General: 
Since Blumgart and Yens (1927) first used a radioactive tracer 
to evaluate the velocity of blood flow in man, substantial 
improvements have been made in imaging devices, isotopes and 
computer techniques. Consequently, these techniques have been 
applied to radionuclide angiographic assessment of cardiac function, 
and particularly to left ventricular function, for which ejection 
fraction (LVEF) has become the most widely used parameter. 
Studies were initially performed with a gamma-camera located at 
the Nuclear Medicine Department of The Christchurch Hospital four 
miles from the Cardiology Department situated at The Princess 
Margaret Hospital. This necessitated the transfer of patients for 
cardiac scans. To obviate this; a "Nuclear Stethoscope" (Bios 
Instruments) was purchased by the department and isotopes were 
delivered to the Department in a lead cannister prior to use. 
2. Blood Labelling: 
The need to perform counts for several minutes requires that 
the isotope remains within the circulation. In the present studies, 
in-vivo labelling of red blood cells (Pavel, Zimmer and Patterson, 
1977) was achieved by intravenous administration of 7 mg of stannous 
pyrophosphate thirty minutes before intravenous injection of 15-20 
mCi of technetium-99m sodium pertechnetate. This provided 
sufficient "tag" for studies to be performed for several hours after 
administration of the isotope if required. 
3. Principle of calculations: 
A count based technique, utilising computer-derived plots for 
changes in counts from end-diastole to end-systole against time, was 
used to calculate left ventricular ejection fraction. The major 
limitation of this technique involves appropriate correction for 
ASSESSMENT OF THE SEVERITY OF HEART FAILURE: 	 37. 
background activity arising from the lung fields, left . atrium, and 
right heart. In all studies, a small zone just lateral to the left 
ventricle was used. 
Ejection fraction was calculated by the equation: 
LVEF = End-diastolic - End-systolic counts X 100 
End-diastolic - Background counts 
• Gamma-camera studies: 
Resting studies were performed with the patient supine and 
images obtained in the modified (caudal tilt) left anterior oblique 
position using a picker Dyna camera equipped with a high-resolution 
parallel-hole collimator. Scintillation data was accumulated in 
histogram mode (64 x 64 ward mode images) in a PDP 11-34 computer 
system using the R Wave of the ECG as the synchronising impulse. 
The cardiac cycle was divided into twelve equal frames, and three 
hundred cycles were counted. 
Calculation of LVEF was performed using a commercially 
available modified Fortran Decus HRTIMG program (Decus No. 11-363, 
August 1978). This program uses an automatic stepping, automatic 
, edge finder routine after selection of an end-diastolic region of 
interest. Background was calculated from a simple level subtraction 
and was chosen from the end-systolic frame as a two pixel 
postero-lateral 90 0  crescent immediately adjacent to the 
end-systolic left ventricular border. A background corrected time 
activity curve was displayed and LVEF calculated from the formula 
given above. 
Validation studies from the Nuclear Medicine Department have 
shown: 
1. A good correlation between LVEF "rived from contrast 
angiography and radionuclide technique (r=0.84; n=23; 
p<0.0001). 
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2. Studies in normals (n=10) showed mean resting EF=62% (range 
50-73%). 
3. Mean serial variability of absolute ejection fraction in 
repeated studies on two different days: 6 + 4.3% (9 normal 
patients) and 3 + 2.4% (10 patients with coronary artery 
disease). 
5. Nuclear Stethoscope: 
The "Nuclear Stethoscope" consists of a single scintillation ' 
probe with a 2 by 1.5 inch sodium iodide crystal and a slightly 
conical collimator with an outer opening of 3 cm diameter. The 
probe is carried by an adjustable arm allowing angulation in two 
different planes. Radioactivity is sampled and displayed with a 
temporal resolution of 10 msec (ventricular function mode) or 50 
msec (beat-to-beat mode) per datum point. A dedicated microcomputer 
calculates left ventricular ejection fraction and other parameters. 
Together with the time-activity curve these data are displayed on a 
screen and could be reproduced by a Tecktronix Recorder. 
With the probe positioned over the chest in a 35 0 left anterior 
oblique position with 50 caudal tilt, the precordium was scanned in 
parallel movements from right to left and in the cranio-caudal 
direction to approximate the left ventricular position. Small 
adjustments of the initial probe angulations were made if required 
according to individual chamber localisations. Correct positioning 
was guided by a search for maximal extension of a broad horizontal 
bar (fig 3.2B). The length of this bar is proportional to the 
amplitude of the time-activity curve and inversely proportional to 
the mean count rate. 
Background activity was recorded at a position inferolateral to 
the heart, where the mean count rate is relatively low and the 
amplitude of the time-activity curve minimal, but still detectable, 
rendering also the bar length minimal (fig 3.2A). This background 
activity was coded into the computer and used for all calculations 
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of left ventricular ejection fraction. The probe was subsequently 
moved back to the left ventricular position . for recording of the 
gated time-activity curve (for two R-R intervals - Ventricular 
Function Curve). Left ventricular ejection fraction was calculated 
by moving two vertical cursors to positions corresponding to the 
end-diastolic and end-systolic count rate of the displayed mean 
time-activity (fig 3.3). 
All investigations using the Nuclear Stethoscope were performed 
by the author. To validate the technique, left ventricular ejection 
fraction was determined by Gamma Camera and Nuclear Stethoscope in 
ten patients with ischaemic heart disease. Results of this study 
show good correlation between the two methods (r=0.85, p<0.001) as 
shown in fig 3.4. These results are similar to the findings of 
Hoilund-Carson et al (1982). In another validation study, ejection 
fraction was determined on two occasions two weeks apart in another 
group of ten patients with heart failure stable on constant 
medication. Overall, mean ejection fraction was the same (22.5 + 
13.4%) on both occasions while mean variability of absolute ejection 
fraction on the two days was 4.1 + 1.6% comparing well with gamma 
camera studies. 
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FIG 3.2 
A. 
B. 
EF= 33% 
Determination of ejection fraction by "Nuclear Stethoscope": 
A. Determination of background counts (note minimum excursion 
of horizontal bar) 
B. Beat-to-beat time-activity curve at greatest excursion of 
the horizontal bar. (See text for full description). 
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FIG 3.3 
EF= 30% 
ECG 
QkS 	QkS 
This figure illustrates the "Ventricular Function Curve" recorded by 
the "Nuclear Stethoscope“. It demonstrates a two minute recording 
of the time-activity curve gated for every second RR interval. A 
more detailed description is provided in the text. 
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Comparison of radionuclide ejection fraction determined by 
gamma-camera and "Nuclear Stethoscope". 
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3.5 M-Mode Echocardiographic Assessment of Left Ventricular Function: 
This technique provides an alternative non-invasive method for 
measuring left ventricular dimensions during systole and diastole. By 
making several assumptions about ventricular shape, volume, and ejection 
fraction may be determined. It should be noted that for M-mode 
echocardiography assumptions are false when regional wall motion 
abnormalities are present thus volume and ejection fraction measurement 
is inaccurate. 
Left ventricular chamber dimension can most accurately be assessed 
by echocardiography at a level between the papillary muscles and the 
free edge of the mitral valve. To standardise the procedure, the 
transducer is placed on the chest wall in that intercostal space which 
permits recording of the mitral valve leaflet when the transducer is 
perpendicular to the chest wall. By tilting the transducer inferiorly 
and slightly laterally, characteristic left ventricular echoes are seen, 
allowing highly reproducible quantitation of ventricular dimensions 
(Popp, 1979). Assuming a uniform geometric model for the ventricle, 
theoretical ventricular volume may be calculated from the single known 
left ventricular dimension. Techniques and equipment used in assessing 
patients with dilated cardiomyopathy are described in Chapter 9. 
The technique was not used to assess left ventricular function in 
patients with ischaemic heart disease, as regional wall motion 
abnormalities are common in this condition. 
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3.6 Exercise Testing: 
Although exercise testing has commonly been used in the diagnostic 
evaluation and follow-up of patients with angina pectoris, exercise has 
only recently been employed to assess the degree of functional 
limitation in patients with heart failure. Franciosa et al (1979) have 
found that the exercise test is better able to categorise patients with 
heart failure than physical examination or resting haemodynamic 
characteristics. Although Patterson et al (1972) demonstrated good 
overall correlation between NYHA Functional Classification and treadmill 
exercise tolerance, significant differences occurred in 25% of patients 
highlighting the subjective nature of historical classification. 
Furthermore, recent studies in patients with heart failure have shown 
that physical findings, chest films, echocardiograms and resting 
haemodynamics are inconsistently altered by therapeutic interventions 
which do increase exercise capacity (Franciosa et al, 1978; Awan et al, 
1977; Aronow et al, 1977). Thus, exercise capacity has become another 
important parameter in assessing the severity of heart failure, as well 
as the response to treatment._ 
In the studies incorporated in this thesis, exercise tests were 
performed on a bicycle ergometer (Elma-Schonander Ergometer EM 369) or 
treadmill (Quinton Model 643) using various progressive, multi-stage 
protocols. These varied with each study, thus the protocol employed 
will be outlined at the appropriate time. All patients exercised until 
the onset of dyspnoea or fatigue, and no-one stopped because of chest 
pain, arrhythmia or electrocardiographic changes. While exercising, 
patients were frequently asked whether they felt too breathless or tired 
to continue. They were given reassurance and encouraged to continue as 
long as objective parameters and my assessment indicated that it was 
safe to do so. Before commencing any trial, patients underwent an 
exercise test so that they would be familiar with test procedures. 
Every attempt was made to standardise conditions for testing. The 
temperature of the study room was maintained fairly constant, and 
patients were studied at the same time of day, at least two hours after 
the last meal. 
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Franciosa et al (1979) and Patterson et al (1972) had previously 
demonstrated that maximal exercise testing could be safely carried out 
and was well tolerated in patients with heart failure. The 
electrocardiogram and heart rate were recorded continuously (Avionics 
Exer Stress Model 3000), while cuff blood pressure was measured every 
minute (Avionics "Pressurometer" Model 1905) and exercise was supervised 
by a physician throughout, usually by myself. An emergency trolley with 
defibrillator, emergency drugs and resuscitation equipment was on hand 
in case of emergency, however none arose during the exercise testing of 
patients in the following studies. 
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3.7 EVALUATION OF RESPIRATORY GAS EXCHANGE DURING EXERCISE: 
The heart and lungs constitute the fundamental elements of the 
body's oxygen transport system. The cardiovascular and respiratory 
systems are functionally integrated into a single metabolic unit, the 
cardiopulmonary unit, to transfer oxygen from the atmosphere to the 
metabolising tissues at a rate commensurate with their needs. Heart 
failure has been defined according to a defect in oxygen delivery 
relative tO the oxygen requirements of the tissues. In patients with 
severe cardiac failure, for example, such a defect may be apparent at 
rest, whereas in patients with less severe disease, the increased oxygen 
demand attendant with exercise is required to expose an abnormality in 
oxygen delivery. The aerobic capacity of the patient with cardiac 
disease will therefore be dictated by the adequacy of the cardiac 
reserve and the relationship between oxygen delivery and the prevailing 
oxygen demand. 
The severity of cardiac disease has traditionally been gauged by an 
analysis of historical information (see section 3.2) which the patient 
relates concerning the levels of exertion that are typically associated 
with the onset of breathlessness and/or fatigue. The severity of heart 
failure may be assessed more quantitatively by the response in oxygen 
delivery during exercise (Weber et al, 1982b). Thus, maximal aerobic 
capacity may be measured, and the adequacy of its measurement may be 
further enhanced by observing the onset of anaerobic metabolism (see 
below). The advent of rapidly responding gas analysers now facilitates 
the determination of these parameters during exercise. 
Measurements of expired oxygen and carbon dioxide concentration 
(Mass spectrometer Perkin-Elmer MGA 1100) and air flow (Fleisch 
pneumotachograph) were made at rest and throughout exercise, using a 
breathing apparatus consisting of a mouthpiece, nose clamp, and low 
resistance Hans-Rudolf valve. Respiratory parameters were derived from 
gas concentration, flow and appropriate conversion factors for ambient 
temperature, barometric pressure, and water vapour. 
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On a breath-by-breath basis, derivations were performed on-line by a 
Digital PD? 11-10 Computer using software similar to that developed by 
Beaver et al (1973). 
Oxygen consumption (V02 , end-tidal carbon dioxide Concentration 
(ETCO2 ) and respiratory quotient (R=Vc02/V02 ) were displayed graphically 
during exercise (fig 3.5). The onset of anaerobic metabolism is 
heralded by the rise in respiratory quotient (Weber et al, 1962b). This 
is more clearly demonstrated by the disproportionate rise in 
ventilation and carbon dioxide production relative to oxygen uptake 
(fig 3.6). This results from impaired delivery oxygen to exercising 
muscles, with conversion to anaerobic metabolism and lactate production. 
The lactate is rapidly buffered by the body's bicarbonate pool, thus 
carbon dioxide production increases. Moreover, ventillation must rise 
more rapidly to maintain eucapnia (Weber et al, 1980). In heart 
failure, the V02 to heart rate relationship is often a bnormal as stroke 
volume is reduced, thus a higher heart rate is required to maintain 
oxygen delivery, thus the oxygen pulse V 02/HR is often higher than 
normal, as seen in fig 3.6. 
1. 
2.4 
VO2 1.2 
(I/min) 
0 
52 
ETCO 
2 
(mmHg) 
20 
1.3 
R 	0.9 
0.5 
kikwiv4 
3 	6 	9 	12 	15 	18 	Max. 
Time (mins) 
ASSESSMENT OF THE SEVERITY OF HEART FAILURE: 	 48. 
FIG 3.5 
Stage 
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On-line graphical display of oxygen consumption (V02 ), end-tidal carbon 
dioxide (ETCO2 ) and respiratory quotient (R) (see text for 
discussion). 
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Relationship between oxygen consumption (V 02 ) and carbon dioxide 
production (V002 ), ventilation (VE) and heart rate. Normal values are 
those used by Jones et al (1975). The solid lines represent + standard 
deviation from the mean values at each level of oxygen consumption. 
CHAPTER it 
MEASUREMENT OF HAEMODYNAMIC PARAMETERS : 
4.1 INTRODUCTION : 
The advent of cardiac catheterisation in the last thirty to forty 
years has revolutionised clinical cardiology, improving diagnosis, 
management and understanding of the pathophysiological basis of cardiac 
disorders. With the realisation that left ventricular end diastolic 
pressure may be adequately assessed by measurement of pulmonary 
capillary wedge pressure, the development of the Swan-Ganz 
balloon-tipped catheter has enabled bedside assessment of intra-cardiac 
pressures. Positioning in the pulmonary artery eliminates the dangers 
of systemic embolisation from prolonged catheterisation of the left 
ventricle, thus allowing a patient to be monitored over a period of 
hours or days. Furthermore, the response to therapeutic manoeuvres may 
be observed. Coupled with these pressure measurements, the presence of 
a thermistor at the tip of the catheter permits the measurement of 
cardiac ouput by a thermodilution technique described below. 
The use of haemodynamics in the assessment of the severity of heart 
failure and response to therapy has already been discussed in the 
previous chapter. In this chapter, I outline methods of catheter 
insertion, intracardiac pressure and cardiac output measurements. 
Forearm plethysmography using a mercury-in-rubber strain gauge was 
utilised in the studies to be described in Chapters 6 and 7, so theory 
and methods will be discussed in section 4.6. 
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4.2 CATHETER INSERTION: 
1. Patient preparation: 
Most patients had already undergone diagnostic cardiac 
catheterisation prior to these studies, so they were familiar with 
the basic techniques. An adequate explanation of the procedure was 
satisfactory to allay fears and most patients did not require 
premedication. 
2. Technique: 
A Swan-Ganz balloon tipped, thermodilution catheter was 
inserted by Seldinger technique * via the subclavian vein on the 
non-dominant side of the body. In studies lasting several hours, 
the catheter was inserted through the median cubital vein. The 
catheter was advanced, under fluoroscopic control, to the right 
atrium where the balloon was inflated, then advanced through the 
right ventricle, and main pulmonary artery to the wedge position, 
usually in the right lower lobe artery. Pulmonary capillary wedge 
pressure was recorded, then with deflation of the balloon, the 
catheter recoiled into the main pulmonary artery where pressure was 
also recorded. In long-term studies, where the risks from distal 
migration of the tip are greater, the catheter was withdrawn into 
the main pulmonary artery if the mean pulmonary capillary wedge 
pressure and pulmonary artery end-diastolic pressure differed by 
less than 5 mm Hg (see section 4.3). The electrocardiogram was 
monitored continuously for early diagnosis of ventricular 
dysrhythmias that may be induced by passage of the catheter through 
the right ventricle. 
For measurement of arterial pressure, the non-dominant radial 
• artery was cannulated by direct puncture or the brachial artery was 
cannulated by Seldinger technique. Because the catheters remained 
in-situ for prolonged periods of time they were flushed at 
half-hourly intervals using heparinised dextrose (500m1 5% Dextrose 
and 2000 units heparin) to prevent obstruction of the lumen. 
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Standard flushing sets were used to facilitate this procedure and 
reduce the risk of infection. Despite these precautions, partial 
obstruction of the Swan-Ganz catheter lumen occurred on one occasion 
with resultant damping of pulmonary artery pressure, necessitating 
replacement of the catheter. 
3. Ethical considerations have already been considered in Chapter 2. 
HAEMODYNAMIC MEASUREMENTS 	 53. 
4.3 PRESSURE MEASUREMENT : 
1. General: 
The measurement of arterial and intracardiac pressure is an 
important facet in assessing myocardial function. Arterial pressure 
is the most easily measured index of myocardial contractile force, 
while left ventricular end-diastolic pressure is used as an index of 
end-diastolic volume or cardiac "preload". 
Pressure changes at the tip of the catheter, transmitted 
through the fluid-filled lumen displace the metal diaphragm of an 
externally placed transducer. This displacement results in a change 
of resistance, which can be measured accurately with a Wheatstone 
bridge circuit and displayed on an appropriately matched recorder. 
2. Equipment: 
Two pressure recording systems were used in the studies to be 
described: 
1. Statham P28 transducer and DR8 Multichannel Recorder (Chapter 
7); 
& 2. Two Statham P50 transducers linked to a Mennen Medical monitor 
and Yokagoma E.W. (2932) photorecorder on a mobile trolley. 
3. Zero Pressure and Positioning of Transducer: 
All intracardiac pressures were measured relative to 
atmospheric pressure. Before each recording, the transducer was 
connected to air to ensure zero pressure. Positioning of the 
transducer relative to the heart is essential as a vertical 
displacement of 1.36 cm produces an apparent variation in pressure 
of 1 mm Hg due to gravity (SG of mercury = 13.6). The mid-axillary 
line, fifth intercostal space was taken as the reference point as 
this represents the approximate position of mid left atrium. 
It should be noted that pressure inside a heart chamber need 
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not necessarily represent true transmural pressure, due to normal 
negative intrathoracic pressure which ranges between 0 and -8 mm Hg 
during normal respiration. To reduce the effect of this factor, all 
intra-cardiac pressures were measured when a breath was held at the 
end of normal expiration. 
4. Calibration: 
Known pressures were applied by means of a mercury manometer to 
the transducer producing displacement of the signal on the chart 
recorder which could be measured. Calibration was performed twice 
daily, and equipment was left turned on throughout each study day. 
5. Representative Traces: 
1. Arterial pressure: 
This tracing (fig 4.1) consists of a systolic wave, 
followed by the incisura, which denotes closure of the aortic 
valve, and then gradual fall in pressure during diastole as 
blood flows from the aorta to the capillary beds. Arterial 
pressure was measured at the peak of systole and at end 
diastole. Mean arterial pressure was determined by electronic 
integration. 
Due to resonance within the arterial system, a wider pulse 
pressure may be measured from a brachial or radial artery than 
from central aortic pressure, while mean pressure may be 
identical or up to 5 mm Hg lower than central aortic pressure 
(Barry and Grossman, 1980). During the studies to be described, 
greater emphasis is placed on temporal changes than on absolute 
values, so these effects were of no consequence. 
2. Pulmonary Artery Pressure: 
Wave forms are similar to arterial pressure tracings with 
systolic, diastolic, mean pressures measured in an identical 
- 100- • 
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fashion. Motion of the catheter within the heart and great 
vessels accelerates the fluid contained within the catheter. 
Such catheter whip artifacts can produce superimposed waves up 
to + 10 mm Hg (Barry & Grossman, 1980). They are particularly 
common in tracings from the pulmonary artery and are difficult 
to avoid. Fortunately this artifact occurred infrequently, but 
when present generally persisted unaltered for the duration of 
the study so its effects on pressure measurement were neglected, 
except that pulmonary artery wedge pressure was measured 
directly rather than assessed by measuring pulmonary artery 
end-diastolic pressure. 
3. Pulmonary Capillary Wedge Pressure: 
By inflation of the balloon at the tip of the Swan-Ganz 
catheter, the pulmonary artery within which it lies is occluded. 
Pressure at this point is similar to left atrial pressure, has a 
similar wave form but a and v waves are damped and delayed. 
Display of a representative wave form was essential (fig 4.1) 
before mean pressure was determined, again by electronic 
integration. 
Under most circumstances, pulmonary artery flow is 
diminished at end-diastole, so that end-diastolic pulmonary 
artery and mean pulmonary capillary wedge pressure are 
approximately equal. Following catheter insertion, these 
pressures were compared. If they differed by less than 5 mm Hg, 
the catheter was withdrawn into the main pulmonary artery and 
pulmonary artery end-diastolic pressure was used as an estimate 
of left atrial pressure. For longer studies, this was necessary 
to reduce the risk of prolonged catheterisation from distal 
migration of the tip which may cause pulmonary infarction or 
rupture of a pulmonary artery. 
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4. Right Atrial Pressure: 
Care was taken to record an adequate wave form (fig 4.1), 
then mean pressure was determined by electronic integration. 
6. Effect of heart rhythm : 
Atrial fibrillation commonly occurs in patients with heart 
failure. Variation in cycle length results in varying filling 
periods with consequent effects on beat-to-beat pressure. In the 
presence of atrial fibrillation, pressure measurements were made on 
as many pressure pulses as possible (greater than ten) and then 
averaged. 
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4.4 MEASUREMENT OF CARDIAC OUTPUT: 
Of the numerous techniques devised over the years to measure 
cardiac output, three have won general acceptance in cardiac 
catheterisation laboratories: thermodilution technique; Fick oxygen 
method; indicator-dilution technique. Each method requires cardiac 
catheterisation. Although several non-invasive methods have been 
developed, they do not appear to be sufficiently reliable for general 
use (Braunwald, 1980). Two methods were used in this thesis: 
1. The Thermodilution Technique: 
Of the three methods, the thermodilution technique has proved 
to be the easiest and most widely accepted method for repeated 
estimations of cardiac output. It avoids problems encountered with 
measurement of oxygen consumption and build-up of indocyanine-green 
dye. Ten mls of 5% dextrose cooled to 1-5 0C was injected through 
the right atrial port of the Swan-Ganz catheter. The temperature of 
the blood in the pulmonary artery was continuously monitored by 
means of a thermistor at the tip of the catheter. The area under 
the resulting curve (fig 4.2) was obtained by electronic 
integration, cardiac output was computed and the result rapidly 
displayed. Recordings were made in triplicate and averaged, while 
results with abnormal temperature-time curves or greater than 10% 
variation were excluded. 
2. Fick Method : 
This method is based on the theoretical principle, enunciated 
by Adolph Fick in 1870, that the total uptake or release of any 
substance by an organ is the product of blood flow to the organ and 
the arteriovenous concentration difference of the substance. For 
the lungs, the substance released to the blood is oxygen, and the 
pulmonary blood flow (cardiac output where a shunt is not present) 
can be determined by measurement of the arteriovenous differences of 
oxygen across the lungs and the oxygen consumption (ml/min). 
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FIG 4.2: MEASUREMENT OF CARDIAC OUTPUT BY THERMODILUTION. 
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Temperature at the tip of the Swan-Ganz is recorded continuously. 
Initially, electronic calibration provides a pen-deflection = -0.5 ° C. 
Following injection of 10m1 dextrose at 0-5 °C into the right atrium, 
change in temperature in the pulmonary artery was recorded. By 
measuring the area under the curve, cardiac output may be determined: 
CO= 
	VipiCi(Tb - Ti) x 0.82 x 60 
pbCb x J ADb (t)dt xK 
where, Vi = volume of injectate (m1); 	Pi = specific gravity of 
injectate; pb = specific gravity of blood; Ci = specific heat of 
injectate; Cb = specific heat of blood; Ti = initial temperature of 
injectate ( °C); Tb = initial temperature of blood ( °C); 0.82 = 
empirical correction factor for indicator loss between end and tip of 
the catheter; K = calibration factor for the curve ( °C/mm);and 
J1° ADb (t)dt = area under the curve registered following injection of the thermal indicator. 
When 10 ml of cooled 5% dextrose is used: 
CO= 
	534.6(Tb - Ti ) 
Area under curve x K 
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Cardiac output is determined from the following formula: 
Cardiac output = oxygen consumption 
 
AV oxygen concentration difference 
4.5 INDICIES DERIVED FROM FLOW AND PRESSURE MEASUREMENTS : 
1. Cardiac Index (CI) = CO/BSA (1/min/m 2 ); 
2. Stroke Index (SI) = Cl/HR (ml/bt/m2 ); 
3. Stroke Work Index (SW1) = SI(MAP - RAP)x0.0136 (gal/m 2 ); 
4. Systemic 	Vascular 	Resistance 	(SVR) 	= 	80(MAP - RAP)/C0 
(dyne-sec-cm-5 ); 
5. Pulmonary Vascular Resistance 	(PVR) 	80(MPA - LVFP)/C0 
(dyne-sec-cm-5 ); 
6. Work Product = HR x SAP. 
Where CO = cardiac output, BSA = body surface area, HR = heart 
rate, MAP = mean arterial pressure, RAP = right atrial pressure, MPA = 
mean pulmonary artery pressure, LVFP = left ventricular filling 
pressure, SAP = systolic arterial pressure. 
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4.6 FOREARM PLETHYSMOGRAPHY : 
1. General: 
The measurement of volume changes in the limbs or in the 
portion of the limbs of man has been recognised as a valuable 
research tool since the beginning of the century (Hewlett & Van 
Zwaluwenburg, 1909). Volume plethysmography with venous occlusion 
became the standard method of estimating peripheral blood flow in 
man. This method, however, is cumbersome, time consuming, requires 
complete immobility and has many sources of error (Lansdowne & Katz, 
1942). 
In 1953, Whitney (1953) described a technique for the precise 
measurement of changes in girth with a mercury-in-rubber resistance 
strain gauge. The principle of this gauge is the effect of 
extension of a small bore rubber tube on the resistance of a mercury 
thread completely filling the bore of the tube. In the .following 
paragraphs I will outline the theoretical and practical aspects of 
this technique, which was used in two studies. 
2. The Technique: 
A cuff is applied around the upper arm and inflated to 40 mm 
Hg. Arterial inflow is not affected, but venous return is blocked, 
thus the forearm increases by a volume equivalent to arterial 
inflow. The circulation to the hand is occluded by a cuff at the 
wrist which is inflated to 200 mm Hg one minute prior to inflation 
of the proximal cuff. 
The proximal cuff which is 4 cm wide is connected by a short 
large bore tube to a pneumatic unit which contains a high rate 
compressor with two large buffers which allows for extremely rapid 
cuff inflation, thus avoiding blood leakage from the very start of 
venous occlusion. The mercury-filled strain gauges have a 0.6 mm 
external diameter and a bore of 0.3 mm. They are very elastic, with 
as little as 200 mg force causing a 1% elongation. Their internal 
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electrical resistance varies in a linear fashion with elongation to 
50% of the initial value. Changes in resistance and hence length 
can be measured accurately using a Wheatstone Bridge. Calibration 
of the strain gauge is independent of initial elongation and 
performed electronically to produce a pen deflection of 8 V/V = 1% 
(see fig 4.4). 
3. Theoretical Aspects: 
The percentage change in volume is related to the percentage 
change in girth if the following assumptions are made: 
1. The length of the limb remains unaltered during volume changes; 
2. The transverse sectional shape remains unaltered during volume 
changes; 
3. The volume change is small when compared with the initial 
volume. 
It is not necessary to assume that the arm is circular but the 
mathematics of the relationship between girth, area and volume 
changes are easier to demonstrate (fig 4.3). More complex 
mathematics summing narrow triangular elements (Whitney, 1953) show 
that the relationship holds true for ellipses if assumption 3 is 
correct. 
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FIG 4.3: RELATIONSHIP BETWEEN GIRTH, AREA, AND VOLUME CHANGES: 
r = radius 
G = girth 
A = area 
V = volume 
 
G = 2ir r 
AG = 2 ir r' - 2 ir r 
AG r' - r 	Ar = 	 1 
A = TT r 2 
A' = 7 r' 2 
▪ • AA 2 , r - r2 	r2 + 2rAr+Ar2 - r 2 
A r2 r 2 
• 2rAr+A r2  
r 2 
When A r is small compared to r and using equation 1: 
AA 2 A r 2& 2 
A G 
Taking assumption 1 and using equation 2: 
Ay _ 2G 
V - G 
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4. Forearm Blood Flow Measurements: 
A representative recording is shown in fig 4.4. 	The initial 
calibration pulse provides 6L1,1/V = 1%. After establishing a stable 
baseline the proximal cuff was inflated to 40 mm Hg. Initially 
arterial inflow is not affected, but venous return is blocked. Thus 
the limb segment increases by a volume equivalent to arterial 
inflow, which can be calculated from the slope of the asymptote and 
has the units of ml/min/100g of tissue. As the venous pressure 
rises, blood flow declines and limb segment volume forms a plateau. 
With rapid deflation of the proximal cuff, maximum venous outflow 
may be calculated in a similar manner to arterial flow. Recorded 
values represent the mean of five determinations with less than 10% 
variation taken at least three minutes apart. 
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FIG 4.4: 	FOREARM BLOOD FLOW MEASUREMENTS: 
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CHAPTER 5 
HORMONE ASSAYS AND METABOLIC BALANCE: 
5.1 GENERAL: 
Hormone assays are essential for the diagnosis and management of 
most endocrine disorders. Until the last decade, only a limited range 
of hormone assays was widely available. With the advent of improved 
techniques, especially radio-immunoassay, a large number of hormones may 
now be assayed, these methods being simpler, cheaper and more sensitive 
than previous methods. Research has blossomed into poorly understood 
hormone systems - their physiological and clinical relevance. 
Elucidation of the role of the renin-angiotensin-aldosterone system, 
circulating catecholamines and antidiuretic hormone in heart failure is 
no exception. 
Correlation of hormonal with haemodynamic indices in heart failure 
under control conditions and following therapeutic intervention forms 
the basis of three studies reported in this thesis. In this chapter, I 
outline assay techniques for each hormone measured. Detailed discussion 
of the relative merits of different assays, however, is beyond the scope 
of this thesis. 
Many biological variables influence hormone levels (table 5.1), 
thus conditions under which the studies reported in Chapters 6 to 8 were 
carefully controlled. Patients remained at rest, in the semi-supine 
position throughout the period of investigation, with constant sodium 
and potassium intake, and with free water intake. Blood samples were 
drawn in the fasting state (0830) and at other times of the day, these 
times being held constant so that direct comparisons could be made. 
Apart from the medication under investigation, all other drug therapy 
was constant throughout the study, administered at the same time each 
day and minimised to reduce hormone inter-reactions. Meals were served 
at the same time each day as digestion has definite haemodynamic and 
metabolic consequences (Grollman, 1929). 
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TABLE 5.1 : SOME FACTORS AFFECTING HORMONE LEVELS : 
Biological variable Hormones affected 
Body Posture RAAS, Catecholamines, ADH 
Stress Cortisol, Catecholamines 
Circadian rhythm Cortisol, Aldosterone, Renin 
Dietary Na and K HAAS, Catecholamines 
Drugs Many 
Fasting Metabolic hormones 
Hydration Antidiuretic hormone 
RAAS = renin-angiotensin-aldosterone system 
The assays were developed in the Department of Endocrinology and 
have been used clinically and experimentally for many years. Normal 
values in healthy volunteers on unrestricted diets are given in Table 
5.2. Quality control was checked by the biochemist Dr. Yandle (Ph.D.) 
and at two weekly intervals by Prof. 	Espiner and Dr. 	Nicholls 
(endocrinologists). 
Many hormones (eg. angiotensin, ADH, catecholamines) are unstable 
in blood. For this reason, blood samples were drawn into appropriate 
chilled tubes, carried on ice to a cold room, and centrifuged 
immediately. The plasma was then frozen and stored at an appropriate 
temperature within 30 minutes of sampling. To avoid inter-assay 
variation, all samples for each patient were stored and assayed 
together. 
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5.2 PLASMA ANGIOTENSIN II: (Nicholls & Espiner, 1976) 
Blood samples were drawn into chilled tubes containing an inhibitor 
solution of 0-phenathroline, EDTA.and neomycin to prevent enzymatic and 
bacterial breakdown of angiotensin II. They were then centrifuged and 
stored in a manner already described. 
Following initial thawing, denaturation and precipitation of 
protein by ethanol to remove interference with angiotensin binding, the 
supernatants were dried and analysed using a radioimmunoassay technique. 
Optimal amounts of anti-serum and labelled (1 125 ) angiotensin had 
previously been determined to produce 50% binding when no "cold" 
angiotensin II was present. The anti-serum used did not significantly 
cross-react with angiotensin I, but did exhibit 100% cross-reactivity 
with the hexa and heptapeptide breakdown products of angiotensin II. 
Once antiserum and tracer were added, samples were incubated at 4 °C for 
24 hours. The AB-AG complex was then separated from free angiotensin II 
by addition of dextran-coated charcoal solution. After centrifugation, 
the supernatant was discarded and counts from the charcoal deposit were 
measured in a scintillation counter. 
A standard curve (fig 5.1) was constructed from concurrently run 
analyses of known concentrations of pure angiotensin II (Beckman Ltd.) 
diluted in human serum albumen. Sensitivity was enhanced by adjusting 
antiserum and tracer quantities to place expected plasma angiotensin II 
levels on the steep portion of the standard curve. The lower limit of 
detection was around It - 5 pmo1/1 (with some variation between assays). 
Excessively high samples were diluted and analyses repeated. When 
antiserum was not present, non-specific binding of tracer averaged 3%. 
The interassay coefficient of variation for the assay was in the range 
of 8 - 15% while intra-assay variation amounted to 6 - 12%. These were 
slightly variable over time, but quite acceptable. 
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Legend for Figure 5.1: 
I 125-AII + AS ' 	 I 125-AII-AB 
In the absence of "cold" angiotensin II (All), 
binding of I 125-AII tracer ("hot" All) was 
predetermined to be approximately 50%. Adding known 
amounts of "cold" All reduced the binding of tracer to 
the antibody (AB), the standard curve could be 
constructed with the aid of a computer. Unknown 
plasma All levels could then be determined by 
measuring the reduction in tracer binding. Accuracy 
was maintained by use of the steep portion of the 
curve and computer-aided transformation of the curve 
to a straight line. 
* Values for binding at each known concentration 
of' 
All (measured in duplicate). 
Represents the working range of the curve. 
Represents the 95% confidence limits for 
duplicate measurements. 
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FIG 5.1: STANDARD CURVE FOR ANGIOTENSIN II RADIOIMMUNOASSAY 
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5.3 PLASMA RENIN ACTIVITY: (Dunn & Espiner, 1976) 
Blood samples were collected into tubes containing EDTA, 
centrifuged and stored as already outlined. Storage at -20 °C did not 
effect enzymatic activity. Samples were subsequently thawed and 
proteolytic enzyme inhibitors (dimercaprol and hydroxyquinoline) added 
to prevent breakdown of angiotensin I. Neomycin was added to the buffer 
to prevent bacterial degradation, and pH was set at 7.4. Samples were 
incubated for three hours in a water bath at 37 0C in duplicate, and also 
at 4°C for determination of baseline levels of angiotensin I. It should 
be noted at this point that the pH for the 37 °C incubation step remains 
controversial, with many laboratories using a pH of 5 - 6 when enzymatic 
activity is greatest. However, a pH of this range is considered by some 
to be non-physiological. The important point is that the pH chosen was 
adhered to throughout, and in our laboratories pH was buffered to 7.4. 
Angiotensin I contents in both the 37 °C and 4°C incubation tubes 
were measured by a radioimmunoassay technique using a specific antibody 
to angiotensin I. This technique is similar to that used for 
angiotensin II, with a standard curve produced in an identical fashion. 
Plasma renin activity, as estimated by the amount of angiotensin I 
generated in a given time, was the mean of the difference in 
angiotensin I between the tubes incubated at 37 0C and the tube at 4 °C. 
Wide variation in plasma renin activity between different plasma samples 
was often encountered, so dilutions of 1:3 and 1:8 were incubated and 
assayed simultaneously to allow use of the optimum portion of the 
standard curve. Occasionally very high levels of plasma renin activity 
were encountered requiring greater dilution and reassay on a subsequent 
day. Plasma renin activity not only depends on renin content, but also 
the presence of substrate (angiotensinogen) which is present in excess 
in most patients except those with hepatic failure or those with 
exceedingly high renin levels. 
Intra- and interassay variation was 6.8% and 8.9% respectively. 
For higher levels inaccuracy was probably greater. 
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5.4 PLASMA ALDOSTERONE: (Lunn et al, 1983) 
Plasma aldosterone was measured by a direct radioimmunoassay 
. technique using a highly specific antiserum (St. Bartholomew's 
Hospital, London) exhibiting very low cross-reactivity with other 
steroids. 100 gl of plasma was mixed with optimal amounts of antiserum, 
buffer and I 125-histamine-aldosterone. Following incubation at 4 °C for 
20 to 48 hours, free aldosterone was separated from the AB:AG complex by 
the addition of dextran coated charcoal buffer and centrifugation. 
Percentage binding of tracer was calculated, thus plasma aldosterone 
could be determined from a concurrently derived standard curve 
constructed from known amounts of pure aldosterone diluted in charcoal 
stripped plasma. 
The assay is sensitive with a good intra- and interassay 
coefficient of variation (8% and 10% respectively). The lower limit of 
detection is 10 pmo1/1, which is well below the normal range of 140 - 
550 pmo1/1. 
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5.5 URINE ALDOSTERONE EXCRETION: (Nicholls et al, 1974) 
Aldosterone is excreted in three main forms: 
1. free aldosterone (0.2%); 
2. aldosterone-18-glucuronide (15%); 
3. tetrahydroaldosterone (40%); 
while the remaining forms cannot be detected by current techniques. As 
it is difficult to measure quantitatively the amount of 
tetrahydroaldosterone excreted in the urine, the method used in these 
studies quantified aldosterone liberated from the acid-labile conjugate 
(aldosterone-18-glucuronide) by hydrolysis at pH 1. Preliminary 
extraction procedures included the removal of other steroids with 
methylene dichloride (as they are less polar), and removal of bile salts 
with sodium hydroxide. Further separation was then performed by paper 
chromatography. 
Radioimmunoassay was performed using predetermined amounts of 
antiserum (kindly donated by the National Institute of Health, Bethesda 
Maryland, USA) and I 125-labelled aldosterone. Following incubation at 
4°C overnight, free and bound aldosterone were separated by the addition 
of saturated ammonium sulphate followed by centrifugation. Percentage 
binding of tracer was determined for unknown samples as well as for 
concurrently run known amounts of aldosterone. From the standard curve, 
recovery factor and total volume of urine collected, aldosterone 
excretion per 24 hours could be calculated. The test is sensitive, and 
has an interassay variation of 10% and intra-assay variation of 8% at 
high values (100 Mmol/day) and 12% at low values (5 mmol/day). 
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5.6 PLASMA AND URINE CORTISOL: 
Plasma and urine cortisol levels were measured by a direct 
radioimmunoassay method using antiserum highly specific for cortisol 
while exhibiting low cross-reactivity with other steroids (Diagnostic 
Products Corp). 25 pl of plasma were mixed with optimal amounts of 
antiserum, and I 125-labelled cortisol, then incubated at 37 0C for 45 
minutes. Urines were handled in a similar fashion, except that an 
initial extraction stage was added. 500 pl of urine were mixed with 
dichloroethane, centrifuged, then the supernatant was removed. 
Following evaporation, a calibrator fluid containing no cortisol was 
used to dissolve cortisol remaining in the tubes. 
After incubation with antiserum and labelled cortisol, free and 
bound cortisol were separated by addition of an antibody specific for 
the cortisol antiserum, and centrifugation. Percentage binding of the 
tracer was calculated for unknown samples along with concurrently run 
known samples. From the standard curve, unknown concentrations of 
plasma and urine cortisol could be determined. 
For plasma cortisol, the lower limit of detection was 17 nmo1/1, 
which is well below the normal range (110-830 nmo1/1). Intra- and 
interassay variation was less than 4% and 8% respectively. 
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5.7 PLASMA CATECHOLAMINES: (Peuler & Johnson, 1977) 
Plasma norepinephrine and epinephrine were measured simultaneously 
using a radioenzymatic method. Thawed plasma (50 Ill) was incubated for 
one hour (37 °C) with catechol-o-methyl transferase 	(rat 	liver 
extraction, harvested locally) and tritiated-S adenosyl-L methionine 
(purchased from New England Nuclear Company). During incubation, 
norepinephrine is converted to H 3-normetanephrine, while epinephrine is 
converted to H3-metanephrine. 	After several extraction steps using 
toluene and acetic acid, thin layer chromatography was performed (using 
an automatic multispotter) to separate the labelled normetanephrine and 
metanephrine. The site of these two products on the chromatography 
plates was then distinguished by ultra-violet light. The spots thus 
separated were removed from the plate and counted overnight in a 
scintillation counter. Counts from the sample are compared with counts 
from a blank, and a sample plus standard (100pg norepinephrine and 
epinephrine) which have undergone all steps of the method. 
Catecholamine concentration is determined by the following formula: 
Catechol. 	CPM(sample) - CPM(blank) 	100pg(standard) 
, X 	 Conc. 	CPM(sample + standard) - CPM(sample) 	sample volume (ml) 
(pg/ml) 
NB: (CPM = count per minute) 
The assay is sensitive to a lower limit of approximately 25 pg/ml 
of epinephrine and norepinephrine, and exhibits 7 - 10% interassay 
variation. Very little crossover in the assay occurs between 
epinephrine and norepinephrine, however metabolites of isoprenaline and 
alpha methyl DOPA may interfere with the assay. Prenalterol added to 
plasma did not interfere with the assay. 
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5.8 Plasma Antidiuretic Hormone (ADH): (Saddler et al, 1983) 
A sensitive assay for plasma ADH has recently been developed in the 
Department of Endocrinology (Sadler et al, 1983). For each sample, 5 ml 
of blood was drawn into tubes containing EDTA, centrifuged immediately 
at 4°C and plasma stored at -60 °C until extraction and assay. 
ADH was extracted 	from 	plasma 	by 	adsorption 	onto 
octadecasilyl-silica, then eluted with acetonitrile, acetic acid, dried 
under a stream of air at 37 °C, then reconstituted in assay buffer. 
Radioimmunoassay for ADH was performed with buffer set at pH 7.4 and at 
4°C. Standards consisted of nine doubling dilutions of synthetic ADH 
covering the range 0.1 to 32 pg. Duplicate aliquots (300 gl) of 
standards and triplicate aliquots of reconstituted plasma extracts were 
taken for assay. Samples were first incubated with specific rabbit 
antiserum (raised locally) for 48 hours. 1 125 labelled ADH (100 gl) and 
normal rabbit serum (1 gl) were added to all tubes and incubated for a 
further 24 hours. Antibody bound and free hormone were separated by the 
addition of donkey anti-rabbit gamma-globulin (Wellcome, UK) incubated 
for 20 hours, then centrifuged. Precipitates were counted for 1 125 
activity and plasma ADH concentrations were calculated using a four 
parameter logistic function to represent the standard dose-response 
relationship. 
The specificity of the hormone assay was good, with very low 
cross-reactivity with structurally similar hormones: 	oxytocin, 
angiotensin I and II, but greater with synthetic analogues: 	lycine 
vasopressin and glypressin. 	Intra-assay variation was 8%, while 
interassay variation amounted to 11%. 
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5.9: METABOLIC BALANCE 
The aim of the dietary measures undertaken in the studies to be 
described, was to maintain a known, constant intake of sodium and 
potassium during the period of study. To minimise variations in the 
electrolyte content of the food, the projected requirements for each 
study was purchased in bulk and deep frozen, to allow the same stock to 
be used throughout. Following consultation with the patient concerning 
dietary preferences, a provisional diet sheet was prepared detailing the 
food items, their weight and estimated sodium and potassium content. A 
day's intake of food (including drinks) was pooled in a bucket, mixed 
with two to three litres of distilled water, and homogenised. From 
this, an aliquot of homogenate was taken for the determination of sodium 
and potassium concentration by flame photometry. Where necessary, 
adjustments to the diet regime were made if the measured electrolyte 
content differed significantly from that calculated by the dietician. 
On a few occasions, repeat analysis of the adjusted diet was made 
because of discrepancy between the initial calculated and analysed 
electrolyte figures. 
For each 24 hour period of metabolic balance, the daily allowance 
of each food item was accurately weighed out. Cooking was carried out 
for a set time interval in the same amount of distilled water each day 
thus avoiding changes in electrolyte loss with cooking from day to day. 
Any food not eaten from one meal was retained and presented again with a 
subsequent meal on the same day, often in another form. If food was not 
eaten by the end of the 24 hour period, it was returned to the diet 
kitchen for weighing and estimation of electrolyte content. 
Fortunately, this was not a common occurrence. Despite the fact that 
the food presented to each patient was the same from one day to the 
next, patient acceptance was, in general, very good and few problems 
were encountered. 
Urine was collected daily for estimation of sodium and potassium 
excretion. Thus, I was able to compare input and output of these 
electrolytes each day. Patients were deemed to be in "positive" balance 
if output was less than input for the measured interval, and vice versa 
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for "negative" balance. There are minor inaccuracies in estimating 
cumulative electrolyte balance from measurements of urine excretion 
alone, since small losses also occur in sweat and faeces, unless 
diarrhoea or excess sweating occurs. 
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TABLE 5.2: NORMAL LABORATORY VALUES: 
PLASMA 
Plasma renin activity 	0.15 - 2.7 nmol/l/hr 
Angiotensin II 	20 - 80 pg/ml (pmo1/1) 
Aldosterone 140 - 550 pmo1/1 
Norepinephrine 	100 - 800 pg/1 
Epinephrine 30 - 180 pg/ml 
Cortisol 110 - 830 nmo1/1 
ADH 	0.75 - 14.3 pmo1/1 
24 HR URINE: 
Aldosterone 	10 - 60 nmol/day 
Cortisol 100 - 500 nmol/day 
NB. These ranges relate to values in normal healthy volunteers on 
unrestricted diets. 
CHAPTER 6 
ACUTE HAEMODYNAMIC, HORMONAL, AND ELECTROLYTE EFFECTS 
AND SHORT-TERM CLINICAL RESPONSE TO ENALAPRIL IN HEART FAILURE : 
6.1 INTRODUCTION: 
Oral angiotensin converting enzyme inhibitors have added a new 
dimension to long-term vasodilator therapy for heart failure (Hamer, 
1982). Captopril, the only currently available oral angiotensin 
converting enzyme inhibitor, has been associated with . potentially 
serious complications (Vidt, Brava, and Fouad 1982). Thus its use has 
been limited to those patients resistant to conventional therapy, in 
whom it has proved most effective (Maslowski et al, 1981a; Dzau et al, 
1980). Enalapril (MK421) is a member of a new group of angiotensin 
converting enzyme inhibitors which lack mercapto function incriminated 
in the side-effects of captopril (Patchett .et al, 1980). Preliminary 
data suggest that it is as effective and longer acting than captopril in 
hypertension (Gavras et al, 1981), and so far serious side-effects have 
not been encountered. 
To date enalapril has not been assessed in heart failure. 	The 
purpose of this study was to document the haemodynamic, hormonal and 
electrolyte effects in patients with stable heart failure, and thereby 
evaluate the role of the renin-angiotensin-aldosterone system in this 
condition. Before discussing this study, it is pertinent to review the 
current role of vasodilator therapy in heart failure. 
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6.2 ROLE OF VASODILATOR THERAPY IN MANAGEMENT OF HEART FAILURE: 
One of the major advances resulting Crom (and increasing . our 
understanding of) haemodynamic studies and cardiac muscle mechanics is 
the concept of "afterload reduction" in heart failure (Zelis et al, 
1979). Cohn et al (1963) demonstrated an increase in cardiac output in 
patients with heart failure who were treated with ant ihypertensive 
drugs. This response was initially attributed to the prevalent notion 
that the failing heart was operating on a descending limb of its 
Frank-Starling curve so that a reduction in filling pressure would 
increase cardiac output. Subsequently it became increasingly apparent 
that a descending limb of the Starling Curve probably did not exist 
except in the pre-terminal phase of severe heart failure. 
Left ventricular outflow resistance, or impedance (or afterload), 
has been well known to physiologists as an important determinant of 
ventricular performance (Imperial, Levy, & Zieske, 1961; Sonnenblick & 
Downing, 1963). The normal heart maintains stroke volume relatively 
constant over a wide range of changes in resistance to outflow, but the 
failing ventricle becomes very sensitive to outflow resistance, such 
that an inverse relationship exists between stroke work and outflow 
resistance (fig 6.1). Reducing the increased outflow resistance in 
heart failure will increase cardiac output and this has been associated 
with symptomatic improvement (Franciosa, 1981). 
Chronic heart failure can be looked on as a vicious cycle initiated 
by a cardiac lesion that impairs cardiac performance and results in 
reduced cardiac output (fig 6.2 taken from Franciosa, 1981). This low 
output may be initially compensated by activation of the sympathetic 
nervous system and renin-angiotensin-aldosterone system, 	which 
ultimately elevates systemic vascular resistance. 	This further 
depresses ventricular performance, thereby completing a positive 
feedback loop. Conventional therapy often fails to significantly raise 
cardiac output or lower systemic resistance, in fact it may enhance 
vascular resistance (see Chapter 8), thus perpetuating the cycle. 
Agents that interrupt this cycle present a new therapeutic approach, 
NORMAL 
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FIG 6.1 EFFECT OF AFTERLOAD ON CARDIAC FUNCTION: 
LEFT VENTRICULAR OUTFLOW RESISTANCE 
This graph shows the relationship of left ventricular stroke work to the 
outflow resistance in the normal and failing ventricle. 	CHF 
congestive heart failure (from Franciosa, 1981). 
FIG 6.2: VICIOUS CYCLE OF HEART FAILURE: (From Franciosa, 1981) 
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many agents available in an oral form having been investigated. These 
include: 
1. Direct vasodilators; eg. nitrates, hydrallazine 
2. Alpha-adrenergic blockers; eg. prazosin 
3. Beta-2 adrenergic agonists; eg. pirbuterol 
4. Converting enzyme inhibitors; eg. captopril, enalapril. 
There is little doubt that initial clinical improvement occurs in 
severely afflicted patients. There has, however, been some 
disappointment with the lack of sustained response in some patients, 
while others require an increase in diuretic dosage (Colucci et al, 
1980a). With long-term prazosin therapy, plasma renin activity and 
plasma norepinephrine levels were increased (Colucci et al, 1980a; Cohn 
et al, 1978). From these findings, the researchers concluded that 
tolerance to vasodilator therapy results from enhanced sympathetic tone 
and activation of the renin-angiotensin-aldosterone system. Several 
researchers have found that the maximum arteriovenous oxygen difference 
during exercise is diminished suggesting that flow is directed away from 
exercising muscle (Moskowitz, Kinney & Zelis, 1978) thereby contributing 
to enhanced sympathetic tone in orderto maintain blood flow to the 
exercising muscle. A rebound deterioration in condition occurs after 
withdrawal of most vasodilators due to the unopposed activation of these 
neurohumoral systems while on treatment. This phenomenon was not 
observed following withdrawal of long-term converting enzyme inhibition 
for four days (Maslowski et al, 1981b) and may be interpreted as showing 
lack of sustained effect. Deterioration in clinical and haemodynamic 
parameters did occur over one month (see Chapter 10) suggesting that 
four days was insufficient time for deterioration to occur. As 
discussed in Chapter 10, the vasodilator action of converting enzyme 
inhibitors does not appear to be opposed by activation of other 
neurohumoral systems. 
Converting enzyme inhibitors appear to be emerging as the 
vasodilator of choice. They block the renin-angiotensin-aldosterone 
system which is thought to contribute most to the increased afterload in 
heart failure, especially in those patients on diuretic therapy who are 
sodium depleted relative to their effective blood volume (see Chapter 
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8). The predominant mechanism of action of converting enzyme inhibitors 
appears to be vasodilatation resulting from a reduction of plasma 
angiotensin II levels, while blockade of diuretic-induced 
hyperaldosteronism (Chapter 8) appears to be an added advantage for long 
term therapy. In the study reported in this chapter, I investigate the 
acute haemodynamic, hormonal and electrolyte effects along with the 
short-term clinical response to enalapril in nine patients in heart 
failure. 
ENALAPRIL IN HEART FAILURE: 	 84. 
6.3 METHODS: 
1. Patients: 
Clinical details of the nine patients are summarised in Table 
6.1. Vasodilators were withdrawn at least four days prior to the 
study, but digoxin (0.125 - 0.25mg/day) therapy was continued in 
unchanged dose throughout. Frusemide (table 6.2) was stopped four 
days before the study in three patients, while the other six were 
maintained on a constant dose during the in-patient period. 
TABLE 6.1: 	CLINICAL DETAILS: 
Patient Age Sex Aetiology Previous Vasodilators 
1 57 M DCM Nil 
2 58 M IUD Prazosin 
3 62 M DCM Nil 
4 59 M IHD Nil 
5 48 M IHD Prazosin 
6 70 M DCM Prazosin, Nitrates 
7 48 M IHD Isosorbide Nitrate 
8 61 M IHD Prazosin 
9 66 F IHD Prazosin 
41, 
DCM = dilated cardiomyopathy; IHD 	ischaemic heart disease. 
Diuretic therapy, NYHA Functional class, and LVEF are listed in 
Table 6.2. 
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FIG 6.3: 	STUDY PROTOCOL: 
Day 0 1 2 3 4 5 
Insert 
Catheters 
(1600) 
CONTROL PERIOD 
ENALAPRIL (0900) 
5mg . 10mg 20mg 
Haemodynamics 
& Hormones 
A 1 	B B A A 
24hr Urine 
Collection 
Electrolytes 
i i 	i 
+ Hormones 
i 
Diet 	. Constant Na 100mmol/day K 60mmol/day 
I 	I 	I 	I 
A = 0830, 1130, 1530hrs 
B = 0830, 1000, 1100, 1300, 1500, 1700, 1900, 2100hrs 
Catheters were inserted at 1600 hr on the day prior to commencing the 
study. The study consisted of a two day control period followed by 
three days of incremental daily doses of enalapril given at 0900 hr. 
Haemodynamic and hormonal measurements were made three times (A) on days 
1, 4, and 5 and eight times (B) on days 2 and 3. Dietary sodium and 
potassium were held constant throughout, while daily urine collections 
were stored on ice for electrolyte, aldosterone, and cortisol excretion. 
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2. Study Protocol: 
• The protocol was approved by the Hospital's Ethical . Committee, 
and all patients gave informed written consent. A dose finding 
study was performed on patient 1. In his case, enalapril was 
administered once daily (0900 hr) in increasing doses of 1.25, 2.5, 
5 and 20mg. For the remaining eight patients, the protocol (fig 
6.3) entailed a control period of two days followed by three days of 
incremental enalapril administration - 5, 10 and 20mg given at 0900 
hrs on days 3, 4 and 5 respectively. Throughout the study and for 
two days prior to its initiation, each patient received a diet of 
constant sodium (91 - 116 mmol/day) and potassium (54 - 67 mmol/day) 
content. Meals were served at 0915 hr, 1215 hr and 1815 hr. All 
urine was collected on ice for electrolyte and hormone analysis. 
The patients remained semi-supine throughout. On the afternoon 
prior to day 1, a triple lumen Swan-Ganz catheter was placed in the 
pulmonary artery for right heart pressure and cardiac output 
measurements (see Chapter 4), and a brachial -artery cannula was 
inserted for pressure recordings and blood sampling for hormone 
analysis. 
In order to provide detailed information of first-dose effects, 
simultaneous haemodynamic and hormone recordings were carried out 
eight times on the first day of enalapril (5mg) treatment (fig 6.3), 
and for comparison at identical times on the preceding control 
(pre-enalapril) day. On all other study days, these measurements 
were performed at 0830 hr, 1130 hr and 1530 hr. Plasma was drawn at 
0830 hr daily for sodium and potassium measurements (flame 
photometry), while plasma ADH levels were measured at 1130 hr daily. 
Digoxin and frusemide (in six patients) were taker: immediately after 
the 0830 hr recordings. 
In three patients, intra-arterial pressure and heart rate were 
measured continuously on the first day of enalapril treatment and 
for comparison on the preceding (control) day using a transducer 
unit, along with the ECG signal from chest leads, on a Medilog Mark 
1 miniaturised tape recorder (Oxford Medical Systems - Millar-Craig, 
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Hawes, & Whittington 1978b). 	After visual editing of the tapes, 
digital hourly means for arterial pressure and heart rate were 
obtained. 
After completion of the in-patient protocol, the subjects were 
discharged from hospital receiving enalapril 5 or 10 mg once or 
twice daily (table 6.2). Before the invasive study and again four 
to eight weeks after its completion (during continued enalapril 
therapy), patients were assessed by physical examination, New York 
Heart Association (NYHA) Functional Classification, maximum exercise 
capacity ("Naughton protocol" - Patterson et al, 1972) and resting 
technetium cardiac scan. 
3. Statistics: 
Repeated measures analyses of variance were performed for all 
variables. For indices exhibiting significant variation between 
days, further comparisons using t-tests with appropriate mean square 
error terms from analysis of variance were performed to determine 
when these changes occurred. Students t-test for paired samples was 
used to evaluate the chronic (four to eight weeks) effects of 
enalapril. Results are presented as mean + standard error of mean 
(SEM). 
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6.4 RESULTS: 
1. General: 
All but one patient (g 2) completed the acute protocol. 	This 
patient developed staphylococcus aureus septicaemia from a 
contaminated catheter on the final day, which responded rapidly to 
antibiotic therapy. His results are included in data analysis for 
the first dose effect of enalapril, and also for follow up since 
enalapril was reintroduced without complications. The pattern of 
hormone and haemodynamic response was similar in patients who 
continued frusemide treatment to those in whom diuretics had been 
withdrawn, thus all results have been combined. 
2. Dose-finding study in Patient 1: 
The effects of four different doses of' emalapril on plasma 
renin activity and mean arterial pressure in patient 1 are shown in 
fig 6.4. It should be noted that chronic frusemide therapy (40 mg 
daily) was stopped four days before the study in this patient. From 
his data and preliminary data in hypertensives, a starting dose of 5 
mg was selected. Results of hormone and haemodynamic measurements 
made in this patient are not considered further, but his follow-up 
data wereanalysed along with the data from the other patients. 
3. Hormone Response: 
Angiotensin II levels were lower two hours after 5 mg of 
enalapril than at the same time (1100 hr) on the previous control 
day (58 + 16 pmo1/1 compared to 81 + 23 pmo1/1, p<C).05). A nadir of 
29 pmo1/1 occurred ten hours after the drug was administered, and 
remained 23 pmo1/1 below matching control levels at 24 hours 
(p<0.05). A reciprocal rise- in plasma remin activity occurred, 
becoming significant four hours after 5mg of enalapril; reaching a 
peak which was four-fold higher than the time-matched control levels 
at six hours; then declining toward control values at twelve and 
twenty-four hours. Plasma aldosterone levels were not altered, but 
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it is noteworthy that baseline plasma aldosterone concentrations 
(360 + 52 pmo1/1 at 0830 hr - thirty minutes before enalapril 
administration) were not elevated. Plasma norepinephrine levels 
four to twelve hours after enalapril tended to be lower than at the 
same time on the preceding control day, but only at eight hours was 
the difference statistically different (494 + 58 pg/ml compared to 
753 + 198 pg/ml, p<0.01). Epinephrine and cortisol levels were not 
altered by enalapril. 
Incremental doses of enalapril produced similar dose-related 
decrements in plasma angiotensin II and increments in plasma renin 
activity when 2.5 and 6.5 hour results were combined and also when 
24 hour post-dose results were considered (fig 6.6). Although 
similar patterns were observed for plasma aldosterone and 
norepinephrine, the changes were not statistically significant. 
Presentation of data in this form was necessary as the duration of 
effect of the drug appeared to be greater than 24 hours, thus a 
baseline was not re-established before the next dose was 
administered. 
Plasma ADH levels measured at 1130 hr on the two control days 
varied between 0.7 and 15.2 pmo1/1, which is similar to the range 
(0.8 to 14.3 pmo1/1) observed in normal laboratory volunteers 
(Saddler et al, 1983). Enalapril treatment was associated with an 
overall decline in plasma ADH levels (see fig 6.12). Although both 
ADH and angiotensin II levels fell during the study, there was no 
relationship between them for the group as a whole (r = -0.03, n = 
32), whilst in individual patients the correlations were variably 
positive or negative. There was, however, a positive and 
statistically significant association between concurrent ADH and 
plasma sodium concentrations (r = 0.45, n = 37, p<0.02). 
Enalapril 
Dose (mg) 5 	20 
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FIGURE 6.4: 	DOSE RESPONSE STUDY IN PATIENT 1: 
10—" 
5 
This graph compares the peak effects on plasma renin activity and mean 
arterial pressure following administration of incremental doses of 
enalapril (1.25, 2.5, 5, and 20 mg) to patient 1. Recordings made at 
1530 hr each day are subtracted from the mean 1530 hr value for the two 
control days. 
FIG 6.5: HORMONE RESPONSE TO FIRST DOSE OF ENALAPRIL: 
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0 	4 	8 	12 24 
Time (hours) 
Plasma hormone levels (mean + SEM) in eight patients with heart failure 
on the control day (closed symbols) and after 5 mg of enalapril (open 
symbols) which was administered at 0900 hr after 0830 recordings on the 
second day. 
* p<0.05, t p<0.01, t p<0.005. 
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FIG 6.6: HORMONAL RESPONSE TO INCREMENTAL DOSES OF ENALAPRIL: 
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Hormone responses to daily increases in enalapril dose in seven patients 
with heart failure (mean • SEM). Values at 2.5 and 6.5 hrs after 
enalapril (open symbols) are combined and compared with time-matched 
levels from two control days (closed symbols)on the right half of the 
figure. On the left, results 24 hrs after enalapril (0830 hr) are 
compared with time matched data on two control days. 
* p<0.05, t p<0.01, t p<0.005. 
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4 • Haemodynamic Response: 
Cardiac index was not altered significantly by the first dose 
of enalapril, but heart rate declined (fig 6.7) with a consequent 
rise in stroke index. Systemic vascular resistance and mean 
arterial pressure were significantly reduced after four hours and 
remained below control-day values until the eighth to twelfth hour 
(fig 6.7). Pulmonary artery end-diastolic pressure and mean 
pulmonary artery pressure also fell, the peak effect occurring at 
six to eight hours. All haemodynamic indices had returned to 
control-day values 24 hours after the first dose of enalapril (fig 
6.7). 
Results of hourly mean values for arterial pressure and heart 
rate recorded in three patients on the second control day and for 24 
hours after enalapril administration are shown in fig 6.8. Both 
parameters were similar in the first two hours of each day, 
confirming steady state conditions. The decline in arterial 
pressure and heart rate was not obvious until the fourth hour after 
administration of enalapril. The greatest differences between the 
two days were 26 mm Hg for systolic pressure and 21 mm Hg for 
diastolic pressure recorded during the seventh hour post enalapril, 
while heart rate was 8 to 11 beats/minute slower. From the 
fifteenth hour, heart rate on the two days was indistinguishable 
from control levels, while arterial pressure remained lower, but 
within 5 mm Hg of control day levels. 
Analysis of incremental dose data showed that cardiac index and 
stroke index increased in a dose-related fashion when results 2.5 
and 6.5 hours after the drug were combined, although this pattern 
was less obvious 24 hours after the drug (fig 6.9). Heart rate, 
mean arterial pressure, systemic vascular resistance and right heart 
pressure showed clear-cut decrements 2.5 to 6.5 hours after 
enalapril, but again the effects were less evident at 24 hours. 
Forearm plethysmography (fig 6.10) demonstrated no significant rise 
in forearm arterial blood flow, although maximum venous flow 
increased slightly. 
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Haemodynamic indices (mean + SEM) on a control day (closed symbols) 
and the following day after 5mg enalapril (open symbols) in eight 
patients with heart failure. After baseline recordings at 0830 hr 
enalapril was given at 0900 hr. 
-0. -0- -0- -0- -43. 
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FIG 6.8: CONTINUOUS RECORDING OF ARTERIAL PRESSURE AND HEART RATE: 
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Legend for fig 6.9 
Haemodynamic responses to increasing doses of 
enalapril in seven patients with heart failure (mean + 
SEM). Results obtained 2.5 and 6.5 hr after enalapril 
(open symbols) 	are combined and compared with 
time-matched levels from two control days 	(closed 
symbols) on the right half of the figure. On the left, 
results 24 hours after enalapril (0830 hr) are compared 
with time-matched values on two control days (closed 
symbols). 
*p<0.05, t p<0.01, p<0.005. 
PAP denotes mean pulmonary arterial pressure. 
PAEDP denotes pulmonary artery end-diastolic 
pressure. 
SVR denotes systemic vascular resistance. 
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FIG 6.9: HAEMODYNAMIC RESPONSE TO INCREMENTAL DOSES OF ENALAPRIL. 
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FIG 6.10: FOREARM BLOOD FLOW: 
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5. Relationships between hormone and haemodynamic responses: 
The degree of activation of the renin-angiotensin system and 
the sympathetic nervous system on control days predicted 
haemodynamic responses to the first dose of enalapril. Thus, 
baseline levels of angiotensin II (mean of 0830 hr measurements on 
days 2 and 3) correlated with maximum increases in stroke index 
(r=0.73) and decreases in systemic vascular resistance (r=-0.83), 
pulmonary artery end-diastolic pressure (r=-0.83), and mean 
pulmonary artery pressure (r=-0.80; p<0.05 to <0.001). Likewise, 
baseline norepinephrine levels were related to the rise in stroke 
index (r=0.69) and the fall in pulmonary artery end-diastolic 
pressure (r=-0.80) and mean pulmonary artery pressure (r=-0.78; 
p<0.05 to <0.01). Comparison of the magnitude of change in hormone 
levels with changes in haemodynamic data was compromised by the 
small number of patients included in the study. 
• 6. Twenty-four hour urine and metabolic data: (fig 6.11) 
Endogenous creatinine clearance tended to increase when 
enalapril treatment was initiated (fig 6.11), but this was not 
significant. Urine sodium excretion was close to intake on the 
control days, but declined during the three days of enalapril 
treatment, when cumulative balance was positive by an average of 21 
mmol/day/patient. A similar trend was seen for potassium, with a 
positive cumulative balance averaging 15 mmol/day/patient. Plasma 
potassium rose from a baseline of 3.57 + 0.17 mmo1/1 to 3.80 + 0.12 
mmo1/1 on the third day of treatment (p<0.01), while initial and 
final plasma sodium levels were similar. Weight and plasma glucose 
levels were unaffected. Urine aldosterone fell in a stepwise 
fashion from 17 + 4 nmol/day and 23 + 4 nmol/day (on control days 1 
& 2) to 10 + 2 nmol/day on the third day of treatment (p<0.01). 
200 
Urinary Na 150 
Excretion 
fmmolJday 100 
//A 7 
50 
UrimmyK 80 
Excretion 
MmmaldaW 6 
//////) 
136 
-134 
Plasma Na 
-132 
130 
[3.8 
Plasma K 
3.6 (mmol/l) 
3.4 
40 
e — 
A 
100 
Creatinine 
Clearance 80 
ImUminl 
Weight (kg) 
60 
75 
61 
70
5 
 
60 
25 
20 
15 
10 
5 
0 
     
          
Urine 
Aldosterone 
Excretion 
htmolidayl 
     
     
 
/ 
  
        
  
1/////) 
     
          
          
.1•1, 
ENALAPRIL IN HEART FAILURE: 
FIG 6.11: METABOLIC EFFECTS OF ENALAPRIL: 
Enalaprd 
I 5rng 110mg120ingl 
99. 
1 	2 3 
Days 
4 - 5 
• Metabolic effects of incremental doses of enalapril compared with 
the two control days. Horizontal dashed lines for plasma ADH and urine 
aldosterone represent the mean of the two control days and for urine 
sodium and potassium excretion the horizontal dashed lines represent the 
mean daily intake (mean + SEM; * p<0.05; t p<0.01; t p<0.005). 
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7. Follow-up data: 
. Clinical assessment: 
After four to eight weeks of enalapril treatment, the NYHA 
functional status had improved by two classes in one patient, 
one class in five patients, while two remained unchanged in 
Class II (table 6.2). 	Clinical parameters of heart failure 
improved in all Class III and IV patients. 	Reintroduction of 
frusemide was required on clinical grounds in two of the three 
patients in whom it was initially withdrawn, but the dose 
required was reduced (table 6.2). In the group of six whose 
frusemide was not withdrawn, the dose at follow-up was decreased 
in two, increased in one and unchanged in two, while one patient 
was stable without frusemide (table 6.2). 
2. Treadmill Exercise Performance: (table 6.2) 
Overall, there was no significant improvement in exercise 
performance, however, patients who were originally more severely 
limited increased their exercise capacity, while less severely 
afflicted individuals showed little change or a slight 
deterioration (fig 6.12). Patient 4 developed intermittent calf 
claudication after enalapril therapy was commenced, which 
curtailed his exercise performance. No significant alteration 
in maximum heart rate, systolic blood pressure or their product 
was observed. 
3. Radionuclide ejection fraction: (table 6.2) 
There was no overall significant improvement in ejection 
fraction, although it increased in six patients. The change in 
exercise performance correlated with the change in ejection 
fraction (r= 0.81; p<0.05) (fig 6.13). 
100. 
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TABLE 6.2: FOLLOW-UP DATA: 
Patient NYHA Class 
. 	.. 
Radionuclide 
LVEF(%) 
Exercise 
Capacity(mins) 
Frusemide 
(mg/day) 
Enalapril 
Dose 
. . 
Pre Post Pre Post Pre Post Pre Post (mg/day) 
1 II II 25 23 - - 40t 0 
2 III II 31 39 16.5 17.5 160t 40 10 
3 II II - - 9.0 12.0 40t 20 20 
4* II II 11 12 26.0 21.7 40 0 20 
5 III II 13 15 - - 80 20 20 
6* IV III 24 28 2.5 6.8 250 500 10 
7* III II 26 36 22.3 21.5 250 250 20 
8 III II 8 6 24.5 18.1 500 500 10 
' 	9# IV II 15 30 0.9 8.3 250 120 10 
i 
Mean 3.0 2.1 19.1 23.6 14.5 15.1 179 161 
SEM 3.2 4.5 4.3 2.6 53 73 _ 
P <0.05 0.05<p<0.1 NS NS 
1 . 
Results are shown before enalapril (Pre), and at follow-up four to 
eight weeks after commencing enalapril (Post). * This patient developed 
claudication during follow-up treadmill exercise testing. NS denotes 
not statistically significant. t = frusemide withdrawn four days before 
invasive.study in these patients. t = LVEF determined "Nuclear 
Stethoscope". 
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FIG 6.12: 
Effect of enalapril on exercise tolerance, 	compared with _ 
pre-treatment exercise tolerance. 
FIG 6.13: 
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Relationships between change of ejection fraction and exercise 
capacity produced by enalapril in six patients. 
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4 • Side effects: 
No serious side effects occurred during the trial period, 
but one patient did develop claudication during follow-up 
exercise testing. No patient developed abnormalities in routine 
blood screen, or SMAC 11 analysis, while proteinuria was not 
encountered. 
8. Relationships between initial response and follow-up data: 
Due to small numbers and biological variability, analysis can 
at best be descriptive. The patients could be subdivided into two 
distinct groups according to prior activation of the 
renin-angiotensin-aldosterone system: 
A. Initial plasma renin activity < 1 nmo1/1/hr; 
and B. Initial plasma renin activity > 1 nmo1/1/hr. 
Patients in the second group, not surprisingly, had higher initial 
plasma levels of angiotensin II, urine aldosterone excretion, 
pulmonary artery end-diastolic pressure, systemic vascular 
resistance and frusemide dose. They were also more severely 
impaired according to NYHA Functional Class. 
Enalapril produced a greater rise in plasma renin in group B, 
while plasma angiotensin II and urinary aldosterone excretion fell 
to a greater extent. This was associated with a better haemodynamic 
response, greater improvement in functional state and exercise 
capacity in two patients. On the other hand, the dose of frusemide 
could be reduced more readily in group A patients following 
completion of the study. 
ENALAPRIL IN HEART FAILURE: 	 105. 
6.5 DISCUSSION: 
Angiotensin converting enzyme inhibition has brought a new 
dimension to the management of cardiac failure. Captopril, the only 
currently available oral converting enzyme inhibitor has proved most 
effective in patients who are resistant to conventional therapy 
(Maslowski et al, 1981a; Dzau et al, 1982). Although side effects are 
not common with captopril, potentially serious complications have been 
reported (Vidt et al, 1982). Enalapril (MK-421), a member of a new 
group of converting enzyme inhibitors which lacks a mercapto function 
and is characterised by weak chelating properties, has recently been 
synthesized (Patchett et al, 1980) and used successfully in hypertension 
(Gavras et al, 1981). Preliminary data suggest it is as effective and 
longer acting than captopril in hypertension, and so far serious side 
effects have not been observed. In this study the hormonal, 
haemodynamic and electrolyte response to enalapril in patients with 
cardiac failure are documented. 
A dose finding study was performed in patient 1. Doses of 2.5 and 
5 mg produced moderate rises in plasma renin activity and fall in mean 
arterial pressure. As preliminary studies in hypertension suggested 
that a starting dose of 5 mg was effective (Gavras et al, 1981), this 
dose was chosen for the present study. 
The data show that enalapril induces clearcut changes in 
angiotensin II, plasma renin activity and urine aldosterone excretion. 
Whilst plasma angiotensin II and urine aldosterone excretion declined, 
there was a reciprocal rise in plasma renin activity resulting from loss 
of tonic inhibition of secretion by angiotensin II. These effects are 
similar to those reported with captopril (Maslowski et al, 1981a; Dzau 
et al, 1980). However, onset of action and the nadir were delayed 
compared to captopril (Ader et al, 1980), and the decline in plasma 
angiotensin II was sustained for 24 hours after a 5mg dose - in contrast 
to the shorter duration of action of captopril in heart failure 
(Nicholls et al, 1982). This observation raises the possibility that 
enalapril might be effective when administered once or at most, twice 
daily. For some indices, the magnitude of change was greater with 10 
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and 20 mg of enalapril than with 5 mg, suggesting that the larger doses 
may be optimal. 
It may appear surprising that plasma aldosterone levels did not 
fall after the first dose of enalapril, especially since our group 
reported the dominant role of angiotensin II in regulating aldosterone 
in heart failure (Nicholls et al, 1981). However, baseline levels of 
plasma aldosterone were not elevated in most of our patients, in 
contrast to those studied prior to the initiation of captopril treatment 
(Maslowski et al, 1981a). The dependence of aldosterone secretion on 
angiotensin II presumably relates to the degree of activation of the 
renin-angiotensin-aldosterone system. Where this is relatively minor, 
as in the present study, blockade of angiotensin II formation might not 
necessarily result in an acute decline in aldosterone. Nevertheless, 
aldosterone excretion fell during the three days of incremental 
enalapril treatment, and a similar (though less impressive) decline in 
plasma aldosterone was observed. In this study, aldosterone secretion 
was regulated in part by angiotensin II, but the primacy of the 
renin-angibtensin system was less obvious than in patients with extreme 
activation of this system. 
Plasma ADH levels prior to enalapril were within our normal range 
for healthy ambulatory volunteers, but decreased gradually during the 
five day study. The regulation of circulating ADH is multifactorial and 
complex (Robertson, 1977). Although the fall in angiotensin II levels 
may have contributed to the observed change (Sladek & Joynt, 1979), the 
lack of statistical correlation either in individuals or in the group as 
a whole tends to mitigate against a cause and effect relationship. 
Instead of a fall in ADH secretion, it is possible that its clearance 
rate increased. ADH is predaminantly cleared by kidney and liver 
(Janacky et al, 1982), thus improved flow to these organs could well 
have increased clearance from plasma. 
The results from this study show objective haemodynamic improvement 
during acute enalapril therapy. The elevated systemic vascular 
resistance was reduced as a consequence of the decline in circulating 
angiotensin II, and perhaps also in part to sympathetic withdrawal as 
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indicated by the fall in circulating norepinephrine levels and reduction 
in heart rate. Unmeasured factors such as bradykinin and prostaglandins 
may also have contributed to the pattern of observed haemodynamic 
changes. Cardiac index increased during the study, while right heart 
pressures declined, presumably as a result of improved left ventricular 
performance but perhaps due in part to a decline in cardiac pre-load. 
The nadir of the haemodynamic response occurred approximately six 
to eight hours after the first dose and corresponded to the nadir of 
hormone changes. The smooth temporal profile may be of practical 
importance where a sudden fall in arterial pressure produced by drugs•
with a faster onset of action (eg captopril) could be hazardous, 
especially in patients with a compromised cerebral or coronary 
circulation (Baker et al, 1980). Despite significantly lower levels of 
plasma angiotensin II 24 hours after the first dose of enalapril, 
haemodynamic indices were not significantly different from baseline 
recordings. Continuous monitoring in three patients (fig 6.8) showed 
that arterial pressure was lower at 24 hours but the differences were 
much less than at peak effect. Greater cumulative effect 24 hours after 
a further 10 mg dose of enalapril showed lower plasma angiotensin II 
levels and systemic vascular resistance, while cardiac index was higher 
(fig 6.6 and 6.9), suggesting that the duration of effect of the drug is 
greater than 24 hours. 
The multiple factors responsible for the excessive vasoconstriction 
characteristic of chronic congestive heart failure include enhanced 
sympathetic nervous activity, activation of the renin-angiotensin system 
and disturbed reactivity of the vessel wall (Zelis et al, 1979). The 
vasoconstriction of chronic heart failure occurs differentially in the 
various regional circulatory beds (Mason et al, 1970). Limb 
plethysmography has failed to show vasodilatation of arteries or veins 
with teprotide (Faxon et al, 1980). Captopril did not affect muscle 
blood flow, but increased limb venous capacitance indirectly, presumably 
as a result of reduced sympathetic tone (Faxon et al, 1981). It appears 
from this study, that enalapril also has little effect on resting limb 
flow in heart failure. The enhanced cardiac output must be selectively 
re-distributed to other regional beds, but, this does not imply that 
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muscle perfusion during exercise is not improved. 
The most striking haemodynamic improvement was observed in subjects - 
in whom activation of the renin-angiotensin-aldosterone system and 
sympathetic nervous system was most intense. These patients were on 
higher doses of frusemide and were subjectively and objectively more 
severely impaired. Moreover, these patients had the greatest 
improvement of symptoms and exercise capacity on enalapril. While 
patients with less activation of the renin-angiotensin-aldosterone 
system had a less marked hormonal, haemodynamic and exercise response, 
the dose of diuretics could be reduced without complication on 
completion of the follow-up protocol. Enalapril diminished the exercise 
capacity in some patients who were initially only mildly impaired. This 
may, in part, be due to withdrawal or reduction in diuretic therapy. 
One patient developed claudication on enalapril, presumably due to 
reduced blood flow resulting from a reduced perfusion pressure across 
fixed stenoses of lower limb arteries. Such ischaemic events appear to 
occur rarely with converting enzyme inhibitors (Romankiewicz et al, 
1983). No other serious side-effects were observed. 
As with captopril (Maslowski et al, 1981a), a positive cumulative 
potassium balance and a rise in plasma potassium were seen, and 
presumably resulted from reduced aldosterone effect. Thus plasma 
potassium needs to be monitored when enalapril treatment is initiated. 
During the first three days of enalapril treatment, a positive 
cumulative sodium balance was also observed. This appears to be of 
little consequence in the longer term since frusemide requirements were 
reduced or unchanged in all but one patient after four to eight weeks of 
treatment. 
Divergent findings and considerable inter individual variation in 
the effects of captopril on renal blood flow and indices of renal 
function have been observed in heart failure patients. Within one to 
two hours of acute captopril administration (50 to 100 mg), mean 
arterial pressure declined, while renal blood flow increased 50 to 60% 
but glomerular filtration rate remained constant (Creager et al, 1981). 
These changes were associated with a two-fold increase in urinary sodium 
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excretion and potassium retention. 	In contrast, completely opposite 
acute effects were observed by Mujais et al (1981), but all parameters 
returned to baseline values after two days of captopril therapy. 
Pierpoint et al (1981) demonstrated similar detrimental effects on renal 
function after three days of captopril therapy and showed an inverse 
relationship between the change in blood pressure and changes in sodium 
excretion suggesting that acute effects were due to reduced perfusion 
pressure. Our data on the use of enalapril is compatible with the 
latter view although we did not assess the effect on renal 
haemodynamics. On the other hand, these acute effects appear to be of 
little long term consequence since frusemide requirements were reduced 
or unchanged in all but one patient after four to eight weeks of 
treatment. However, it should be noted that Dicarlo et al (1982) have 
recently found that an increase in diuretic therapy was required 
following long term therapy with enalapril. The long term effects of 
enalapril on renal function will thus require further investigation. 
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6.6 CONCLUSION: 
Enalapril is a long-acting converting enzyme inhibitor which 
induces clear-cut haemodynamic improvement in patients with heart 
failure. Because of its long duration of action and delayed onset, 
hypotension is more gradual in onset than the only currently available 
converting enzyme inhibitor, captopril. This should reduce acute 
ischaemic complications that occur occasionally with captopril. The 
drug will probably be effective when given once or at most twice daily, 
thus it will probably replace captopril, especially as there appear to 
be less side-effects with enalapril. 
The magnitude of haemodynamic improvement is related closely to 
pre-treatment activity of the renin-angiotensin-aldosterone system and 
sympathetic nervous system. Chronic therapy is well tolerated with no 
major side-effects apart from the development of calf claudication in 
one patient. Clinical condition improved in most patients while 
exercise performance improved in those patients who were initially 
severely afflicted. Short-term studies such as this one, however, do 
not allow extrapolation to long-term effects or changes in mortality. 
Such studies are warranted. 
CHAPTER 7 
HAEMODYNAMIC, HORMONAL AND ELECTROLYTE EFFECTS OF PRENALTEROL 
INFUSION IN HEART FAILURE : 
7.1 INTRODUCTION: 
It would be rational to concentrate therapeutic endeavours on the 
primary pathophysiological abnormality in cardiac failure - diminished 
myocardial contractility. However, there has been no major advance in 
chronic inotropic treatment for heart failure since the introduction of 
digitalis, and even now the place of this agent for patients . in sinus 
rhythm remains uncertain (Selzer, 1981). Several potentially useful 
agents have been investigated (Slutsky 1981, Lejemetel et al 1979, 
Dawson et al 1981). 
Reports that a selective beta-1 agonist, prenalterol, improves 
myocardial function in patients with heart failure are encouraging, 
especially as the drug may be effective when given by mouth (Waagstein 
et al, 1979). At present, available data relate largely to its 
administration over a period of minutes only and there is a dearth of 
dose/response information. Moreover, the effects of the drug on 
neurohumoral systems and electrolytes have received scant attention. 
The present study documents haemodynamic, hormonal and electrolyte 
changes during three days of an incremental prenalterol infusion in six 
patients with cardiac failure. 
Before describing the study in detail, it is pertinent to briefly 
review the place of inotropic therapy in chronic heart failure. 
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7.2 	THE ROLE OF INOTROPIC THERAPY IN CHRONIC HEART FAILURE: 
As I outlined in Chapter 1, the aim of treatment of chronic cardiac 
failure is to correct and reverse the pathological sequence that led to 
the development of the clinical syndrome. This entails: 
1. Improving myocardial contractility; 
2. Reducing the workload of the heart by restriction of physical 
activity and vasodilators; 
3. Reducing salt and water retention. 
At the turn of the century, there was great enthusiasm for finding 
effective inotropic agents (Coupland 1897, Yoo 1906). Today the search 
continues. Digitalis is the only inotropic agent currently recognised 
as effective in the long-term management of chronic heart failure. Even 
now, the place of this agent for patients in sinus rhythm remains 
uncertain (Selzer, 1981). Symptoms of cardiac failure often persist 
despite digitalis and diuretic therapy. Consequently, the pharmaceutical 
industry has invested considerable effort in developing new inotropic 
agents (Table 7.1). Some potent cardiotonic agents such as dobutamine, 
dopamine and amrinone will augment cardiac performance in patients 
refractory to standard treatment (Leier et al, 1977; Benotti et al, 
1978), thus they may improve the outlook of such patients. 
Inotropic agents act directly on the failing myocardium to augment 
its contractile state and improve pump function (Weber, 1982a). 
Systemic blood flow is augmented and apportioned to each organ according 
to the autoregulatory behaviour of its vascular bed. Thus, oxygen 
delivery to the metabolising tissues is enhanced while ventricular 
filling pressure and organ congestion decline. 
At the cellular level, contractility is governed by the quantity of 
calcium ion released at the actomyosin junction (Fabiato A & S, 1977). 
Inotropic agents with a recognised mechanism of action augment 
myocardial contractility by increasing the amount of calcium ion 
available to the contractile proteins. Cardiac glycosides inhibit the 
sodium pump of the sarcolemma, thereby allowing intracellular 
accumulation of sodium which displaces bound calcium ions (Opie, 1980). 
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Sympathomimetic agents (Table 7.1) bind reversibly to beta-adrenergic 
receptors on the cardiac cell surface, activate adenyl cyclase thereby 
raising intracellular cyclic AMP production. Glucagon and xanthines 
have the capacity to increase intra- cellular cyclic AMP without 
involving the beta-receptor. The elevation of the intracellular 
concentration of cyclic AMP may increase the number of active or open 
sarcolemmal calcium ion channels, thereby increasing the intra-cellular 
concentration of this ion (Weber, 1982a). The mechanism by which the 
bipyridine derivative amrinone augments myocardial contractile state 
remains unknown (Aloussi et al, 1979). 
Investigations of the role of these new inotropic agents in chronic 
heart failure, however, are preliminary at present. Some major 
questions remain to be answered: 
1. Is the inotropic effect sustained in the long-term? 
2. Will the chronic increment in contractility prove harmful to the 
failing heart by increasing the oxygen requirements of the 
myocardium? 
3. Sympathomimetic agents often precipitate ventricular arrhythmias in 
low output syndromes due to myocardial infarction (Opie, 1980). 
Will they do the same in heart failure? 
4. What are the effects of these agents on neurohumoral systems, 
suspected to play a part in the development of tolerance to other 
forms of therapy? 
These questions, with particular reference to prenalterol, will be 
addressed in the discussion to the following investigation. 
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TABLE 7.1 INOTROPIC AGENTS AND THEIR MODE OF ACTION: 
1. Calcium 
2. Digitalis Glycosides 	Na-K ATPase inhibition 
3. Sympathomimetics: 
a. Intravenous 
Norepinephrine 
Isoprenaline 	B l stimulation increases 
Epinephrine intracellular Cyclic AMP 
Dopamine 
Dobutamine 
b. Oral 
Prenalterol 	B l stimulation 
Butopamine 
Pirbuterol 	B2 & (?) B l stimulation 
Salbutamol 
4. Xanthines (eg theophylline) 	Phosphodiesterase inhibition 
increases cyclic AMP 
5. Glucagon 	Increases cyclic AMP 
6. Amrinone 
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7.2 METHODS : 
1. Patients and study protocol: 
The protocol was approved by the hospital's Ethical Committee, 
and all patients gave informed written consent. 
Clinical details of the six patients are summarized in Table 
7.2. All had suffered at least one episode of pulmonary oedema, but 
had responded to routine treatment. At the time of entrance to the 
study, their therapy (Table 7.2) had remained unchanged for at least 
three months. Patient 1 was also being treated with perhexilene and 
disopyramide which were withdrawn one week prior to the study. 
TABLE 7.2: 	PRETREATMENT PATIENT CHARACTERISTICS: 
Patient Age 
(yr) 
Sex NYHA 
Class 
LVEF 
* 
Aetiology Drug therapy 	, 
(mg/day) 
..., 
I
-
 (NJ
 In
 
 
60 M III 14% IHD D(0.25),F(120),P(2) 
54 M II 22% DCM D(0.25),F(80) 
53 M II 28% DCM D(0.25),F(120),HD(50) 
58 M II 13% DCM D(0.5),F(80),P(10) 
60 M III 23% IHD D(0.25),F(200),P(20),T(100) 
46 M II 17% DCM D(0.25),F(40),HD(100) 
, 
* = measured by single plane angiography 
DCM = dilated cardiomyopathy 
IHD = ischaemic heart disease 
D = digoxin 	F = frusemide 
P = prazosin HD = hydrallazine 
T = triamterene 
PRENALTEROL IN HEART FAILURE: 
Legend for Figure 7.1: 
Catheters were inserted at 1600 hr on the day prior 
to commencing the study, which entailed a two day 
"run-in" period, followed by three days of incremental 
infusion of prenalterol, then a two day "run-out" 
period. Haemodynamic and hormonal measurements were 
made twice daily at 0830 and 1530 hrs. Dietary sodium 
and potassium were held constant throughout. Daily 
collections of urine were stored on ice for electrolyte 
and hormone excretion. 
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FIGURE 7.1: 	STUDY PROTOCOL 
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2. Study Protocol: 
The seven day protocol, summarised in fig 7.1, entailed a two day 
"run-in" period, three days of incremental prenalterol infusion, and two 
"run-out" days after the termination of prenalterol therapy. Throughout 
the seven days each patient received a diet of constant sodium 
(38 - 45 mmol/day), potassium (51 - 67 mmol/day), and carbohydrate 
content. All urine obtained by means of an indwelling bladder catheter, 
was retained as 24 hour collections on ice for electrolyte and hormone 
analysis. The patients remained semi-supine throughout. Blood sampling 
for hormone and electrolyte measurements, and haemodynamic recordings 
were carried out twice daily at 0830 hours (fasting) and 1530 hours. 
Digoxin and diuretics were administered immediately after the 0830 hr 
recordings, whilst vasodilator therapy was given after the 0830 hr and 
1530 hr recordings. The dose of these medications remained constant for 
each patient. 
3. Prenalterol Administration: 
The drug was diluted in a 5% dextrose-in-water solution, and 
infused intravenously in an incremental fashion at 60,120 and 240 
nmol/minute, each rate for 24 hours, beginning at 0900 hr. The dextrose 
solution was administered at 10 ml/hr throughout using an IVAC pump. 
During "run-in" and "run-out" days, 5% dextrose was infused at the same 
rate (10 ml/hr) through the right atrial port of the Swan-Ganz catheter. 
Patient 6 developed acute gout, consequently the protocol in this case 
was shortened to two days of prenalterol infusion at 60 and 120 nmol/min 
each for 24 hours followed by one "run-out" day. For technical reasons, 
patient 3 was only studied for one "run-out" day. As a result of these 
protocol deviations, the data for patient 6 are considered separately,. 
and graphical display of the data only shows complete "run-out" data for 
the first day. 
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4 • Haemodynamic Measurements: 
On the morning of the first study day a triple lumen Swan-Ganz 
catheter was inserted (see Chapter 4) under strictly sterile conditions 
into the pulmonary artery for measurements of right heart pressures and 
cardiac output. A radial artery was cannulated for arterial pressure' 
monitoring and for blood sampling. Haemodynamic recordings, and blood 
sampling for hormone analysis were performed concurrently at 0830 hr and 
1530 hr daily. Forearm blood flow was measured at 1600 hr each day by 
plethysmography using a mercury-filled rubber strain gauge (Chapter 4). 
5. Hormone and Electrolyte Measurements: 
Arterial samples were drawn at 0830 hr and 1530 hr daily for the 
measurement of plasma renin activity, angiotensin II, aldosterone, 
cortisol, epinephrine and norepinephrine (see Chapter 5). Fasting 
plasma glucose (glucose oxidase method) was determined daily at 0830 hr, 
whilst fasting arterial samples were drawn for measurements of plasma 
insulin (Scott et al, 1980), glucagon (Aquilar-Parada et al, 1969), and 
pancreatic polypeptide (by radioimmunoassay using a polyethylene glycol 
separation technique), at 0830 hr on the second "run-in" day and again 
at 0830 hr at the completion of the third day of prenalterol infusion. 
Urine aldosterone and cortisol excretion were measured in 24 hour 
collections by radioimmunoassay. Sodium and potassium in plasma, urine 
and duplicate diets were determined by flame photometry. 
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6. Statistical Methods. 
Repeated measures analyses of variance were carried out on all 
variables using programme P2V of the BMDP package. The initial 
hypothesis tested was that no daily variation occurred, and where 
variables were measured twice daily, no diurnal variation occurred. For 
indices exhibiting significant daily variation, further comparisons 
using T-tests, with appropriate mean square error terms from the 
analysis of variance, were performed to determine when these changes 
occurred. In the case of variables measured twice daily, the 
interaction of days and time of day was clearly non-significant, thus it 
was possible to compare the daily mean values for each index. 
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7.4 RESULTS: 
1. General: 
Prenalterol was well tolerated, there being no subjective 
changes on close questioning. No serious arrhythmias were observed 
during the study, and the incidence of ventricular premature beats 
measured at one minute intervals at 0830 hr and 1530 hr daily, was 
not altered by prenalterol administration (fig 7.2). As the study 
in patient 6 was shortened, his data are presented separately. 
2. Haemodynamic responses: 
Cardiac index increased from a pre-treatment mean value (+ SEM) 
of 2.4 + 0.2 1/min/m2 , to 2.7 + 0.2, 2.8 + 0.3, and 3.0 + 0.3 
1/min/m2 on subsequent days of prenalterol infusion, then declined 
to a mean of 2.6 + 0.8 1/min/m 2 upon cessation of the drug (fig 
7.3). This represented 13%, 17% and 25% increments in cardiac index 
above baseline during the three days of prenalterol infusion. 
Stroke index changes paralleled those of cardiac index (fig 7.3). 
Forearm blood flow, as measured directly by strain gauge 
plethysmography increased in a dose-response fashion from a baseline 
of 2.9 + 0.6 ml/min/100g of tissue to a maximum of 4.0 + 0.6 
ml/min/100g of tissue on the third prenalterol day, then declined 
when the drug was withdrawn (fig 7.3). These changes in measured 
forearm blood flow matched stepwise decrements in calculated 
systemic vascular resistance (fig 7.4). 	Mean pulmonary artery 
pressures and right atrial pressures were unchanged, 	but a 
statistically significant decline in pulmonary capillary wedge 
pressure was noted during the lowest rate of prenalterol infusion, 
and was sustained during the final two study days (fig 7.3). 
Heart rate and arterial pressure showed no tendency to increase 
during prenalterol administration, and the product of rate and 
systolic pressure therefore remained stable (fig 7.4). While 
systemic vascular resistance declined significantly, the calculated 
pulmonary vascular resistance was not altered (fig 7.4). 
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FIGURE 7.2: 	EFFECT OF PRENALTEROL ON VENTRICULAR ECTOPY: 
The frequency of ventricular premature beats (VPB/min) was measured over 
a one minute interval at 0830 and 1530 hrs daily. Results are expressed 
as mean + SEM. _ 
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Legend for Figure 7.3: 
Haemodynamic indices in five patients with heart 
failure before, during and after prenalterol infusion 
(mean + SEM). Recordings were made 6.5 and 23.5 hrs 
after commencing each infusion rate. The discontinuous 
lines represent mean "run-in" levels for each index. 
The bars with asterisks indicate significant changes 
from the "run-in" values (* p<0.05, ** p<0.01). mpA = 
mean pulmonary artery pressure, PCWP = mean pulmonary 
capillary wedge pressure, and RAP = mean right atrial 
pressure. 
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FIGURE 7.3: HAEMODYNAMIC EFFECTS OF PRENALTEROL: 
Prenalterol Infusion  
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Legend for Figure 7.4: 
Haemodynamic variables (mean + SEM) measured at 
1530 and 0830 hrs daily in five patients with heart 
failure. The discontinuous horizontal lines represent 
mean "run-in" values. The bars with asterisks indicate 
significant changes from these levels (* p<0.05, ** 
p<0.01). Arterial pressures are plotted as systolic (S), 
mean (M), and diastolic (D) values. The heart rate by 
systolic arterial pressure product (HR x SBP) is in 
arbitrary units. 
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FIGURE 7.4: HAEMODYNAMIC EFFECTS OF PRENALTEROL: 
Prenatterol Infusion 	I 
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Comparing data from the "run-in" day and the final infusion 
day, prenalterol induced clear-cut increments in stroke work index 
in all patients with concomitant decrements or little change in 
pulmonary capillary wedge pressure (fig 7.5A). On the contrary, 
withdrawal of prenalterol resulted in a decline in stroke work index 
in each case, along with minor and variable changes in wedge 
pressure (fig 7.5B). 
3. Hormone and Electrolyte Responses: 
Baseline levels of plasma renin activity, angiotensin II and ' 
plasma aldosterone were moderately elevated as might be expected 
during long-term treatment with diuretics. Prenalterol therapy 
resulted in a greater than two-fold rise in plasma renin activity 
and somewhat lesser increments in angiotensin II and plasma 
aldosterone (fig 7.6). Urine aldostei-one increased in a step-wise 
fashion, and along with plasma renin activity and angiotensin II, 
tended to decline when prenalterol infusion was ceased (fig 7.6). 
No change was observed in cortisol levels or in circulating 
norepinephrine and epinephrine levels (fig 7.6). 
Urine sodium excretion tended to decline during prenalterol 
administration and increased to exceed dietary intake when the drug 
was withdrawn (fig 7.7). These changes, along with those in body 
weight (fig 7.7) were not statistically significant. Urine 
potassium equalled dietary intake before prenalterol, then declined 
during the three days of infusion, and subsequently returned to 
baseline (fig 7.7). While these fluctuations again were not 
statistically significant, there was a significant rise in plasma 
potassium concentration on the final two study days (fig 7.7). 
Fasting plasma insulin levels increased 	two-fold during 
prenalterol administration (fig 7.7). 	The tendency for fasting 
glucose levels to rise during the study did not reach levels of 
statistical significance. No changes in plasma glucagon (216 + 36 
pgiml on Day 2; 253 + 64 pg/ml on Day 5), or pancreatic polypeptide 
(318 + 78 pg/ml on Day 2; 531 + 128 pg/ml on Day 5) were seen. 
10 
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FIGURE 7.5 
A. 12 A S WI (g.m/m 2) 
B. 
LS, PCWP (mm Hg) 
-3-2-1 0 1 2 3 
\ 
-6 
 
-8 
A SWI 
(g. m/m2) 
- - -:3 - I2 :1 o 1 	i 
6. PCWP (mm Hg) 
Changes in Stroke Work Index (A SWI) and in mean pulmonary capillary 
wedge pressure ( A PCWP) firstly with the introduction of prenalterol 
(A), and secondly upon withdrawal of the drug (B). In fig 7.5A, data 
from the "run-in" day for each patient are compared with that during the 
third prenalterol infusion day, whilst in fig 7.5B results from the 
third day of prenalterol administration are compared with the subsequent 
day after discontinuation of the drug. In fig 7.5B, data from two 
patients fell on the same line. 
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Legend for Figure 7.6: 
Hormone data before, during, and after prenalterol 
in five patients with heart failure (mean + SEM). The 
discontinuous horizontal lines represent mean "run-in" 
(pre-prenalterol) values for each index. Bars with 
asterisks indicate statistical significance (* p<0.05, 
** p<0.01) compared to "run-in" levels. 
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Electrolyte, body weight, glucose, and insulin data (mean + SEM) from 
five patients treated with prenalterol for three days. The mean dietary 
intakes of sodium and potassium are represented by the discontinuous 
horizontal lines. (* p<0.05, ** p<0.01 when data was compared to that 
on day 2). 
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Haemodynamic and hormonal responses to prenalterol infusion in • Patient 6 have been graphed separately (fig 7.8). Inclusion of his 
results in the data analysis enhanced the levels of significance 
already reported. 
4. Dose Response Data: 
Dose response data are available for the five patients studied 
at each of the three infusion rates (table 7.3). Infusion at 60, 
120, and 240 nmol/min produced 'steady-state plasma prenalterol 
concentrations of 52 + 3, 121 + 6, and 194 + 9 nmo1/1 respectively. 
Cardiac index, stroke index and forearm blood flow increased in a 
linear fashion, while pulmonary capillary wedge pressure (PCWP) fell 
at the lowest infusion rate then remained stable. The increase in 
plasma renin activity, angiotensin II, and aldosterone plateaued 
during the second day of prenalterol infusion. 
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FIGURE 7.8: HAEMODYNAMIC AND HORMONE DATA FOR PATIENT 6: 
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TABLE 7.3: 	DOSE RESPONSE DATA FROM FIVE PATIENTS: 
STUDY DAY 2 3 4 5 6 
Infusion Rate 
(mmol/min) 
0 60 120 240 0 
Prenalterol steady- - 51.9 121.3 194.0 - 
state plasma conc. 
(nmo1/1) 
13.3 +6.2 +8.5 
Cardiac Index 2.4 2.7 2.8 3.0 2.6 
(1/min/m2 ) +0.3 +0.4 +0.4 +0.4 +0.3 
Forearm Bl. Flow 2.9 3.3 3.7 4.0 3.4 
(ml/min/100g) +0.7 +0.4 +0.8 ±0.6 +0.5 
Pulm Cap Wedge Press 13.7 10.5 11.5 11.0 10.7 
(mm Hg) +1.6 +1.7 +1.6 +1.6 +1.4 
Plasma Renin Activity 2.2 3.6 4.6 4.5 3.9 
(hmol/l/min) +0.6 +1.0 +1.5 _ +1.5 +1.3 - 
Angiotensin II 55 71 77 70 69 
(pg/ml) +16 ±20 +23 +21 +23 
Aldosterone 526 589 664 659 638 
(pmo1/1) +93 +74 +70 +84 +78 
_ 
Mean + SEM 
Haemodynamic and hormonal indices are expressed as daily means. 
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7.5 DISCUSSION: 
Present day therapy of heart failure relies heavily on correction -
of abnormal fluid accumulation and vascular tone. The primary 
abnormality in most types of cardiac failure namely, impaired myocardial 
contractility, is less well managed. Digitalis remains the only agent 
for chronic ambulant therapy. It is a weak inotropic drug compared to 
the modern synthetic amines (Goldstein et al, 1980) and its long-term 
usefulness in patients in sinus rhythm remains controversial (Selzer, 
1981). 
Prenalterol, a synthetic selective beta-1 agonist is free from 
several of these disadvantages. Since it can be given orally it is a 
potential substitute for digitalis for the ambulatory management of 
cardiac failure (Waagstein et al, 1979). Short term studies have 
confirmed its inotropic action and freedom from acute toxicity (Svendsen 
et al, 1980; Hutton et al, 1980; Awan et al, 1981; Kirlin and Pitt, 
1981) but there is little data available on the dose-response 
characteristics of the drug in heart failure patients. Its effect on 
important neurohumoral systems and electrolytes in cardiac failure 
required clarification. This information is of crucial importance since 
the long-term efficacy of the drug will be determined by these changes. 
Our study confirms that prenalterol increases cardiac output and 
stroke work while decreasing the left ventricular filling pressure. 
This is the hallmark of the action of an inotropic drug in heart 
failure, although it is virtually impossible to separate vasodilator 
from inotropic effects of a drug in the intact human (Rude et al, 1981). 
In isolated heart muscle studies, prenalterol has been shown to have 
definite inotropic properties (Mattson et al, 1982). Awan et al (1981) 
have reported that prenalterol induces vasodilatation on the basis of • 
the fall in calculated systemic vascular resistance, and our data 
support their observations. Furthermore, forearm blood flow 
measurements confirm vasodilatation in this vascular bed. 
Vasodilatation has been reported with other inotropic drugs including 
cardiac glycosides (Mason & Braunwald, 1964), terbutaline (Slutsky, 
1981), amrinone (LeJemetel et al, 1979) and pirbuterol (Dawson et al, 
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1981). This effect is only prominent in cardiac failure patients, being 
absent An 'animals and healthy volunteers. Awan et al (1981).  suggest - 
that this vasodilatation may be due to the improvement in cardiac output 
inducing a withdrawal of inappropriately raised sympathetic tone. This 
study did not address the underlying mechanism, but the lack of any 
change in circulating catecholamines suggests that sympathetic 
influences were not major determinants. Another possibility is beta-2 
mediated vasodilatation, since prenalterol presumably only has a 
relatively selective beta-1 agonist activity. The adrenergic receptors 
located in the heart that regulate myocardial contractile state have 
been termed beta-1, while those receptors that promote tracheal and 
vascular smooth muscle relaxation are termed beta-2 (Lands et al, 1967). 
Controversy, however, surrounds this simplistic classification, as well 
as the issues of receptor typing according to the end organ, the 
relative distribution of receptors within an organ and the manner in 
. which compounds may differ in their effects on chrono- and inotropic 
response, both of which are presumably beta-1 effects (Weber, 1982a). 
Whatever the reason, the vasodilatation produced by prenalterol is 
likely to be beneficial since it would tend to offset the 
vasoconstriction that occurs in cardiac failure. It thus supplements 
the inotropic action by concomitant afterload reduction. 
The haemodynamic effects of prenalterol appeared to be 
dose-dependent, increasing in a linear fashion and declining rapidly 
when the infusion was discontinued. Some residual elevation of stroke 
output remains, which may be of therapeutic significance. In this 
regard, the persistence of inotropic activity for as long as three 
months has been reported after dobutamine infusion (Unverforth et al, 
1980). Heart rate did not alter significantly with increasing doses of 
prenalterol confirming the lack of an important chronotropic action. 
Similarly, there was no change in the arterial pressure and the 
pressure-rate product, which is an indirect measure of myocardial oxygen 
demand. This important facet of the drug's action requires confirmation 
by direct measurement, because the indirect assessment of cardiac oxygen 
response may be fallacious (Rouleau et al, 1981). 
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The effects of positive inotropic agents on _myocardial oxygen 
consumption depend on their influence on two major determinants of 
myocardial oxygen consumption: wall tension and contractility, which 
change in opposite directions. In individuals with normal cardiac 
function, drugs that stimulate myocardial contractility elevate oxygen 
consumption, since heart size and, therefore, wall tension are not 
reduced and do not offset increased metabolism produced by stimulation 
of contractility (Braunwald & Sobel, 1980). In the failing dilated 
ventricle, inotropic agents increase contractility so that the left 
ventricular end-diastolic pressure and volume fall :substantially. On 
the basis of the Laplace relation (Mirsky et al, 1979) , this reduction 
in volume leads to a reduction in intramyocardial tension, which tends 
to reduce myocardial oxygen consumption. This fall is offset by the 
increase in contractility, which tends to augment myocardial oxygen 
consumption. The net result of these opposing effects produces no 
change, a small increase, or a small decrease in myocardial oxygen 
consumption. Thus, the change in myocardial oxygen demand produced by 
an inotropic agent will depend on the extent to which myocardial tension 
is reduced in relation to the extent to which the contractile state is 
augmented (Covell, Braunwald & Ross, 1966; Sonnenbliek et al, 1968). 
Two groups (Kupper et al, 1980; Tweddel et al, 1982) have reported that 
prenalterol administration to patients with heart failure produces 
small, but non-significant rises in myocardial oxygen demand determined 
from myocardial A-V oxygen difference and coronary sinus blood flow 
measured directly, using the method described by Ganz et al, (1971). 
One patient, (Kupper et al, 1980) however, increased his myocardial 
lactate production suggesting that the rise in myocardial oxygen demand 
in this patient produced significant myocardial ischaemnia. Obviously, a 
chronic increment in contractility may be detrimental in some patients, 
and more research is required to enable recognition of such patients. 
Isoprenaline is a potent, nonspecific beta-adrenoceptor agonist 
that provokes a considerable rise in heart rate and can precipitate 
arhythmias (Loeb et al, 1973). Similarly, dopamine and dobutamine also 
produce ventricular arrhythmias (Kersting et al, 1976; Golberg et al, 
1977). Increased ventricular ectopy (Kirlin & Pitt, 1981) following 
nrena1tprn1 thpranv haA hppn rpncIptpd in Anyna natli nFq 	hiiF 1-_hi A 1 Ai 
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matched by other reports of no such adverse effects (Tweddel et al, 
1982; Awan et al, 1981). We did not observe a significant increase in 
ventricular ectopy, but further research is required to determine the 
safety of oral therapy with regard to the production of lethal 
arrhythmias. 
This study demonstrates activation of the juxtaglomerular apparatus 
with release of renin during prenalterol infusion. Since stimulation of 
beta-1 receptors has been shown to augment renin release (Himori et al, 
1979; Kopp et al, 1980) , this effect of prenalterol is not surprising. 
That this action of prenalterol may be physiologically important is 
confirmed by concomitant increments in plasma angiotensin II and 
aldosterone levels. There are several important questions raised by 
these data. Firstly, cardiac function was maintained and even enhanced 
despite the vasoconstrictor action of angiotensin II. This suggests 
that the inotropic and vasodilating .actions of prenalterol were 
sufficiently powerful to overcome any increase in afterload, at least in 
the short term. Secondly, it is not clear whether activation of the 
renin-angiotensin-aldosterone system is sustained during long-term 
therapy. If it were, then a decline in cardiac output due to increased 
afterload and accumulation of fluid secondary to elevated aldosterone 
levels may occur leading ultimately to blunting or a loss of therapeutic 
response. 
Long-term studies using oral therapy are required to determine 
whether tolerance to therapy occurs. The data presented here would 
suggest that activation of the renin-angiotensin-aldosterone system, if 
sustained, may well lead to tolerance and this will need to be 
investigated. Blockade of the renin-angiotensin system by means of a 
converting-enzyme inhibitor may then be required to maintain the initial 
therapeutic effect. Attenuation of the haemodynamic effects of 
pirbuterol (a beta-2 agonist) have recently been associated with 
"down-regulation" of beta-receptors (Colucci et al, 1980b). These 
researchers report a decrease in lymphocyte beta-adrenoceptor density in 
these patients. However, other mechanisms for the attenuation of effect 
were not looked at. The effect on lymphocyte beta-receptors probably 
does not represent changes in myocardial receptors, so other mechanisms, 
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such as activation of the renin-angiotensin-aldosterone system may have 
produced the attenuation of pirbuterol effect. Al3 outlined in Chapter 
1, the failing heart's ability to respond to sylitkletic catecholamines is 
preserved in contrast to a damped response to sympathetic nerve 
stimulation (Covell et al, 1966; Goldstein et *11, 1975). Presumably, 
myocardial beta-receptor density is enhanced, alttlough the opposite was 
found in patients with severe pre-terminal heart failure undergoing 
cardiac transplantation (Bristow et al, 1982). 
Oral prenalterol may improve exercise performance (Waagstein et 
al, 1979). Another group demonstrated greater short-term improvement 
in haemodynamics during exercise than at rest (Tweddel et al, 1982). 
Systemic vascular resistance during exercise was reduced by 20%, but 
only 11% at rest. Although I was unable to dymnstrate that the decline 
in systemic vascular resistance at rest was related to a decline in 
sympathetic activity (as judged by circulating catecholamine levels), 
this effect may be more apparent during exercise- Enhanced activity of 
the sympathetic nervous system during exercise provides inotropic 
support for the failing myocardium, while concomitant peripheral 
vasoconstriction (alpha-receptor activation) has a detrimental effect 
(Higgins et al, 1972). From a theoretical point of view, an improvement 
in cardiac output during exercise induced by selective beta-1 
stimulation should reduce peripheral sympathetic activity, thereby 
reducing vascular resistance to a greater extent during exercise, 
improving muscle blood flow and enhancing exercise capacity. 
Beta receptors modulate the release of many hormones including 
those concerned with glucose homeostasis. A significant rise in plasma 
Insulin levels was observed during the present study. Animal data 
suggest that the adrenergic receptors responsible for enhancing insulin 
secretion are beta-2 in type (Miller, 1981). him et al (1980) observed 
an increase in insulin during prenalterol administration in normal 
volunteers, together with the observations in this study, suggest either 
that stimulatory beta-1 receptors exist on thepaancreatic beta cell, or 
that prenalterol has sufficient beta-2 agonist action to release 
insulin. Alternatively, prenalterol may primarily increase blood 
glucose levels by enhancing gluconeogenesis, thereby increasing release • 
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of endogenous insulin. Although we saw no significant change in 
glucose, glucagon or pancreatic polypeptide levels it would appear 
prudent to monitor blood glucose during future long-term studies of 
prenalterol, especially in diabetics. Since insulin reportedly 
increases myocardial contractility in cardiac failure (Farah & Aloussi, 
1981) it is interesting to speculate whether the increase in plasma 
insulin observed in this study contributed to the inotropic effect of 
prenalterol. 
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7.6 CONCLUSION: 
Prenalterol infusion in six patients with heart failure increased 
cardiac index and stroke index in a dose-response fashion without 
adversely affecting heart rate, arterial pressure or right-heart 
pressures. Forearm blood flow rose in a step-wise fashion during the 
incremental infusion of prenalterol. Activation of the 
renin-angiotensin-aldosterone axis was observed, and if sustained during 
long-term oral prenalterol treatment could serve to negate, in part, the 
beneficial haemodynamic effects. 
CHAPTER 8 
THE STABILITY OF HAEMODYNAMIC AND HORMONAL PARAMETERS, 
AND THEIR INTER-RELATIONSHIPS 
IN HEART FAILURE: 
8.1 INTRODUCTION: 
Although haemodynamic and hormonal inter-relationships have 
been studied extensively in cardiac failure (Levine et al 1982b, 
Kluger et al 1982, Curtiss et al 1978, Dzau et al 1981), there are 
few reports of "baseline" controlled observations extending beyond a 
few hours. As well as providing insight into spontaneous variations 
of cardiac and hormonal function, this information is required to 
interpret drug intervention studies using invasive techniques, where 
the effects of bed rest, circadian rhythm, concurrent drug therapy 
. and stress due to catheterisation and unfamiliar surroundings are 
all too often ignored. 
For a period up to 24 hours after cardiac catheterisation and 
bedrest, haemodynamic and hormone indices vary significantly 
(Maslowski et al, 1981a; Thaulow et al, 1982). To date, the 
stability of these parameters over longer periods of time has not 
been reported. In this chapter, I document the variation in cardiac 
function and hormone levels measured over a 48 hour period in 
twenty-one patients studied under basal conditions. The effects of 
NYHA Functional Class, diuretic therapy, diet, sodium balance, 
aetiology and cardiac rhythm on haemodynamic, hormonal and 
electrolyte indices were then assessed, along with relationships 
between these parameters. 
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8.2 METHODS: 
1. General: 
The control data from fifteen patients included in the 
previous two chapters are analysed here in greater detail. To 
enhance patient numbers, the control data from a previous study 
performed in this unit (Maslowski et al, 1981a) were included. 
I was not involved in this investigation, which documented the 
effect of captopril in six patients with stable heart failure, 
however a similar protocol was followed, with haemodynamic a:nd 
hormonal measurements being performed at identical times (0830 
and 1530 hrs). 
2. Patients: 
The clinical details of the twenty—one patients are 
summarised in Table 8.1. They were accepted for study only if 
their clinical state was stable for one month prior to 
investigation. All patients gave informed consent, with each 
study protocol having been approved by the Hospital's Ethical 
Committee. Left ventricular failure resulted from ischaemic 
heart disease in fourteen patients, and dilated cardiomyopathy 
in seven patients. In all but two patients, a definitive 
diagnosis was established or confirmed by cardiac 
catheterisation (seventeen patients) or post mortem examination 
(two patients). Dilated cardiomyopathy was diagnosed according 
to the criteria of Goodwin and Oakley (1972). Seven patients 
were in NYHA Functional Class II, eight were in Class III and 
six were in Class IV. Left ventricular radionuclide ejection•
fraction varied from 8 to 32% (mean = 21%). Six patients were 
in atrial fibrillation, while the remainder were in sinus 
rhythm. No patient was oedematous at the time of study. 
Digoxin (0.125 to 0.25 mg/day) and frusemide (40 to 1000 mg/day) 
therapy remained unchanged throughout the period of study, but 
other drugs were withdrawn at least five days before the study. 
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TABLE 8.1 	CLINICAL DATA: 
Patient Sex Age NYHA 
Class 
LVEF 
(%) 
Frusemide 
Dose (mg) 
Aetiology Rhythm 
1* M 63 III - 500 IHD SR 
2* F 72 IV - 1000 IHD AF 
3* M 54 IV 26 250 IHD SR 
4* M 63 IV 29 250 IHD SR 
5* M 65 III 19 120 IHD AF 
6* M 72 IV 21 1000 IHD AF 
7t M 57 II 25 80 DCM SR 
8 t M 62 II 18 40 DCM AF 
9t M 48 III 24 80 IHD SR 
10t M 59 II 11 40 IHD SR 
11t M 48 III 26 250 IHD AF 
12t M 70 IV 24 160 DCM SR 
13t M 61 III 8 500 IHD SR 
14t M 58 III 32 160 IHD SR 
15t F 66 IV 15 250 IHD SR 
16t M 46 II 17 500 DCM SR 
17t M 60 III 14 120 IHD SR 
18t M 54 II 22 80 DCM SR 
19t M 58 II 13 80 DCM AF 
20t M 53 II 28 120 DCM SR 
21t M 60 III 23 200 IHD SR 
LVEF = left ventricular ejection fraction; 
IHD = ischaemic heart disease; DCM = dilated cardiomyopathy; 
SR = sinus rhythm; AF = atrial fibrillation. 
= Maslowski et al, 1981a 
t = Chapter 6 
t = Chapter 7 
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Protocol: 
Throughout the two day period of study and for at least one 
day prior to its initiation, each patient received a diet of 
constant sodium and potassium content (K = 42 to 80 mmol/day). 
Twelve patients received a low sodium diet (Na = 19 to 48 
mmol/day), while nine received a normal sodium diet (Na = 91 to 
106 mmol/day). Meals were served at 0915 hr, 1215 hr and 1815 
hr. All urine was collected on ice for electrolyte and hormone 
analysis. 
The patients remained semi-supine throughout. 	Patients 7 
to 21 were catheterised on the afternoon prior to the first day 
of study, while patients 1 to 6 were catheterised on the morning 
(0800 hr) of the first day. A triple lumen Swan-Ganz catheter 
was placed in the pulmonary artery for right heart pressure and 
cardiac output measurements, and a radial or brachial artery 
cannula was inserted for pressure recordings and blood sampling 
for determination of plasma hormone levels. Measurements were 
performed twice daily at 0830 hr and 1530 hr. In patients 7 to 
15, further measurements were performed on the second control 
day at 1000, 1100, 1300, 1500, 1700, 1900 and 2100 hrs. 
Blood was drawn at 0830 hr daily for sodium and potassium 
measurements (flame photometry). Plasma ADH levels were 
determined at 1130 hr in patients 7 to 15 but in patients 16 to 
21, measurements were made at 0830 hr, thus time-matched 
measurements for plasma ADH and sodium concentration were not 
obtained. Digoxin and frusemide were administered after 
completion of the 0830 hr recordings. 
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4. Statistics: 
To assess daily and diurnal variation, repeated measures 
analyses of variance were performed for all variables using 
programme P2V of the BMDP statistics package. The patients were 
then grouped according to their NYHA functional classification, 
dose of frusemide ("Low" -160 mg/day or less; "High" - greater 
than 160 mg/day), aetiology (ischaemic heart disease or dilated 
cardiomyopathy), cardiac rhythm (sinus or atrial fibrillation) 
and dietary sodium intake (low: 19 to 48 mmol/day; normal: 91 
to 106 mmol/day). The effect of natriuresis following strict 
bed-rest was assessed by arbitrarily dividing the patients into 
two groups according to the difference between urinary excretion 
and dietary intake: "natriuresis" > 20 mmol/day; "balance" 
< 20 mmol/day. 
Results are presented as mean + standard error of the mean 
(SEM) unless stated otherwise. To remove the possible effect of 
stress from unfamiliar surroundings and recent catheterisation, 
mean values from 0830 and 1530 hr recordings on the second day 
were used in the calculation of correlation coefficients. 
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8.3 RESULTS: 
1. General: 
In considering the spontaneous variation of hormonal and 
haemodynamic parameters, the data from patients 1 to 6 were 
considered separately because measurements were commenced soon 
after catheterisation. For all other analyses, data from all 
patients were considered together, with greater emphasis being 
placed on the second day of measurements. 
2. Spontaneous Variation: 
1. Measurements from Patients 1 to 6: 
Comparing daily means for Day 1 and Day 2, cardiac 
index increased slightly from 1.65 + 0.21 1/min/m2 to -1.73 + 
0.24 1/min/m2 (NS), while mean pulmonary artery pressure 
(38.9 + 5.3 mm Hg to 33.7 + 5.4 mm Hg), left ventricular 
filling pressure (23.3 + 1.8 to 20.8 + 2.1 mm Hg) and right 
atrial pressure (9.1 + 3.6 mm Hg to 7.0 + 3.4 mm Hg) 
declined significantly (p<0.05). There was little variation 
in levels of plasma renin activity, angiotensin II or 
aldosterone, however plasma epinephrine (150 + 67 pg/ml to 
99 + 27 pg/ml) and cortisol (574 + 126 nmo1/1 to 491 + 74 
nmo1/1) did decline, but these changes did not achieve 
conventional levels of significance. Graphical display of 
this data is provided in figures 8.1 and 8.2 along with the 
response to captopril in these patients (from Maslowski et 
al, 1981a). 
2. Day 1 versus Day 2: 
For those patients (7 to 21, n = 15) in whom 
measurements commenced at least twelve hours after 
catheterisation, haemodynamic indices were not significantly 
different on Day 1 compared to Day 2 (Table 8.2). Plasma 
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Hormone indices measured before and during captopril treatment in five 
patients with resistant cardiac failure. Results are expressed as mean + 
SEM (from Maslowski et al, 1981a). 
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renin activity and urine aldosterone excretion were higher 
on the second day (p<0.001, p<0.05 respectively), while 
plasma epinephrine, body weight, plasma sodium and urinary 
sodium excretion were significantly lower (p<0.05) (Table 
8.3). 
3. Diurnal Variation: 
Cardiac index was significantly higher at 1530 hr than 
at 0830 hr (p<0.01), while plasma cortisol was lower at 1530 
hr (p<0.05). Results from more frequent observations in 
nine patients from the second day are shown in Fig 8.3. 
Cardiac index was generally lowest at the 0830 hr recording, 
and appeared to rise after meals. The renin-angiotensin-
aldosterone system was mildly activated after the 
administration of frusemide and digoxin given at 0900 hr, 
however the changes observed did not reach conventional 
levels of statistical significance. Systemic arterial 
pressure remained steady throughout (fig 8.3). 
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TABLE 8.2 	SPONTANEOUS VARIATION OF HAEMODYNAMIC DATA IN 
15 PATIENTS STUDIED AT LEAST 12 HOURS AFTER CATHETERISATION: 
Day 1 Day 2 Significance 
0830 ' 	1530 0830 1530 1. 	v 2. am v pm 
Cardiac Index 2.45 2.69 2.40 2.48 NS <0.005 
(1/min/m2 ) . 	.. .t0.16 t0.14 .19.13 t0.14 k Syst. Press. 125 127 128 'm 122 NS NS 
(mm Hg) +6 +7 +7 +6 
I Diast. Press. 69 69 72 68 NS NS 
(mm Hg) . 12 +4 . 1 3 . 13 Mean Art. Press. 87 89 91 86 NS NS 
(mmHg) Hg +3 +4 t4 +4 
Mean PA Press. 24.1 24.1 24.7 25.3 NS NS 
(mm Hg) +1.4 1.1.4 1 .7 -11.8 
PAEDP 15.9 16.1 - 16.5 17.3 NS NS 
(mm Hg) , 11.4 11.4 +1.7 +1.8 
R Atrial Press. 5.8 5.5 5.9 8.0 	' NS NS 
(mm Hg) +1.1 +1.0 +1.1 -1-1.0 . 	. Ventricular Rate 83 85 87 87 NS NS 
(bt/min) +6 +5 +4 +5 
Body Weight 70.8 70.4 <0.05 
(Kg) +2.6 +2.5 
Results are expressed as mean + standard deviation. 
NS = not significant, PAEDP = pulmonary artery end-diastolic 
pressure, PA = pulmonary artery. 
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TABLE 8.3: SPONTANEOUS VARIATION OF HORMONE AND ELECTROLYTE DATA 
IN 15 PATIENTS STUDIED AT LEAST 12 HOURS AFTER CATHETERISATION: 
, 
Day 1 Day 2 Significance 
0830 
. 	. 
v 	1530 0830 
. 
, 1530 1. 	v 2. . am v pm 
PRA 
, 	(nmol/l/hr) 
2.11 
+0.58 
2.17 
+0.55 , 
2.59 
+0.72 
• 
2.92 
+0.66 
<0.005 
■ 
<0.05 
Angiotensin II 
, 	(pg/m1) 
48.9 
+7.2 
59.8 
+9.0 
55.6 
+8.1 
61.5 
+10.2 
NS 
- 
NS 
Aldosterone 
. (pmo1/1) 
403 
. +49 
• 
410 
+60 
451 
+61 
489 
+77 
NS NS ' 
Cortisol 
, (nmo1/1) 
521 
+50 
450 
+67 
539 
+50 
467 
+64 
NS 
. 
<0.05 
ADH 
, 	(pg/m1) 
5.1 
r 	±'L6 
4.6 
+3.8 
■ 
NS 
• . 
- 
. Urine Aldo. Excr. 
(nmol/day) 
23.9 
+3•7 
30.7 
+5.1 
<0.05 - 
Urine Cort. Excr. 
. 	(nmol/day) 
335 
. 	+34 
319 
+32 
NS - 
Norepinephrine 
, 	(pg/m1) 
568 
■ 
+62 
594 
+73 
500 
+64 
607 
+89 
NS NS 
Epinephrine 
(pg/m1) 	_ 
146 
+28 
128 
+18 
128 
+36 
109 
+18 
<0.05 NS 
Plasma Na 
, 	(mmo1/1) 
135.9 
+0.8 
134.7 
+0.8 
<0.05 - 
Urine Na Excr. 
(mmol/day) 
107 
+10 
89 
+11 -- 
<0.05 - 
Results are expressed as mean + standard deviation. 
NS = not significant, PRA = plasma renin activity, 
ADH = anti-diuretic hormone. 
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FIG 8.3: FREQUENT RECORDINGS IN NINE PATIENTS: 
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Haemodynamic and hormone indices measured nine times during a 24 hr 
period in nine patients. Meal hours are indicated as follows: B = 
breakfast; L = lunch; D = dinner. Significant changes from the first 
0830 hr recording for each variable are shown by the symbols: * p<0.05; 
t p<0.01. 
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3. Effects of NYHA Functional Class: 
Analysis of variance for NYHA Functional Class and time of 
measurement demonstrated clear cut differences between the 
classes for cardiac index, mean pulmonary artery pressure, 
plasma renin activity, angiotensin II and aldosterone levels, 
with no interaction with time of measurement. The mean of four 
measurements for each patient, along with group means are 
illustrated in fig 8.4. Compared with Class II and III, cardiac 
index was lower in Class IV while plasma renin activity, 
angiotensin II, aldosterone and mean pulmonary artery pressure 
were higher. Although lower levels of plasma norepinephrine 
were observed in Class II patients, there was considerable 
overlap between the groups (fig 8.4), thus analysis of variance 
produced no significant difference overall. However levels in 
Class II were lower than those in combined Class III and IV as 
assessed by Student's t-test (p<0.05). Plasma ADH levels were 
slightly higher in Class III and IV patients when compared to 
Class II patients (6.1 + 1.5 pg/ml compared with 4.0 + 2.0 pg/ml 
respectively), but the difference was not significant. 
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FIG 8.4: 	EFFECT OF NYHA CLASS ON HAEMODYNAMIC & HORMONE PARAMETERS: 
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with mean for each patient (four values/patient). 
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4 • Effect of Frusemide Dose: 
When the patients were separated into low dose (<160 
mg/day, n = 11) and high dose (>160 mg/day, n = 10) groups, 
significantly greater activation of the renin-angiotensin-
aldosterone system was apparent in the high dose group. 
Comparing the mean of four measurements for each patient over 
two days, plasma renin activity was 1.1 + 0.3 mmo1/1/hr for the 
low dose and 4.3 + 0.7 nmol/l/hr (p<0.005) for the high dose 
group, while plasma angiotepsin II levels were 43.5 + 7.4 pg/ml 
and 106 + 21.4 pg/ml (p<0.01), plasma aldosterone levels were 
353 + 63 pmo1/1 and 645 + 86 pmo1/1 (p<0.001), and urinary 
aldosterone excretion levels were 21.4 + 3.9 mmol/day and 34.6 + 
4.6 mmol/day (p<0.05) for low and high dose groups respectively. 
Plasma ADH was also significantly greater in the high dose group 
(7.1 + 1.5 pg/ml compared to 3.0 + 0.7 pg/ml, p<0.05). 
Close correlation was observed between frusemide dose (log 
transformation) and plasma renin activity, angiotensin II and 
aldosterone levels (r=0.75; r=0.76; r=0.75 respectively, 
p<0.001) (fig 8.5). A weaker relationship between plasma ADH 
levels and log frusemide dose was also observed (r=0.55, 
p<0.05). Note that each point on these graphs represents the 
mean of two measurements performed on the second day. 
• 
• 
• • • 
• 
• 
• 
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FIG 8.5: 
FRUSEMIDE INDUCED ACTIVATION OF THE RENIN—ANGIOTENSIN—ALDOSTERONE SYSTEM 
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These graphs demonstrate the relationship of plasma renin activity, 
plasma angiotensin II, and aldosterone to frusemide dosage (log 
transformation). 	Each data point represents 	the mean of 	two 
measurements on the second day for each hormone. 
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5. Effect of Metabolic Balance: 
1. Dietary Sodium Intake: 
Twelve patients received a "low" sodium diet (19 to 48 
mmol/day) while nine received a "normal" diet (91 to 106 
mmol/day). The functional status, and frusemide dosage for 
the two groups were similar. Plasma aldosterone levels and 
urinary aldosterone excretion were higher in the "low" 
sodium group than in the "normal" sodium group (624 + 84 
pmo1/1 versus 381 + 84 pmo1/1 and 35.1 + 4.4 mmol/day versus 
20.7 + 4.2 mmol/day respectively, p<0.05). Plasma renin 
activity and angiotensin II levels were elevated in the low 
sodium group, but these differences did not reach levels of 
statistical significance (3.2 + 0.6 nmol/l/hr versus 2.4 + 
1.0 nmol/l/hr and 96 + 22 pg/ml versus 58 + 13 pg/ml 
respectively). Other hormonal and haemodynamic parameters 
were not influenced by dietary sodium intake. 
2. Degree of Natriuresis: 
The degree of natriuresis appeared to be unrelated to 
NYHA Functional Class or diuretic dosage. There were no 
differences in haemodynamic or hormonal indices between the 
group of patients with significant natriuresis (see 
methods), and those patients in sodium balance. However, 
weight loss was higher in the former group (p<0.05). 
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6. Effect of Aetiology: 
No differences in haemodynamic or hormonal variables were 
evident on the basis of aetiology (ischaemic versus idiopathic 
cardiomyopathy). 
7. Effect of Cardiac Rhythm: 
Compared with patients in sinus rhythm, those patients in 
atrial fibrillation had a lower cardiac index (1.68 + 0.20 
1/min/m2 compared to 2.51 + 0.14 1/min/m 2 , p<0.005) and heart 
rate (p<0.05), while pulmonary artery end-diastolic pressure 
(21.3 + 2.6 mm Hg versus 16.8 + 1.5 mm Hg) and right atrial 
pressure (9.7 + 3.2 mm Hg versus 5.7 + 1.1 mm Hg) were 
significantly higher (p<0.05). No hormone or electrolyte 
differences were noted. 
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8. Hormone and Electrolyte Relationships: 
For the twenty-one patients, mean results from the second 
day of recordings were taken for calculation of correlation 
coefficients. Plasma aldosterone correlated very closely with 
plasma renin activity (r=0.72, p<0.001) and plasma 
angiotensin II (r=0.70, p<0.001). Furthermore plasma 
angiotensin II correlated significantly with plasma renin 
activity (r=0.65, p<0.01). The relationship of plasma 
aldosterone with plasma potassium was negative (r=-0.11) and 
with plasma cortisol was positive (r=0.33), but neither reached 
levels of statistical significance. 
Positive, but non-significant correlations were observed 
between plasma renin activity and concurrently measured plasma 
norepinephrine . (r=0.35) and epinephrine levels (r=0.41, 
0.10<p<0.05). Likewise, the negative relationships between 
plasma sodium and plasma renin activity (r=-0.33), plasma 
angiotensin II (r=-0.34) and ADH (r=-0.07) were not significant. 
Plasma angiotensin II correlated closely with plasma 
creatinine (r=0.55, n=20, p<0.01) and plasma urea (r=0.69, 
p<0.005) while plasma renin activity and plasma aldosterone 
showed similar significant, but weaker correlations. No 
significant association between plasma ADH levels (n=15) and 
plasma sodium (r=-0.07), angiotensin II (r=0.14), or 
norepinephrine (r=0.19) was observed. 
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9. Hormone & Haemodynamic Relationships: (Table 8.3) 
As in section 8, mean results from the second day of 
recordings were taken for calculation of correlation 
coefficients. Negative correlations were noted between plasma 
angiotensin II levels and cardiac index (r=-0.51, p<0.05) as 
well as diastolic arterial pressure (r=-0.70, p<0.001), while 
positive relationships were observed .with right heart pressures: 
mean pulmonary artery (r=0.53, p<0.05), 	pulmonary artery 
end-diastolic 	pressure (r=0.58, p<0.01), and right atrial 
pressure (r=0.56, p<0. 01). Similar but generally weaker 
correlations between plasma renin activity, aldosterone and the 
above haemodynamic variables were observed (Table 8.3). 
There was no relationship between plasma catecholamine 
levels and cardiac or hormonal function with the exception of 
ventricular filling pressures. Plasma norepinephrine and 
epinephrine correlated significantly with pulmonary artery 
end-diastolic pressure (r=0.55 and 0.56, p<0.01 respectively) 
and right atrial pressure (r=0.62, p<0.01 and r=0.44, p<0.05), 
but not with cardiac index, arterial pressure or heart rate. No 
clear cut relationship was found between calculated systemic 
vascular resistance and any of the hormone measurements, but it 
did correlate with plasma urea (r=0.60, p<0.01). 
There were no close relationships between plasma ADH and 
any index of cardiac function. 
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TABLE 8.3: 	HORMONE - HAEMODYNAMIC RELATIONSHIPS 
, 
CI SAP 
. 
DAP MAP MPAP 
. 
PAEDP , RAP HR SVR 
PRA -0.10 -0.12 -0.45 
* 
-0.32 0.36 0.50 
* 
0.48 
* 
0.11 0.02 
A II -0.51 
* 
-0.23 -0.70 
t 
-0.53 
* 
0.53 
* 
0.58 
t 
0.56 
t 
-0.14 0.25 
ALDO -0.10 0.13 -0.48 
* 
-0.19 0.17 0.15 0.34 0.04 0.04 
NOREPI -0.19 -0.24 -0.05 -0.08 0.28 0.55 
t 
0.62 
t 
0.10 0.30 
. 
EPI -0.07 -0.32 -0.18 -0.25 -0.32 0.56 
t 
0.44 
* 
0.12 0.13 
CORT 0.12 -0.06 0.13 0.00 0.14 0.00 0.53 
* 
0.09 0.07 
4 
ADH -0.26 -0.07 0.43 0.18 0.07 0.02 -0.02 -0.23 0.29 
NA -0.36 -0.52 
* 
-0.07 -0.33 0.17 0.29 0.08 0.22 0.35 
. 
K 0.07 -0.26 0.01 -0.14 -0.06 -0.09 -0.22 0.49 
* 
-0.12 
CR -0.32 -0.05 -0.41 -0.27 0.29 0.18 0.27 -0.09 0.26 
UREA 
, 
-0.53 
t 
-0.06 -0.30 -0.18 0.16 0.33 0.32 -0.08 0.60 
t 
CR CL 
. 
0.39 0.02 0.41 0.24 -0.32 -0.26 -0.09 
- 
0.28 
. 
-0.25 
* = p<0.05; 	t = p<0.01; 	t = p<0.001. 	CI = cardiac index; 
SAP,DAP,& MAP = 	systolic, diastolic, and mean arterial pressure 
respectively; MPAP = mean pulmonary artery pressure; PAEDP = pulmonary 
artery end diastolic pressure; 	RAP = right atrial pressure; SVR = 
systemic vascular resistance. 	Plasma levels of renin activity, 
angiotensin II, 	aldosterone, norepinephrine, epinephrine, cortisol, 
antidiuretic hormone, sodium, potassium, and creatinine are denoted by the 
following symbols: PRA, All, ALDO, NOREPI, EPI, CORT, ADH, NA, K, 4 CR. 
CR CL = creatinine clearance. 
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8.4 DISCUSSION: 
Direct measurement of cardiac output and intra-cardiac 
pressures has become the time-honoured method for assessing the 
severity of cardiac dysfunction and the effects of therapeutic 
intervention (Braunwald, 1980). Following right heart and arterial 
catheterisation, control data are usually collected over a period of 
minutes to hours before the initiation of a new therapeutic regime. 
In a recent study performed in this unit (Maslowski et al, 1981a), a 
significant decline in right heart pressures, plasma epinephrine and 
cortisol levels (see fig 8.1 and 8.2) was observed during a 48 hour 
control period following cardiac catheterisation. These findings 
suggest that the stress of initial catheterisation adversely effects 
haemodynamic and hormonal parameters, and with bed rest, these 
recordings return to a true baseline. As a result of these 
observations, the protocol for subsequent investigations was altered 
so that catheters were inserted on the afternoon prior to, rather 
than on the morning of the first day of control measurements. I now 
report on the stability of these control measurements in these 
patients (n = 15). 
Haemodynamic parameters did not alter over the two study days, 
apart from cardiac index which increased in relation to meals, a 
phenomenon documented many years ago (Grollman, 1929). Minor 
metabolic fluctuations were observed. Urine sodium output exceeded 
dietary intake throughout, while body weight was lower on the second 
day, even though oedema was not evident. Presumably this was due to 
the natriuresis of bedrest and adjustment to the constant dietary 
intake. Plasma renin activity and urine aldosterone levels were 
higher on the second day, while plasma epinephrine levels were 
slightly higher on the first day. Levine et al (1982b) have shown 
that the activity of the renin-angiotensin-aldosterone system 
remains constant over a three day period in ambulant patients with a 
stable clinical condition. 	However, the stress of cardiac 
catheterisation on 	the third day enhanced activity of the 
sympathetic nervous system as gauged by a rise in plasma epinephrine 
levels. 	This stress probably accounted for the higher levels in 
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this group of patients, as well as the greater fluctuations observed 
in patients 1 to 6. 
A recent report (Thaulow et al, 1982) confirmed our impression 
that the stress of cardiac catheterisation significantly influences 
haemodynamic measurements for a considerable period of time. These 
investigators demonstrated a progressive fall in right heart 
pressures over an eighteen hour period following cardiac 
catheterisation. If drug intervention had been undertaken (with 
prazosin) during this period, these changes could have been 
attributed to a beneficial drug action. This highlights the 
difficulty in the interpretation of short-term investigations of the 
haemodynamic response to therapy where the effects of a changing 
baseline are all too often ignored. The present data would suggest 
that haemodynamic and hormonal indices adjust during the first 
twelve to eighteen hours after catheterisation and bed Pest, then 
remain stable for a.period of at least 48 hours. Stability over a 
longer period of time would be expected, thus an adequate base-
line was probably established for the investigations described 
in Chapters 6 & 7. 
Few studies use time-matched control data against which 
experimental results can be judged, thus they do not account for 
shifts in baseline produced by diurnal factors known to affect many 
of these indices. Despite this word of caution, little diurnal 
variation was observed, apart from cardiac index, plasma rerun 
activity and cortisol. The patients with heart failure included in 
this study failed to show the usual diurnal pattern of change in 
arterial blood pressure reported for normal and hypertensive 
individuals (Millar-Craig et al, 1978a). More frequent recordings 
in nine patients confirmed these findings (fig 8.3), along with 
continuous 24 hour monitoring in three of these patients (see fig 
6.8). To my knowledge, this phenomenon has not previously been 
reported. The reasons for this discrepancy are not apparent from 
the present study. 
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In contrast to the brisk response of the renin-angiotemsln 
system to frusemide observed in individuals with normal cardiac 
function (Rosenthal et al, 1968; Hesse et al, 1975), I observed a 
blunted response to frusemide in nine patients on chronic therapy 
(fig 8.3) similar to the first dose effects of frusemide reported 
earlier from this unit (Ikram et al, 1980). Possible reasons for 
this blunted response include: 
1. Augmented delivery of sodium chloride to the macula densa which 
may reduce renin secretion as it does in normal subjects who are 
sodium depleted (Judson & Helmer, 1971); 
2. Possible suppression of rerun release by digoxin (Antonello et 
al, 1976); 
3. Lack of significant fall of right atrial pressure in our 
patients, which in normal individuals contributes to min 
release (Kiowski and Julius, 1978). 
Plasma aldosterone failed to show the significant diurnal 
variation reported by Sakamaki et al (1981). In their study, eight 
of eleven patients had mild heart failure (NYHA Class II) and were 
on little or no diuretic therapy. In patients with moderate to 
severe heart failure on diuretic therapy, activation of the 
renin-angiotensin system probably opposes and diminishes the effect 
of ACTH levels. 
The results from this study clearly show that there are two 
major factors that determine the activity of the 
renin-angiotensin-aldosterone system in compensated heart failure: 
. 1. Severity of cardiac disease; 
2. Doses of frusemide therapy. 
Plasma renin activity, plasma angiotensin II and aldosterone levels 
were greater with increasing severity of heart disease as judged by 
NYHA Functional Class (fig 8.4). As expected greater haemodynamic 
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abnormalities were found in the more severely afflicted groups. 
Cardiac index was lower while pulmonary artery pressures were higher 
in Class III and IV patients (fig 8.4). Furthermore, there was a 
close negative relationship between plasma angiotensin II (the major 
effector hormone of the renin system) and cardiac index, diastolic, 
and mean arterial pressure, while a close positive relationship was 
observed with right heart pressures. Such relationships were not 
seen with plasma norepinephrine, which is taken as a good index of 
"global" sympathetic function (Goldstein, 1981). 
Elevations of • plasma renin activity and aldosterone 
concentration have not been consistently observed in heart failure 
(Merril et al, 1946; Brown et al, 1970; Sanders & Melby, 1964; 
Wolff et al, 1959; Genest et al, 1968; Chonko et al, 1977; Kubo 
et al, 1980). These studies can be criticised for lack of clear 
definition of the clinical status of their patients, and failure to 
control other factors affecting this hormone system - body posture, 
diet and drug therapy (Levine et al, 1982b; Haber, 1969; Dzau et 
al, 1981; Meurer et al, 1972). Dzau et al (1981) have suggested 
that the system is activated following an acute diminution in 
cardiac function or increased metabolic demand, but returns to 
normal as plasma volume expands and patients enter a "compensated" 
state. From our data "compensation" would appear to be incomplete 
in Class III to IV patients as the renin-angiotensin system remains 
abnormally activated, albeit not to the same extent as during acute 
decompensation. 
Diuretic therapy plays a major role in activating the 
renin-angiotensin-aldosterone system in heart failure. The relative 
contribution of frusemide dosage and the severity of myocardial 
dysfunction, however, could not be gleaned from our results. Knight 
et al (1979) demonstrated a close relationship between frusemide 
dose and plasma aldosterone levels. These data confirm the primacy 
of angiotensin II in controlling aldosterone secretion in heart 
failure under the conditions of study, relegating other 
secretagogues (ACTH and potassium) to relatively minor roles. 	The 
close correlation of plasma angiotensin II to haemodynamic 
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abnormalities in heart failure would tend to indicate that diuretic 
therapy_ may be a major faotor in.producing increased ventricular 
afterload and hyperaidosteronism. Acute haemodynamic improvement 
follows blockade of the formation of angiotensin II (see Chapter 6) 
and this appears to be greater in patients with greater activity of 
the renin-angiotensin-aldosterone system on higher doses of 
diuretics. Moreover, this effect appears to be sustained (see 
Chapter 10), in contrast to other vasodilators to which tolerance is 
often observed (Colucci et al, 1980a;. Packer et al, 1981). 
Dietary sodium intake did not appear to affect activation of 
the renin-angiotensin-aldosterone system greatly, as mean plasma 
renin activity and angiotensin II levels were similar in "low" and 
"normal" sodium intake groups, although plasma and urine aldosterone 
levels were definitely higher in the "low" intake group. Earlier 
work in heart failure patients is difficult to interpret, as Chonko 
et al (1977) found elevated plasma aldosterone levels despite sodium 
loading, while Sanders & Melby (1964) found no correlation between 
sodium balance and aldosterone excretion. In normal individuals and 
hypertensive patients, sodium restriction induces marked activation 
of the renin system (Haber, 1976). From the data presented here, 
this effect appears to be blunted in heart failure, presumably 
because cardiac dysfunction and diuretic therapy have a greater 
effect. 
There was an inverse relationship between plasma sodium and 
plasma renin activity, although this was not as strong as others 
have reported (Levine et al, 1982a; Brown et al, 1970). This may 
be explained by the smaller range in plasma sodium concentration 
(130- 141 mmo1/1) in our patients. I also confirmed a relationship 
between plasma rerun activity and urea and creatinine (Brown et al, 
1970). These authors suggest several reasons for the above 
relationships: 
1. A primary reduction in renal blood flow in heart -failure may 
increase plasma renio activity, creatinine, and urea, while 
lowering plasma sodium; 
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2. Renin may alter intra-renal haemodynamics resulting in 
inappropriate concentration of urine, with an increase in plasma 
urea, and sodium; 
3. Diuretic therapy promotes sodium loss, and stimulates renin 
secretion thus enhancing the relationship between these two 
parameters. 
Compared to the renin-angiotensin system, sympathetic activity 
(as reflected by circulating catecholamines) was not strongly 
related to NYHA Functional class, frusemide dosage or haemddynamic 
parameters. Other workers have reported a better 
separation of plasma norepinephrine levels according to NYHA Class 
(Thomas & Marks, 1978), and significant relationships with 
haemodynamic parameters (Levine et al, 1982b; Kluger et al, 1982; 
Francis et al, 1980). In these studies, haemodynamic measurements 
were performed soon after cardiac catheterisation, thus their 
assessment is likely to have been affected to a greater extent by 
stress. The sympathetic nervous system is integrally involved with 
minute-to-minute regulation of the circulation, while the 
renin-angiotensin system is probably involved in longer-term 
regulation (Guyton, 1981). It is perhaps not surprising, then, that 
measurements performed well after cardiac catheterisation do not 
show the same strong association with sympathetic activity as do 
short-term studies. Undoubtedly, the results from the present study 
more truly represent long-term changes that occur in heart failure, 
and may well explain, in part, the dramatic long-term effectiveness 
of angiotensin converting enzyme inhibitors (see Chapter 10) 
compared with other vasodilators (eg. prazosin, hydrallazine) where 
tolerance to therapy often occurs (Colucci et al, 1980a; Packer et 
al, 1982). 
Control of ADH secretion is multifactorial and complex 
(Robertson, 1977), the major routes and rate of clearance from 
plasma have yet to be clarified in cardiac failure. It is difficult 
to comment on the role of antidiuretic hormone in the patients in 
this study. Measurements were made at different times of the day 
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(1130 hr in eight patients and 0830 hr in six patients) while fluid 
intake was not strictly controlled. Levels of plasma antidiuretic 
hormone were generally within the range observed in healthy 
volunteers on an unrestricted diet and fluid intake. The data 
failed to show any close association of known or suspected stimuli 
with concurrent antidiuretic hormone levels. These include arterial 
pressure, left ventricular filling pressure, plasma sodium and 
angiotensin II levels. Interestingly, there was a significant 
association with frusemide dosage (r= 0.55, n = 15, p <0.05). 
Elucidation of the role of antidiuretic hormone in heart failure 
will require further study with better control of fluid intake and 
blockade of antidiuretic hormone action and/or formation. 
The grouping of such heterogenous disorders as ischaemic and 
dilated cardiomyopathy in a therapeutic trial causes some concern as 
the response to intervention may be affected by the underlying 
myocardial pathology. Under the conditions of our study, 
haemodynamic and hormonal indices could not be distinguished 
according to the aetiology of heart failure. Apparently the 
haemodynamic and neurohumoral changes are non-specific and secondary 
to impaired myocardial function, at least in the latter phases of 
cardiac failure. Furthermore, cardiac rhythm did not appear to 
influence activation of the renin-angiotensin-aldosterone system or 
the sympathetic nervous system, despite cardiac index and heart rate 
being lower, and ventricular filling pressures higher in the 
presence of atrial fibrillation. 
CONTROL HAEMODYNAMIC & HORMONE PROFILES: 	 166. 
8.5 CONCLUSION: 
Cardiac catheterisation and bed rest appear to significantly 
influence cardiac function and hormone levels for a period of at 
least twelve hours. These changes seriously limit interpretation of 
short-term haemodynamic studies, especially with those investigating 
hormone-haemodynamic interactions in heart failure. Following this 
period of instability, cardiac function and hormone levels are 
relatively stable, more truly representing baseline levels. Having 
established such a baseline, the effects of therapeutic intervention 
on cardiac and hormone function may be more adequately assessed, 
especially as time-matched control recordings for any diurnal 
variation. 
Activation of the renin-angiotensin-aldosterone system was 
largely dependent on frusemide dosage and severity of underlying 
myocardial dysfunction as judged by NYHA Functional Classification 
and haemodynamic parameters, while dietary sodium intake and plasma 
sodium played only a minor role. Judging by circulating 
catecholamines, the sympathetic nervous system was activated in some 
Class III and IV patients, but relationships with haemodynamic 
parameters were not as close as with plasma angiotensin II levels. 
This may explain, in part, the dramatic effectiveness of angiotensin 
converting enzyme inhibitors compared with other vasodilators 
(including postsynaptic alpha-1 antagonists - eg. prazosin) to 
which some patients become tolerant. 
Activation of the renin-angiotensin-aldosterone system and the 
sympathetic nervous system did not appear to be affected by under-
lying myocardial pathology or heart rhythm. 
CHAPTER 9 . 
BETA-BLOCKADE IN DILATED CARDIOMYOPATHY - 
IS IT BENEFICIAL 1 
9.1 INTRODUCTION: 
Since 1975 a Swedish centre has published a series of papers 
purporting to show that beta-blockade improves symptoms and survival in 
dilated (congestive) cardiomyopathy (Waagstein et al 1975, Swedberg et 
al 1979, 1980a, 1980b). The authors have claimed improvement in the 
clinical state, exercise capacity and ventricular function assessed by 
non-invasive methods. Furthermore, they claim that their patients' 
heart failure relapses on withdrawal of beta-blockade (Swedberg et al, 
1980b). 
This paradoxical form of therapy is completely contrary to our 
concepts of the role of the sympathetic nervous system and circulating 
catecholamines. Based on a substantial body of clinical and 
experimental data, the activation of the sympathetic nervous system 
(Chidsey et al, 1965; Braunwald, 1979) associated with a mild elevation 
of circulating catecholamines (Thomas and Marks, 1978) observed in 
cardiac failure is an important compensatory mechanism. Furthermore, 
blockade of this system by guanethidine (Gaffney and Braunwald, 1963) or 
propranolol (Epstein &Braunwald, 1966) results in greater impairment of 
cardiac function at rest or during exercise (Epstein et al, 1965). 
All the Swedish studies were deficient in that they were neither 
controlled nor double-blind. Thus, the only rationale for beta-blockade 
at the present time is empirical observation. Whilst this is not 
unusual in therapeutics, it does require a highly critical evaluation of 
the adequacy of supporting evidence. The minimum requirement for 
acceptance of any new therapy is a positive result from a randomised 
controlled trial conducted in an adequate number of patients according 
to an appropriate protocol. The positive observations should be 
independently confirmed by one or more centres. In the absence of such 
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trials, the therapeutic value of this treatment remains to be proved. 
The purpose of this study was to investigate the effects of oral 
beta-blockade in dilated cardiomyopathy by means of a controlled, 
cross-over, double-blind trial. 
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9.2 PATIENTS AND METHODS:, 
1. Patients: 
Seventeen patients were studied, sixteen men and one woman with 
an age range of 30 to 62 years (mean 52 years). Table 9.1 gives the 
clinical details as well as other medications taken during the trial 
period, which were held constant throughout. 
Congestive cardiomyopathy was diagnosed on the criteria of 
Goodwin and Oakley (1972). Coronary artery, pericardial, valvular, 
and congenital heart disease were excluded by prior right and left 
heart catheterisation, angiocardiography and selective coronary 
angiography. Secondary cardiomyopathies were excluded by 
appropriate tests and infiltrative cardiac muscle lesions by 
haemodynamic studies and endomyocardial biopsy. 
All patients had had at least one episode of congestive cardiac 
failure resulting from cardiac muscle dysfunction. None of the 
patients had obstructive airways disease. 
BETA-BLOCKADE IN DILATED CARDIOMYOPATHY 	 170. 
TABLE 9.1 	CLINICAL DETAILS : 
Patient 
number 
Sex Age Possible 
Aetiology 
NYHA 
Class 
Rhythm Other medications 
1 M 43 Ale II AF Warfarin 
2 M 62 Ale III SR Diggoxin, Thyroxine 
3 M 58 IP III AF Diggoxin, Thiazide 
4 M 49 Ale II SR Diggoxin, Frusemide 
5 M 62 Ale III AF Diggoxin, Frusemide 
6 M 42 Ale III SR Diggoxin, Frusemide 
7 M 30 IF II SR Disoxin, Frusemide 
8 M 60 Ale II AF Digoxin, Frusemide 
9 M 44. Ale III AF Disoxin, Frusemide 
10 M 41 Ale III SR 	- Disoxin, Frusemide 
11 M 52 Ale III SR Disoxin, Frusemide 
12 F 55 IF III SR Diggoxin, Frusemide 
13 M 61 IF II SR Diggoxin, Frusemide 
14 M 57 Ale II AF Digoxin 
15 M 53 Ale II SR Frusemide 
16 M 64 IF III AF Withdrawn from study 
17 M 56 Ale III SR Withdrawn from study 
Ale = Alcohol ; IP = Idiopathic; 
AF = Atrial Fibrillation; 
SR = Sinus Rhythm. 
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2. Protocol: 
At the start of the trial, the patients had a standard 6ft 
chest X-ray, an echocardiogram, and a familiarisation treadmill 
exercise test. They then entered a randomised double-blind 
crossover trial of one month's treatment with acebutolol ("Sectral") 
200mg orally twice daily and placebo. Acebutolol was chosen because 
it has partial agonist activity and some cardioselectivity (Mason et 
al, 1978), thus it lies midway between the two groups of 
beta-blockers used in the Swedish Studies. The one month treatment 
period was chosen since most benefit was reported to occur early 
(Swedberg et al, 1980a). At the end of each treatment period they 
were re-investigated with a chest x-ray, echocardiogram and exercise 
test. 
. 	Echocardiograms were recorded on an 'Ekoline' 21 recorder 
(Smith-Kline Instruments). 	The standard technique described by 
Feigenbaum (1972) was employed for examination of the mitral and 
aortic valves and the sizing of the left atrium and ventricle. Much 
time and care was taken to get the antero-posterior diameter of the 
left ventricle just below the aortic root and through, or very close 
to both the anterior and posterior mitral leaflets. Three cardiac 
cycles were averaged when the patient was in sinus rhythm, while 
five cycles were averaged when the patient was in atrial 
fibrillation. The stroke volume was calculated from the 
end-diastolic and end-systolic volumes derived by the cube method 
(Pombo, Troy & Russel, 1971) and the cardiac output was estimated 
from the stroke volume and heart rate recorded during the procedure. 
For technical reasons four patients could not be studied adequately 
by echocardiography. 
Progressive multi-stage, exercise testing was performed on a 
treadmill, Quinton Model 643, according to the "Bruce Protocol" 
(Bruce, Kusumi & Hosmer, 1973). The patients were exercised until 
they signalled that they could no longer continue. 
Electrocardiogram and heart rate were recorded on an Avionics "Exer 
Stress" Model 3000. and blood pressure measurements prior to, and 
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during the test were performed at one minute intervals with an 
Avionics "Pressurometer" Model 1905. Ventricular extrasystoles' 
during exercise were assessed according to the modified Lown Grading 
System (Lown & Wolf, 1971). 
On-line computer analysed breath-by-breath measurements of 
oxygen consumption (V 02 ), carbon dioxide production (V002 ) and 
ventilation (VE ) during exercise were performed on thirteen 
patients (see Chapter 3). 
3. Statistical Analysis: 
Statistical analysis was performed by Student's paired T-test 
when comparing the effect of acebutolol with that of placebo, and 
Student's T-test when comparing unpaired group means. An analysis 
of variance excluded significant order effect, but confirmed 
significant drug effects shown by paired T—test. 
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9.3 RESULTS: 
1. Effect on Clinical State: 
Of the fifteen patients who completed the study, none reported 
an improvement in symptoms and NYHA Functional Class was not 
altered. Two patients were withdrawn before completion of the 
trial: 
1. Patient 16 died from pulmonary embolism and acute pulmonary 
oedema while on placebo; 
2. Patient 17 experienced profound hypotension after the first dose 
of acebutolol, requiring inotropic support with isoprenaline. 
Challenge with lower doses of acebutolol also caused significant 
hypotension. 
2. Effect on Ventricular Function: (Table 9.2) 
Beta-blockade significantly increased cardiothoracic ratio. 
Echocardiography showed slight reductions in left ventricular 
systolic and diastolic diameter and volume, and left atrial size, 
while there was a slight rise in stroke volume and ejection 
fraction. None of these changes, however, were significant. The 
estimated cardiac output was significantly lower on beta-blockade 
largely due to the significant reduction in heart rate. 
3. Effect on Exercise Performance: (Table 9.2) 
The duration of exercise was significantly reduced (p<0.01), 
while resting and maximum heart rate and systolic blood pressure 
were very significantly reduced (p<0.001). There was a slight 
reduction in oxygen consumption, carbon dioxide production, and 
ventilation at maximum exercise, but none of these changes was 
statistically significant. There was no change in the anaerobic 
threshold when respiratory quotient (R) was compared with V02 
BETA-BLOCKADE IN DILATED CARDIOMYOPATHY 	 174. 
TABLE 9.2 	RADIOGRAPHIC, EXERCISE, AND ECHO DATA: 
I 	
• 
Chest X-Ray: 
Acebutolol 
. 
Placebo n p 
0.55 + 0.07 0.51 + 0.08 15 <0.01 Cardiothoracic Ratio 
Exercise data:, 
6.53 + 3.90 7.33 + 3.75 15 <0.01 Endurance Time (min) 
Resting HR 69.9 + 	13.7 90.9 + 15.9 15 <0.001 
Maximum HR 117 + 29 156 + 29 15 <0.001 
Resting SBP (mm Hg) 128 + 13 140 + 17 15 <0.01 
Maximum SBP (mm Hg) 173 + 30 204 + 32 15 <0.01 
V02 Max (1/min) 
(mn) ' VCO2 Max 	 1/i 
1.7 
1.8 
+ 0.6 
+ 0.8 
1.8 
2.0 
+ 0.6 
+ 0.9 
13 
13 
NS 
NS 
R Max 1.1 + 0.2 1.1 + 0.2 13 NS 
VE Max (1/min) 56.7 + 24.5 61.8 + 23.8 13 NS 
Echocardiographic data: 
SD 	(cm) 6.4 + 0.9 6.6 + 	1.1 11 NS 
SS 	(cm) 5.0 + 	1.0 5.2 + 	1.2 11 NS 
Left atrial size (cm) 4.4 + 0.9 4.6 + 	1.0 11 NS 
LVEDV 	(cm3 ) 223 + 	61 233 + 	73 11 NS 
LVESV 	(cm3 ) 125 + 	54 140 + 	68 11 NS 
Ejection Fraction (%) 47 + 	13 44 + 	15 11 NS 
Stroke Volume 	(cm3 ) 98 + 	23 93 + 	33 11 NS 
Cardiac Output (1/min) 6.2 + 	1.4 7.4 + 2.0 11 <0.05 
/ 
n = number of patients studied. 
Results are expressed as mean + standard deviation. 
SD = diastolic ventricular diameter, SS = systolic vent. diameter, 
R = respiratory quotient, NS = not significant (ie p>0.05). 
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4. Effect on Ventricular Extra-systoles During Exercise: 
There was no significant difference in Lown Grading Score 
(results not shown) between placebo and active conditions using the 
Wilcoxon Matched Pairs Signed Ranks test (p=0.20). 
5. Effect of Functional Class: 
NYHA Class III patients were more severely afflicted than class 
II patients. Exercise capacity was lower (4.9 + 3.1 min. compared 
to 10.0 + 2.4 min., p<0.01), as was maximum oxygen consumption (16.8 
+ 4.7 ml/Kg/min compared to 27.5 + 4.7 ml/Kg/min, p<0.005) and 
maximum heart rate (138 + 23 bt/min compared to 177 + 18 bt/min, 
p<0.005). Cardiothoracic ratio, echocardiographic dimensions and 
ejection fraction also demonstrated greater impairment of cardiac 
function in Class III patients, however differences did not achieve 
conventional levels of statistical significance. 
Acebutolol produced a greater reduction in exercise capacity in 
Class III patients (27% compared to 6% in Class II, p<0.01). 
Similarly, maximum heart rate was reduced to a greater extent (28% 
compared to 18%, p<0.05), as was the resting heart rate (24% 
compared to 18%, p=0.07). The effect of acebutolol on other 
parameters was not influenced by NYHA Functional Class. 
6. Effect of Rhythm: 
Comparing patients in sinus rhythm with those in atrial 
fibrillation (results not shown) for all parameters, there was no 
statistically significant difference between acebutolol and placebo, 
except that acebutolol produced a greater reduction in resting heart 
rate in patients with atrial fibrillation (p<0.05). 
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9.4 DISCUSSION: 
Currently, the role of beta-blockade therapy in 	dilated 
cardiomyopathy remains controversial. The initial encouraging reports 
(Waagstein et al 1975, Swedberg et al 1980a, 1980b) have not been 
followed by independent confirmation by others or a controlled study by 
its originators. Anecdotal reports of benefit in small numbers of 
patients (Dwyer 1981, Alexander 1981) are counter-balanced by 
descriptions of serious haemodynamic complications in as few cases 
(Kohn, 1978; Hoffbrand, 1980; Breizis, Salnikowicz & Basin, 1981). 
In view of the importance of the sympathetic nervous system in 
stimulating the contractility of the normal myocardium, the activity of 
this system has also been studied extensively in patients with 
congestive heart failure. As outlined in Chapter 1, plasma 
norepinephrine provides an index of the activity of the sympathetic 
nervous system, at rest and during exercise, (Goldstein, 1981). During 
exercise, no change or very little increase in the norepinephrine 
concentration occurs in normal subjects, but much greater increases are 
seen in patients with congestive heart failure (Chidsey et al, 1962), 
presumably because of an increased activity of the sympathetic nervous 
system during exercise in these patients. 
The importance of the increased activity of the sympathetic nervous 
system in maintaining ventricular contractility when the function of the 
myocardium is depressed is also shown by the effects of adrenergic 
blockade in patients with heart failure. Antiadrenergic drugs 
(guanethidine and P ropranolol) may cause sodium and water retention, as 
well as intensification of heart failure (Gaffney & Braumald, 1963; 
Epstein & Braunwald, 1966). Haemodynamic deterioration and reduced 
exercise capacity have also been reported (Ikram et al, 1979; Taylor & 
Silke, 1981). The sympathetic nervous system plays an important 
compensatory role in heart failure and, until now, heart failure has 
been considered a major contraindication to the use of beta-blocking 
drugs (Taylor & Silke, 1981). 
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A healthy person responds to beta-blockade with a fall in resting 
heart rate and blood pressure (Lewis et al, 1973) and an increase in 
cardiac size (Chamberlain, 1966). The rise in heart rate and blood 
pressure in response to dynamic exercise is attenuated, leading to 
reduction of exercise capacity (Epstein et al, 1965). In patients with 
ischaemic heart disease and normal left ventricular function, 
beta-blockade diminishes myocardial oxygen consumption at any given 
level of activity, largely due to the reduction in heart rate (Epstein & 
Braunwald, 1966). The resultant elevation of anginal threshold 
(Armstrong et al, 1977) leads to enhanced exercise tolerance (Gianelly 
et al, 1969). In patients with ischaemic heart disease associated with 
depressed myocardial function, the detrimental effect of beta-blockade 
on ventricular function appears to over-ride any improvement in anginal 
threshold, thus exercise capacity is reduced (Taylor & Silke, 1981). 
The present study failed to confirm the improvement in exercise 
performance reported by the Swedish workers. Moreover, exercise 
performance deteriorated to a greater extent in NYHA Class III patients, 
the very patients reported to derive most benefit from beta-blockade. 
Maximum heart rate was lower in Class III than in Class II patients, 
suggesting greater impairment of sympathetic drive to the myocardium in 
these patients (Goldstein et al, 1975). It was not surprising, then, 
that exercise performance was curtailed to a greater extent in Class III 
patients as they are likely to be more sensitive to beta-blockade. 
Before beta-blockade, the response of heart rate and oxygen uptake 
to submaximal exercise was qualitatively normal in Class II and Class 
III patients, but following beta-blockade the response was depressed as 
illustrated in fig 9.1. This figure demonstrates that the oxygen pulse 
(V02/HR) was higher during beta-blockade, suggesting that cardiac output 
was maintained and stroke volume was higher at a given workload. The 
additional possibility of lowered mixed venous oxygen tension was not 
investigated. Furthermore, the curtailment of exercise was due to 
cardiac effects of beta-blockade (ie. on heart rate) and not due to the 
effect on airway resistance, since maximum oxygen consumption and 
ventilation were unchanged. 
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FIG 9.1 
 
(a) Placebo 
Heart Rate 
beats/min 
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100 
50 
• Vo2 (I/min) 
 
1 2 	3 
(b) Acebutolol 
Heart Rate 
beats/min 
150 
100 
V/o2 (I/min) 
50 
1 
	
2 	3 
• 
Graphical display of heart rate (HR) and oxygen consumption (V02 ) 
measured on patient 15 during exercise: (A) on placebo; and (B) on 
acebutolol. Normal values are those used by Jones et al (1975). The 
boundaries represent + standard deviation from the mean values at each 
level of oxygen consumption. 
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I found a significant fall in resting and post-exercise blood 
pressure (in one case necessitating withdrawal from the study). One 
might have expected this to be associated with a fall in vascular 
resistance. However, in ischaemic cardiomyopathy, beta-blockade reduces 
arterial pressure while vascular resistance remains high, presumably due 
to a greater fall in cardiac output (Taylor & Silke, 1981). No patient 
reported improvement in symptoms on beta-blockade, and NYHA functional 
class was unchanged in all patients. The absence of benefit in this 
study is unlikely to be due to failure of patient compliance since the 
resting heart rate and blood pressure were reduced after beta-blockade. 
With regard to the effects of beta-blockade on ventricular function 
in dilated cardiomyopathy, the Swedish evidence for improved left 
ventricular function was based on a decrease in cardiac volume as judged 
by cardiothoracic ratio and echocardiographic measurements, an increase 
in echocardographically determined ejection fraction and diminished 
intensity of the third heart sound on phonocardiography. This 
improvement is contrary to findings of other studies on the effect of 
beta-blockade on ventricular function. In an earlier acute intravenous 
investigation reported from this unit (Ikram et al, 1979), beta-blockade 
produced further dilatation of the left ventricle, as assessed by left 
ventricular cineangiography. In particular, the end-systolic volume 
(which is indicative of contractile function) increased by 21%. Graber 
et al (1971) and Mason et al (1978), using thermal dilution and computer 
fluoroscopy of surgically implanted markers, had earlier shown greater 
dilatation after beta-blockade in dilated cardiomyopathy and 
transplanted hearts. The favourable reports from Sweden were concerned 
with chronic oral administration, thus extrapolation from the above 
short-term studies is difficult because the observed acute changes may 
not necessarily reflect long-term effects. 
From the present study, however, oral beta-blockade produces 
further cardiac enlargement in dilated cardiomyopathy and does not 
corroborate the findings of the Swedish investigators. Echocardiography 
clearly demonstrated the increase in left ventricular volume, which is 
the hallmark of this disorder, but was unable to detect any significant 
deolinp in vAntrioular volumA or imnrovpmont in aiaw.finn 
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beta-blockade. M-mode echocardiographic assessment of left . ventricular 
function may be very unreliable in such patients as they often have 
gross dilatation, minimal wall excursion, as well as regional wall 
motion abnormalities and functional mitral incompetence. Any 
"improvement" in ventricular function, as assessed by ejection fraction, 
may result from increased mitral regurgitation or reduced ventricular 
afterload due to a fall in arterial blood pressure. 
Another double-blind placebo-controlled study using metoprolol in a 
one-by-one month crossover design has subsequently been reported (Currie 
et al, 1982). Nine patients who filled the clinical criteria for 
dilated cardiomyopathy, all in NYHA Class III with ejection fraction of 
less than 35% (determined by echocardiography) were evaluated by 
Swan-Ganz catheterisation, supine exercise testing and radionuclide 
angiography. Four patients felt better on metoprolol, while five felt 
better on placebo. 	Ejection fraction, cardiac index,. pulmonary 
end-diastolic pressure and exercise performance were not altered. 	In 
this study, two patients were subsequently found to have severe three 
vessel coronary artery disease demonstrated by coronary angiography, 
highlighting the difficulty in clinically differentiating ischaemic 
cardiomyopathy from idiopathic dilated cardiomyopathy. It should be 
noted that coronary angiography was not performed routinely on the 
patients included in the Swedish studies. 
There has been much speculation on how beta-blockade may be 
beneficial (Taylor & Silke, 1981). Detrimental effects of 
catecholamines on the failing myocardium have been postulated to cause 
cardiac dysrhythmias or myocardial damage similar to those seen 
occasionally in patients with phaeochromocytoma (Waagstein et al, 1975). 
Elevated levels of plasma catecholamines are encountered in heart 
failure irrespective of aetiology (Thomas & Marks, 1978), are similar to 
levels seen in patients with ischaemic cardiomyopathy (see Chapter 8), 
and are nowhere near the levels seen in phaeochromocytoma. Furthermore, 
Amorin et al (1981) were not able to demonstrate sympathetic 
overactivity in patients with early dilated cardiomyopathy, investigated 
before the onset of circulatory congestion. Suppression of renin levels 
by beta-blockade (Davies et al. 1977) has also been nostulated to he 
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beneficial. Neither the Swedish workers nor I investigated the effects 
of beta-blockade on the renin-angiotensin-aldosterone system, but I did 
investigate the effect of beta-1 adrenoceptor stimulation on this system 
in another study (Chapter 7). In this study, I found that prenalterol 
stimulated the renin-angiotensin-aldosterone system, but in the 
short-term this did not appear to effect the direct action of the drug 
on the myocardium. Although it is difficult to extrapolate to long-term 
effects, the direct suppression of myocardial function by beta-blocking 
agents probably overrides any beneficial effect produced by reduction of 
renin release in heart failure. 
The effect of beta-blockade on survival in dilated cardiomyopathy 
was not investigated in this study, but the Swedish findings (Swedberg 
et al , 1979) deserve some comment in this discussion. They report 
improved survival in 24 patients treated with beta-blockers compared 
with an historical control group. The pitfalls of using historical, as 
opposed to concurrent, randomised controls has been documented recently 
(Sacks et al, 1982). The positive outcome of trials using historical 
controls depends overwhelmingly on the historical control group doing 
significantly worse than randomised controls for the same therapy. 
Furthermore, the use of historical controls irrevocably biases the study 
in favour of the new therapy. If the Swedish control group is examined 
in this light, the 10% three-year survival in the control group is very 
low when compared to three-year survival of 52, 75 and 50% reported in 
three large series from the Mayo Clinic (104 cases), Georgetown 
University (115 cases) and the Hammersmith Hospital (74 cases) (Fuster 
et al, 1981; Segal et al, 1978; Goodwin, 1970 respectively ). It is 
very likely that if the Swedish researchers had used randomised 
controls, their positive conclusion may have been a negative one. At 
the very least, the evidence is inconclusive on the point of survival. 
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9.5 CONCLUSION: 
To date the effect of long-term beta-blockade in dilated 
cardiomyopathy has only been evaluated by two double-blind studies, both 
of which do not support a beneficial effect of these drugs. Whilst 
beta-blockade was surprisingly well tolerated, there are a number of 
case reports of severe cardiac failure and hypotension, hence, 
beta-blockade is not entirely benign in this condition. Dilated 
cardiomyopathy is not a homogeneous entity, so there may be small 
subsets of patients who will benefit from beta-blockade. Until the 
matter is resolved by randomised double-blind study in adequate numbers 
of patients, routine administration of beta-blocking agents in dilated 
cardiomyopathy cannot be recommended. 
CHAPTER 10 
WITHDRAWAL OF LONG-TERM CAPTOPRIL THERAPY FOR HEART FAILURE: 
A ONE MONTH CONTROLLED, DOUBLE-BLIND STUDY 
10.1 INTRODUCTION: 
To date, the sustained effectiveness of vasodilators in the 
long-term management of heart failure remains in doubt (Colucci et al, 
1980a; Packer et al 1978,1982). In the case of angiotensin converting 
enzyme inhibitors, available data for long-term effectiveness consists 
of uncontrolled studies lasting less than six months where neither the 
patient nor the observer were blinded (Romankiewicz et al, 1983). This 
issue must remain in doubt until confirmed by a double-blind placebo 
controlled trial. 
The sustained effectiveness of other vasodilators has been inferred 
from studies which demonstrated acute haemodynamic rebound following 
cessation of treatment (Packer et al, 1979; 	Black & Mehla, 1979; 
Hanley et al, 1980). 	Such deterioration in cardiac function was not 
observed after withdrawal of long-term captopril therapy for four days 
(Maslowski et al, 1981b). This may be interpreted as showing lack of 
long-term efficacy, or alternatively, four days may have been 
insufficient time for deterioration to occur. In this chapter, I report 
the effect of one month, double-blind withdrawal of long-term captopril 
therapy on cardiac and respiratory function, exercise performance and 
plasma electrolytes in ten patients with heart failure. 
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10.2 PATIENTS AND METHODS: 
1. Patients: 
The study population (Table 10.1) comprised ten patients aged 
49 to 74 years with heart failure due to ischaemic heart disease 
(n = 8) or dilated cardiomyopathy (n = 2). They had been severely 
disabled (NYHA Class III or IV) before the addition of captopril to 
digoxin and frusemide therapy. Captopril induced a pronounced 
clinical improvement (Table 10.1) and at the time of the present 
study, all but three were in NYHA Class II after a mean treatment 
period of 12.5 months (range 4 to 25 months). Following improvement 
with captopril, frusemide therapy was withdrawn in patient 9 without 
clinical deterioration. Left ventricular function was quite 
severely depressed as indicated by a mean ejection fraction of 26.5% 
(range 12 to 40%). For at least one month prior to investigation 
clinical state and drug therapy were stable. Medications were 
continued unchanged throughout the period of investigation, digoxin 
being administered at a dose of 0.0625 mg to 0.25 mg daily, while 
frusemide therapy is documented in Table 10.1. 
2. Protocol: 
The protocol was approved by the Hospital's Ethical Committee, 
and all patients gave informed, written consent. The study entailed 
random, double-blind withdrawal of long-term captopril therapy for a 
period of one month. Patients were allocated randomly to placebo 
and captopril groups according to a predetermined scheme drawn up by 
the Squibb Company, which was not disclosed to the investigators. 
The company also provided placebo tablets of identical shape, size, 
colour, and taste. All patients continued on their usual dose 
schedule. At the beginning and end of the period of study, cardiac 
and respiratory function were assessed at rest and during exercise. 
Clinical state was assessed weekly, and I was available at all times 
if the patient's condition deteriorated suddenly. 
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TABLE 10.1: 	CLINICAL DETAILS 
No. Group Age Sex Rhythm Aet Initial , 
Response 
Treatment 
Period(mo) 
Daily 
Dose(mg) 
Frusemide 
Dose (mg) 
1 C 51 M SR DCM IV -'III 9 75 750 
2 P 70 M SR IHD IV -III 15 150 250 
3 P 58 M SR IHD III- • II 4 75 40 
4 C 56 M SR IHD III- • II 8 75 120 
5t P 74 F AF IHD IV -.III 18 150 1000 
6t C 56 M SR IHD IV •-• II 23 150 750 
7t C 66 M AF IHD III- • II 25 75 250 
8t P 52 M SR DCM III- • II 8 75 80 
9t P 49 M SR IHD III-. 	II 11 75 0 
10t C 59 M SR IHD III-. II 5 100 40 
The trial groups that patients were randomly allocated to are denoted by P = 
placebo group, and C = control group who remained on captopril therapy. SR 
= sinus rhythm, AF = atrial fibrillation, IHD = ischaemic heart disease, DCM 
= dilated cardiomyopathy. t = LVEF determined with the "Nuclear 
Stethoscope" at the beginning and end of the trial period (other studies 
were performed by Gamma Camera). 
CAPTOPRIL WITHDRAWAL 	 186. 
At the weekly clinic visits, patients were questioned closely 
for symptomatic changes. NYHA Class was assessed, and physical 
examination performed.. Blood samples were taken for measurement of 
haematological and biochemical parameters. At the beginning and the 
end of the study, urine was collected for a 24 hour period to 
measure creatinine clearance. Computer-aided spirometry (see below) 
and radionuclide left ventricular ejection fraction were also 
performed at these times. 
Invasive haemodynamics at rest and during exercise were 
assessed twice, at the beginning and the end of the study. At 0800 
hr on each day of invasive investigation, a Swan-Ganz catheter was 
inserted via a brachial or subclavian vein for measurement of right 
heart pressures and cardiac output in triplicate by thermodilution 
technique. A radial or brachial artery cannula was inserted in the 
same arm for measurement of arterial pressure and blood sampling. 
As each invasive study was relatively brief, the risk of 
complications from distal migration of the tip of the Swan-Ganz 
catheter were 	minimal 	so pulmonary capillary wedge pressure was 
measured in 	every 	case. Captopril was 	administered, 	in 	the 
patients' usual 	dose, 	at 0700 	hrs while 	diuretic 	therapy was 
withheld on the day of invasive investigation. 
Baseline resting haemodynamic recordings were performed in the 
supine position at 1230 and 1245 hr (four hours after insertion of 
catheters). If recordings were stable, a further dose of captopril 
(or placebo on the second study day) was administered at 1300 hr, 
and haemodynamic recordings were repeated at 1500 hr. Patients were 
then transferred to the exercise room, seated on a bicycle ergometer 
(Elma-Schonander Ergometer EM 369), with the catheterised arm being 
supported at the level of the left atrium. On-line breath-by-breath 
measurements of oxygen consumption, carbon dioxide production and 
ventilation were performed. Instantaneous gas concentrations were 
measured with a respiratory mass spectrometer (Perkin-Elmer MGA 
1100), a Fleisch pneumotachograph, and data processing was performed 
with a Digital PDP 11-10 computer, using software similar to that 
used by Beaver et al (1973). 
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After a suitable period of adjustment and when graphical 
display of oxygen consumption was stable, haemodynamic measurements 
were performed in duplicate, three minutes apart. The patients then 
commenced graded exercise with three minute stages of incremental 
workloads (50 - 150 kpm/min). These steps were predetermined from a 
familiarisation exercise test performed less than a week prior to 
entering the study to ensure that each patient exercised for 
approximately ten to twelve minutes. After two minutes of each 
stage of exercise, haemodynamic measurements were performed and 
blood was drawn for arterial lactate as well as arterial and venous 
haemoglobin oxygen saturation (Instrumentation Lab Inc Co-oximeter 
IL 182). Cardiac output during exercise was determined by Fick 
method. Each patient exercised for as long as he could before 
terminating, at which time haemodynamics and blood sampling were 
again repeated. Anaerobic threshold (Weber et al, 1982b) was 
achieved in all but one patient. 
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3. Statistics: 
Statistical analysis was performed by Student's paired T-test 
when comparing results within each group. Differences between each 
group were analysed by Student's T-test. Results are expressed as 
mean + standard error of the mean (SEM) unless stated otherwise. 
4. Computer-assisted Spirometry: 
• Spirometry was performed on an Ohio 840 Dry Rolling Seal 
Spirometer thirty minutes after the exercise test. Patients 
inspired maximally, then forced expiration was performed into the 
spirometer. Interactive graphics (using a Digital PDP 11-10 
Computer and a Tektronix 4012 Graphics Terminal) provided immediate 
analysis and display of the data. Corrections for ambient 
temperaure and barometric pressure were made automatically. 
Immediate display allowed recognition of a poorly performed test, so 
that the test could be repeated as required. Normal values, 
determined from reported regression equations (Cherniack & Raber, 
1972), were also displayed. An example of a computer generated 
output is shown in Fig 10.1. 
PRE BRONCHOD I LATOR 0 
=LOW L/SEC 
.VOL(ML) 2799.. COMPUTER SP/ROMETRY RESPIRATORY UNIT PMH 
5.6 
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Figure 10.1: 	Computer-Assisted Spirometry 
MALE AGE 52. 	HT 173.CMS BRONCHOD/LATCR: 	PRE 28-APR-82 	00:41 (PRED) 	(SEE) FEV1 ML 1947. 3342. 550. FVC ML 4539. 740. FEV1/FOC% 72. 73. 8. PEFR L/SEC= 5.61 8.78 1.86 MMEF L/SEGig 1.22- 3.37 1.12 MET SEC -1.10 0.58 0.13 MEF50 - L/SECil 1.71 5.26 1.51 FET SEC . 	- 6.30 
Flow-volume curve during forced expiration 
FEV = forced expiratory volume in 1 second 
FVC = forced vital capacity 
PEFR = peak expiratory flow rate 
. 
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10.3 RESULTS: 
1. The Captopril Group: 
Despite random allocation to placebo and captopril groups, 
some significant differences between the groups were 
encountered. Haemodynamic abnormalities were greater in the 
captopril group. Cardiac index was lower (2.03 + 0.11 1/min/m2 
compared to 3.32 + 0.38 1/min/m 2 in the placebo group, p<0.05) 
while mean pulmonary artery pressure (42.0 + 3.8 mm Hg v. 21.8 
+ 2.0 mm Hg, p<0.01) and pulmonary capillary wedge pressure 
(28.8 + 2.2 v. 13.4 + 1.6 mm Hg, p<0.01) were higher. Arterial 
• pressure and right atrial pressure were also higher in the 
captopril group, but the differences were not significant. 
Despite these differences in resting haemodynamics, maximum 
oxygen consumption was similar in both groups. 
After one month, haemodynamics in the captopril group 
tended to improve (Table 10.2) with falls in arterial pressure, 
right heart pressures and heart rate. These changes did not 
reach conventional levels of statistical significance, largely 
due to the smaller number of patients in this group, as one 
patient (No 6) in the captopril group had to be withdrawn from 
the study before it was completed. He developed acute lobar 
pneumonia complicated by acute on chronic renal failure three 
weeks after the first investigation. Consequently, his data have 
been excluded from most analyses, apart from the analysis of the 
effect of a single dose of captopril while on chronic therapy. 
2. Clinical Findings in the Placebo Group: 
Three significant clinical events occurred in the five 
patients in whom captopril was withdrawn: 
1. Patient 2 complained of increasing dyspnoea over the first 
two weeks of the study, and as a result of this he asked to 
be withdrawn from the study. Repeat invasive investigations 
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were performed on the fourteenth day of the protocol, before 
the code was broken. Captopril was then recommenced with 
subsequent clinical improvement. 
2. Patient 8 deteriorated from NYHA Class II to III, however he 
was happy , to complete the protocol, and he improved when 
captopril was re-introduced. 
3. Patient 5 complained of weakness and palpitations after ten 
days. On examination, she was pale and sweaty, while her 
blood pressure and heart rate were higher. Plasma potassium 
had fallen from 3.8 mmo1/1 to 2.5 mmo1/1 necessitating 
additional potassium supplementation. 	Symptoms of heart 
failure had not changed, so the treatment code was not 
broken, and the patient continued the trial. 	Plasma 
potassium had increased to 3.3 mmo1/1 by the time of second 
study. 
Overall, cuff blood pressure increased significantly in the 
placebo group, however changes were not as dramatic as those 
measured by arterial cannulation, presumably because clinic 
times could not be standardised to a uniform time after the last 
dose of captopril. Body weight increased slightly from 68.8 + 
16.2 Kg to 69.4 + 16.2 Kg, while resting radionuclide ejection 
fraction declined from 27 + 6% to 26 + 5%, neither change being 
significant. 
3. Biochemical changes: 
Plasma potassium tended to fall in those patients withdrawn 
• from captopril, with the greatest fall occurring in patient 5 
who was taking the largest dose of frusemide (1000 mg). No 
significant alterations in plasma sodium, urea, creatinine or 
creatinine clearance were observed. A fall in haemoglobin in 
the placebo group (14.5 + 1.1 g/dl to 13.8 + 1.3 g/dl), although 
small, did reach levels of statistical significance. No such 
changes were seen in the captopril group. 
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4 • Resting Haemodynamics: 
1. Effect of single dose of captopril while on chronic therapy: 
At the time of the first study all ten patients were 
receiving captopril therapy. Resting haemodynamics were 
recorded two hours after a dose of captopril (1500 hr), 
measurements having already been performed at 1300 hr, six 
hours after the preceding dose taken at 0700 hr. 'Comparing 
the 1300 and 1500 hr results, the only parameter to show 
significant changes (Table 10.3) was arterial pressure. For 
this reason, results at each measurement time were combined, 
and daily means on the first and second study compared. 
2. Effect of Captopril Withdrawal: 
When haemodynamics were reassessed one month after 
cessation of long-term captopril therapy (Placebo group - 
Table 10.2), mean arterial pressure had increased from 80 + 
8 mm Hg to 96 + 9 mm Hg (p<0.05), left ventricular filling 
pressure had risen from 13.4 + 1.6 mm Hg to 17.8 + 1.9 mm Hg 
(p<0.05), while right atrial pressure was higher (6.8 + 2.0 
mm Hg to 9.8+ 1.3 mm Hg, p<0.05). Cardiac index declined 
while ventricular rate and mean pulmonary artery pressure 
rose slightly, but these changes were not statistically 
significant. 
Comparison with the captopril group was hampered by 
significant differences between the two groups at entry, and 
the small number of patients in each group. Nevertheless, 
the mean individual differences in arterial pressure and ' 
pulmonary capillary wedge pressure were significantly 
different when analysed by Student's T-test (p<0.05). 
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TABLE 10.2: 	RESTING HAEMODYNAMICS AND SPIROMETRY: 
' 
, 
Placebo Group (n=5) Captopril Group (n=4) 
Study 1 Study 2 Study 1 Study 2 
Cardiac Index 3.32 + 3.11 2.03 2.13 
(1/min/m2 ) +0.38 +0.54 +0.11 +0.11 
Syst Art Press 125 142 * 135 120 
(mm Hg) +14 +17 +19 +10 - 
Diast Art Press 61 74 * 76 67 
(mmHg) Hg +3 +5 +8 +4 - 
Mean Art Press 80 96 * 96 84 
(mm Hg) +8 +9 +11 - +5 
Mean Pulm Art Pr 21.8 ++ 25.4 42.0 30.5 
(mm Hg) +2.0 +4.0 +3.8 +4.9 - 
PCWP 13.4 ++ 17.8 * 28.8 18.5 
(mm Hg) +1.6 - +1.9 - +2.2 - +4.4 
Right Atrial Press 6.8 9.8 * 10.0 6.5 
(mm Hg) +2.0 - +1.3 - +0.8 - +2.6 
Ventricular Rate 78 85 78 74 
(bt/min) +7 +12 
- 
+8 +3 
FVC (1)' 3.21 3.01 	* 3.65 3.96 
+0.57 +0.57 +0.18 +0.33 
FEV 1 	sec (1) 2.18 2.07 2.53 2.78 
+0.33 +0.31 _ +0.36 - +0.36 - 
FEV 1 /FVC Ratio 68.6 70.6 68.8 70.0 
(%) +3.1 +3.6 +6.5 +5.7 _ 
Pk Expir Flow Rate 5.54 5.76 8.10 8.83 
(1/min) +0.90 +0.87 - +1.80 +1.50 - 
Mean + SEM. PCWP = pulmonary capillary wedge pressure. 
FVC = forced vital capacity. FEV = forced expiratory volume. 
Significant differences between placebo and captopril groups on 
study day 1 are indicated by + = p<0.05, ++ = p<0.01, while 
significant difference between the two study days is indicated by * = 
p<0.05. 
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TABLE 10.3: 
EFFECT OF A SINGLE DOSE OF CAPTOPRIL WHILE ON CHRONIC THERAPY 
Time post dose (hr.) 6 	(1300) 2 	(1500) Significance 
Cardiac Index 2.88 2.93 NS 
(1/min/m2 ) +0.30 +0.37 
Ventricular Rate 79 79 NS 
(bt/min) +4 +5 
Syst Arterial Pressure 141 127 <0.01 
(mm Hg) +12 +11 — 
Diast Arterial Pressure 74 67 <0.05 
(mm Hg) +5 +6 
Mean Arterial Pressure 95 88 <0.05 
(mmHg) Hg +6 +8 — 
Mean Pulmonary Art Press 28 25 NS 
(mm Hg) +4 +3 
Pulm Cap Wedge Pressure 18 17 NS 
(mm Hg) +3 +2 
Right Atrial Pressure 7 8 NS 
(mmHg) Hg	. +1 +1 
Systemic Vascular Resist 1408 1379 NS 
(dyne-sec-cm-5 ) +147 +221 
- 
Haemodynamic measurements in 10 patients (mean + SEM) 2 hours (1500) 
after a dose of captopril, compared to measurements 6 hours after the 
previous dose. 
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5. Exercise Capacity: 
In those patients in whom captopril was withdrawn, exercise 
duration declined from 13.5 + 3.1 min to 11.4 + 3.0 min 
(p<0.05), while in the captopril group, exercise duration was 
not altered (9.8 + 1.5 min compared to 9.8 + 0.5 min). 
Haemodynamics at maximal (table 10.4) and submaximal exercise 
(results not shown) were not significantly different in either 
group of patients. 
6. Respiratory Function: 
Forced vital capacity declined (p<0.05) in the group in 
whom captopril was withdrawn, but indices of upper airway 
resistance remained unchanged (Table 10.4). At peak exercise, 
oxygen consumption declined from 1.28 + 0.35 to 1.12 + 0.29 
1/min, carbon dioxide production declined from 1.42 + 0.46 to 
1.33 + 0.36 1/min, however neither change achieved conventional 
levels of statistical significance. Respiratory quotient and 
maximum ventilation were unchanged, as was oxygen extraction 
(Table 10.4). Arterial lactate at maximum exercise increased 
significantly in the captopril group (p<0.05) but declined in 
the placebo group, although this change was not significant. 
Comparisons of mean individual differences between each group, 
however, did show that trends were significantly different 
(p<0.01). 
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TABLE 10.4: HAEMODYNAMIC AND RESPIRATORY DATA AT MAX EXERCISE: 
,  
Placebo Group Captopril Group 
Study 1 Study 2 Study 1 
9.8 
+1.5 
'Study 2 
9.8 
t0 .5 
Exercise Duration 
(min) 
13.5 
+3.1 - 
11.4 * 
-13.0 
Cardiac Index 6.7 6.9 4.7 4.7 
(1/min/m2 ) 	• +1.4 +1.8 +0.3 , +0.5 
Ventricular Rate 139 134 141 136 
(bt/min) , +6 +8 ±17 . I18 
Syst Art Press 176 161 167 165 
(mm Hg) +17 _ +18 , 	+25 +16 
Diast Art Press • 	84 86 79 82 
(mm Hg) +3 +6 , +10 _ +3 
Mean Art Press 116 111 107 107 
(mm Hg) +6 +9 +14 +5 .• Mean PA Press 37 34 56 45 
(mm Hg) +7 +7 +8 +6 
V02 (1/min) 1.24 1.12 1.26 1.24 
, +0.35 _ +0.29 . +0.15 +0.17 
VCO2 (1/min) 1.42 1.33 1.47 1.50 
+0.46 _ +0.36 _ +0.18 _ +0.21 _ 
' Ventilation 43.8 44.6 53.0 54.3 
(1/min) +13.0 _ +11.0 +3.3 +4.9 
1. 
Art Lactate 5.4 4.3 4.6 5.6 * 
(mmo1/1) +1.8 +1.3 +1.5 +1.4 _ 
Mean + SEM. V02 = oxygen consumption. V00 2 = carbon dioxide 
production. For each group, significant differences between the two 
study days are shown by * = p<0.05. 
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10.4 DISCUSSION: 
Exacerbation of heart failure may follow the abrupt withdrawal 
of vasodilator therapy (Packer et al, 1979; Black & Mehla, 1979; 
Hanley et al, 1980). These authors interpreted the observed changes 
as evidence for continuing effectiveness of vasodilator therapy. 
Such haemodynamic deterioration was not observed after cessation of 
captopril therapy for four days (Maslowski et al, 1981b). This 
might be taken to suggest that the drug has little or no effect in 
the long-term or, alternatively, that four days may be insufficient 
time for deterioration of cardiac function. In this study, I 
investigated the effects of ceasing captopril therapy for one month; 
the placebo controlled double-blind, protocol being chosen to 
facilitate the interpretation of results. 
None of the patients in the captopril group exhibited a change 
in clinical status, although one patient had to be withdrawn because 
of an incidental illness. Significant clinical events occurred in 
three of five patients in whom captopril was withdrawn. The 
clinical state deteriorated considerably in two patients, with one 
patient shifting from NYHA Functional Class II to III and the other 
patient (already in Class III) asking to be removed from the study, 
because of increasing dyspnoea two weeks after commencing placebo 
medication. Potentially serious hypokalaemia developed over a 
period of ten days in patient 5. Overall, a fall in plasma 
potassium was noted (Table 10.2), but did not achieve levels of 
statistical significance. These effects are not surprising since 
initiation of therapy with converting enzyme inhibitors induces a 
positive cumulative potassium balance and a minor rise in plasma 
_potassium (see Chapter 6) due, •in part, to a fall in plasma 
aldosterone. In the absence of converting enzyme inhibition, plasma 
aldosterone levels in heart failure correlate closely with the dose 
of frusemide therapy (Chapter 8). Thus, the rise in plasma 
aldosterone attendant upon withdrawal of converting enzyme 
inhibition is likely to be greater in those patients on larger 
frusemide doses, such as patient 5 who required 1,000 mg daily. 
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The deterioration in clinical state was associated with an 
overall decline in left ventricular function as judged by resting 
haemodynamic parameters, whereas there was a tendency for 
improvement in the captopril group. Arterial pressure rose 
significantly, but resting cardiac output was sustained by a rise in 
filling pressures which probably induced greater pulmonary 
congestion and thus, a decline in forced vital capacity. It would 
appear that haemodynamic deterioration occurs gradually after the 
cessation of captopril therapy. In an earlier study from this unit 
(Maslowski et al, 1981b), haemodynamic or clinical deterioration did 
not occur during a four day period of withdrawal of long-term 
captopril therapy. Arterial pressure rose as a consequence of the 
rise in plasma angiotensin II, although greater activation of the 
sympathetic nervous system (as judged by the rise in plasma 
norepinephrine) may have contributed. Heart rate also rose 
significantly, correlating with rises in plasma angiotensin II and 
norepinephrine, but cardiac output, and right heart pressures 
remained unaltered. Sodium retention or potassium depletion did not 
occur in this study, but the rise in plasma and urine aldosterone 
levels suggested that these changes may have developed had the 
period of withdrawal been longer. In the present study, sodium and 
water retention did not appear to be a major problem, as body weight 
did not rise significantly. 
As mentioned earlier, rebound haemodynamic changes occur 
rapidly following the withdrawal of other vasodilators (Packer et 
al, 1979; Black & Mehta, 1979; Hanley et al, 1980). The 
haemodynamic response to vasodilator therapy results from two 
counteracting forces (Packer et al, 1981): 
1. Direct peripheral vasodilating effects of the drug; 
2. Secondary activation of counterposing mechanisms which cause 
peripheral vasoconstriction and tachycardia. 
The second factor is perhaps largely responsible for the rebound 
haemodynamic changes induced by withdrawal of therapy, and has also 
been incriminated in the development of tolerance to these agents 
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(Colucci et al, 1980; Packer et al, 1982). As acute rebound was 
not observed following captopril withdrawal, the gradual 
deterioration appeared to be largely due to withdrawal of direct 
effects of the drug. Thus counterposing mechanisms reducing the 
effect of agents such as captopril do not appear to be great, and 
this may well contribute to the sustained effectiveness of this form 
of therapy. 
In open trials, captopril therapy has been shown to improve 
exercise capacity in patients with severe heart failure (reviewed by 
Romankiewicz et al, 1982). In one study, single-blind withdrawal of 
therapy for two weeks resulted in a significant decline in exercise 
capacity (Cowley et al, 1982). The reasons for improved exercise 
capacity remain uncertain at the present time, but may be due to 
decreased pulmonary congestion or improved skeletal muscle perfusion 
during exercise which delays conversion to anaerobic metabolism. 
From the small numbers of patients that I studied, firm conclusions 
cannot be drawn. I found that captopril withdrawal produced a 
significant decline in exercise duration associated with a possible 
fall in maximum oxygen consumption and carbon dioxide production. 
Haemodynamic measurements did not appear to be different at 
submaximal or maximal levels of exercise, however, movement 
artifacts increased the error of measurement. The changes in 
arterial lactate are difficult to interpret with any certainty. 
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10.5 Conclusion: 
Withdrawal of long-term captopril therapy may result in serious 
hypokalaemia, especially in those patients on large doses of 
diuretic therapy. An acute rebound haemodynamic response has not 
been observed, thus neurohumoral factors that counteract effects of 
many vasodilators are not greatly activated. Haemodynamic 
deterioration does occur gradually and is associated with an 
increase in symptoms and decline in exercise performance. These 
data indicate that captopril has a pronounced and sustained 
haemodynamic effect in patients with severe cardiac failure, which 
is reversed after temporary withdrawal of the drug. 
CHAPTER 11 
CONCLUSIONS 
"No scientific investigation can be final, it merely 
represents the most probable conclusion which can be drawn 
from the data at the disposal of the writer. A wider range of 
facts, or more refined analysis, experiment and observation 
will lead to new formulae and new theories. This is the 
essence of scientific progress." 
	
Karl Pearson 	( 1898 ) . 
Although a large number of points have been discussed in the 
preceding chapters, only what appear to be the major findings will be 
summarised here. In the first three studies (Chapters 6, 7 and 8), 
investigations were performed under standard conditions of sodium and 
potassium balance and body posture, while usual digoxin and frusemide 
therapy remained constant. Measurements performed under control 
conditions and following therapeutic intervention allowed accurate 
interpretation of hormone levels and their relationships to haemodynamic 
abnormalities, as well as interpretation of the effects of therapeutic 
intervention. 
For a period of at least twelve 	hours 	after cardiac 
catheterisation, haemodynamic and hormone parameters vary significantly. 
After this period of instability, a relatively stable baseline is 
achieved and remains that way for at least a further 48 hours. It is at 
this time that haemodynamic-hormone inter-relationships may be more 
accurately assessed, unrelated to the stress of catheterisation - these 
effects are all too often ignored, especially in short-term studies 
investigating therapeutic intervention. Study protocols that include an 
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adequate period of stabilisation and control measurements, such as those 
studies outlined in Chapters 6 & 7, allow greater accuracy in the 
assessment of the effects of new forms of therapy. 
Activation of the renin-angiotensin-aldosterone and sympathetic 
nervous systems at rest was most evident in those patients with severe 
heart failure, on higher doses of frusemide. There was a close 
correlation between levels of angiotensin II and plasma renin activity 
with haemodynamic abnormalities of heart failure - reduced cardiac 
index, elevated right heart pressures and vascular resistance, while 
much weaker relationships were observed between plasma catecholamines 
and these haemodynamic abnormalities. These findings vary significantly 
from the findings of other workers in that the reverse situation has 
generally been observed. This is probably due to failure to delay 
recordings until the stress of catheterisation has abated. 
Hyperaldosteronism observed in patients with stable heart failure 
appeared to be largely due to diuretic-induced activation of the 
renin-angiotensin system. Activation of this system appears to maintain 
arterial pressure in the face of reduced cardiac preload and output 
induced by diuretic therapy. Vasoconstriction resulting from elevated 
plasma angiotensin II levels may contribute to increased afterload in 
heart failure, and this may ultimately be detrimental to the failing 
myocardium in the long-term, despite short-term symptomatic benefit 
provided by these agents. 
The angiotensin converting enzyme inhibitor, enalapril, effectively 
reduced elevated angiotensin II levels. This was associated with a 
beneficial haemodynamic response which was most evident in those 
patients with greater initial activation of the 
renin-angiotensin-aldosterone system on the higher doses of frusemide. 
At a one to two month follow-up, exercise capacity had improved in these 
patients. Sustained benefit of this form of therapy was confirmed by a 
withdrawal study (Chapter 10): the cessation of long-term captopril 
therapy following a double-blind protocol demonstrated haemodynamic 
deterioration and reduced exercise capacity in those who were withdrawn 
from the medication. 
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Furthermore, significant symptomatic deterioration occurred in two 
patients while serious hypokalaemia developed in another. 
A number of vasodilators have been assessed for efficacy in the 
ambulatory management of heart failure, but many lack sustained benefit. 
The development of tolerance to these agents may arise for several 
reasons. As the renin-angiotensin system has been implicated in the 
resistance to these agents as well as diuretic therapy, failure to block 
this system probably plays a major role in the reduction of 
effectiveness of many of these vasodilators. Once the patient fails to 
respond to sodium restriction or low dose diuretic therapy, angiotensin 
converting enzyme inhibitors will probably become the treatment of 
choice. Enalapril will probably supplant captopril because it produces 
fewer side-effects and hypotension is induced more gradually. Safety of 
this agent will pave the way for evaluation in less severely afflicted 
patients. Symptomatic, haemodynamic or exercise improvement is not 
likely to be great in mildly impaired patients, but the effect of 
angiotensin converting enzyme inhibition on prognosis and prevention of 
gradual decline in cardiac function will need to be investigated by 
studies involving large numbers of patients. 
Turning to the role of the sympathetic nervous system in heart 
failure, other workers have demonstrated that depletion of myocardial 
norepinephrine occurs in severe heart failure, while receptor function 
remains normal. Stimulation of cardiac beta-adrenergic receptors 
supports the failing myocardium, while stimulation of alpha-adrenergic 
receptors produces vasoconstriction in some vascular beds, diverting 
blood to vital organs, but increasing ventricular afterload, which may 
ultimately be detrimental to cardiac function. Many positive inotropic 
agents, including several potent synthetic catecholandnes, are currently 
being investigated in chronic heart failure, but their place in the 
ambulatory management of this syndrome remains in doubt. Administration 
of the beta-1 adrenergic agonist, prenalterol, produced a beneficial 
haeModynamic response consistent with its inotropic properties. 
Vasodilatation occurred either as a result of direct beta-receptor 
induced dilatation or withdrawal of increased activity of the 
sympathetic 	nervous 	system. 	Concomitant activation of the 
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renin-angiotensin-aldosterone system may diminish the 	overall 
effectiveness of this drug with long-term oral therapy, thus angiotensin 
converting enzyme inhibition may be necessary , to achieve maximal 
benefit. 
A group of Swedish authors have suggested that sympathetic 
overactivity may be deleterious in patients with dilated cardiomyopathy, 
contrary to current teaching. 	From empirical observations in 
non-controlled studies, 	they claim that beta-adrenergic blockade 
improves symptoms, cardiac size, exercise performance and prognosis in 
this condition. This casts doubt on our current concept of the role of 
the sympathetic nervous system in supporting the failing myocardium. 
From data presented in Chapter 8, I could find no difference in hormonal 
indices between patients with ischaemic heart disease and those with 
dilated cardiomyopathy. The study documented in Chapter 9 was the first 
placebo controlled, double-blind trial to investigate the effects of 
beta-blockade in patients with dilated cardiomyopathy. Heart size 
increased while exercise capacity declined on acebutolol. I could' not 
support the Swedish findings and until their work is followed by a 
properly controlled study with an adequate number of subjects, 
beta-blockade in this condition cannot be recommended. 
It is difficult to comment on the role of ADH in the patients in 
whom levels were measured. Generally, levels were within our laboratory 
range for healthy volunteers. ADH levels declined slightly during 
enalapril therapy, while prenalterol did not appear to effect levels in 
three patients. The data failed to show any close association with 
known or suspected stimuli of ADH release (arterial pressure, left 
ventricular filling pressure, plasma sodium or angiotensin II) although 
there was a significant correlation to frusemide dosage. Control of ADH 
secretion is multifactorial and complex, while the major routes of 
clearance from plasma have not yet been clarified in heart failure. 
Elucidation of the role of ADH in heart failure will require further 
study with better control of fluid intake and blockade of ADH action 
and/or secretion. 
CONCLUSIONS 	 205. 
To conclude, the studies incorporated in this thesis contribute 
significantly to our understanding of the role of neurohumoral systems 
in the pathophysiology and management of heart failure. . 
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